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Abstract 
Prostatic differentiation is modelled through enrichment for stem-like populations through a 
combination of putative stem-cell markers. However, in vitro cultures demonstrate a 
phenotypic drift that abrogates normal physiology. Induced Pluripotent Stem Cell (iPSC)-
reprogramming allows for any somatic cell to be transformed into an embryonic-stem-cell-
like state although molecular properties as well as differentiation abilities are limited by the 
primary tissue type of origin. This project describes the derivation of Prostate-iPSC (Pro-
iPSC) from the prostate of an individual in his sixth decade. Prostate cells were re-
programmed through use of a specific Cre-Recombinase/LoxP polycistronic transduction 
protocol. Resultant iPS clones (14 cell lines) were checked for identical DNA fingerprinting 
with the parent fibroblasts and then tested for pluripotency and exogene silencing. 
Morphologically the Pro-iPSC are identical to human embryonic stem cells. Normal 
karyotyping was confirmed following which Pro-iPSC were immunostained for a panel of 6 
pluripotent markers including nuclear-transcription factors Oct4 and NANOG. Messenger 
RNA studies confirmed a gene-expression  profile that was similar to embryonic-stem cells. 
These Pro-iPSC are able to differentiate into all the three germ layers (embryoid body and 
teratoma formation) and demonstrate in vitro differentiation along a prostate-specific lineage 
when treated with specific differentiation media. Preliminary tissue recombination grafts of 
Pro-iPSC with the urogenital messenchyme have further demonstrated in vivo differentiation 
of these cells along a specific urological route. In conclusion a novel iPSC model has been 
established whereby aged prostatic fibroblasts have been progressively de-differentiated into 
a primitive embryonic state - this model demonstrates crucial events in prostate embryology 
which in turn allows the scrutiny of some complex signalling pathways as well as molecular 
mechanisms behind prostate carcinogenesis. 
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Chapter 1.  
Introduction 
1. An introduction to prostate cancer 
1.1. Epidemiology of prostate cancer  
Prostate cancer is a disease of increasing concern amongst developed nations and is an 
emerging malignancy in developing countries, it is a leading cause of death in men 
worldwide (Haas, Delongchamps et al. 2008) . Prostate cancer is the most frequent cancer in 
the USA after skin cancer (Haas, Delongchamps et al. 2008). Analyses of autopsy specimens 
suggest that more than 60% men will be histologically positive for prostate cancer by the age 
of 85 years (Haas, Delongchamps et al. 2008, Burton, Martin et al. 2013).  Prostate cancer is 
also the commonest form of cancer in men in Europe as well as the European Union 
accounting for 20.3% and 24.1% of total incident cases, respectively (Ferlay, Autier et al. 
2007). Along with colorectal, lung and breast, prostate cancer accounts for 10-50% of the 
total cancer burden in the world and is documented to be a major contributor to the total 
DALYs (Disability-adjusted life-years) amounting to a loss of 169.3 million years of healthy 
lives across the globe(Soerjomataram, Lortet-Tieulent et al. 2012). In Europe, 2.6 million 
new cases of prostate cancer are detected each year (Heidenreich, Aus et al. 2008) – this 
cancer is responsible for 9% of all cancer deaths in the EU (Black, Bray et al. 1997). In the 
UK, prostate cancer accounts for 24% of all new male cancers detected and 1 in every 10 
men face the risk of being diagnosed with this condition in their lifetime (July, 2010). The 
apparent increase in the number of diagnoses has been attributed to the incidental detection of 
this disease following transurethral resection of the prostate (TURP) and also due to the use 
of prostate specific antigen (PSA) testing (NICE 2008).  
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The GLOBOCAN project evaluated this disease to be the second most frequently diagnosed 
cancer responsible for 14% of total new cancer cases and the sixth leading cause of cancer 
deaths in males (6% of total cancer deaths in males) (Jemal, Bray et al. 2011). In year 2010, 
there were more than 40,000 new cases of prostate cancer reported in the UK (Figure 1.1) 
(CRUK 2010). The crude rate for prostate cancer incidence in the UK was 134, meaning that 
for every 100,000 males there were 134 new prostate cancer cases being reported (CRUK 
2010). Projections of cancer incidence are therefore important in assessing the effectiveness 
of current healthcare interventions and in overhauling current therapeutic regimens to 
improved standards (Mistry, Parkin et al. 2011). In the year 2010, the life-time risk or the risk 
of a new-born developing prostate cancer at some point of life was 1 in 8 (CRUK 2010). It 
has been documented that the increased diagnoses of new prostate cancer cases will continue 
over the next few decades unless appropriate lifestyle-interventions are in place (Mistry, 
Parkin et al. 2011, Greenberg, Wright et al. 2013). These figures emphasise on the need for 
management strategies that will address quality of life following disease diagnosis. 
 
The aetiology of prostate cancer has been attributed to several factors, with perhaps the most 
important one being increasing age. Prostate cancer diagnosis is less than 1% in those below 
the age of 50 years and the incidence peaks between the ages 75-79 (CRUK 2010). This 
underscores the need for preclinical models in this field to be more accurate in representing 
this condition as a disease of ageing. The prevalence of prostate cancer refers to the number 
of cases of patients who have been diagnosed with prostate cancer and are still alive; 
although deaths due to prostate cancer has decreased by a fifth in the last 20 years prostate 
cancer associated deaths are on the rise due to better detection rates and increased life 
expectancy (CRUK 2010). The worldwide prevalence of prostate cancer in year 2008 was 
around 3 million (Figure 1.2) (UK 2013). 
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England Wales Scotland 
Northern 
Ireland 
United 
Kingdom 
Cases (thousands) 35 2.5 2.7 0.9 41 
Crude Rate 135.5 167.4 105.9 106.5 133.7 
 
Figure 1.1. Prostate cancer incidence statistics across the United Kingdom. The statistical 
data represent the number of new cases, crude and European age-standardised (AS) Incidence 
rates per 100,000 population  age around 85 years. Table adapted from(CRUK 2010). 
http://www.cancerresearchuk.org/cancer-info/cancerstats/types/prostate/incidence/#source34  
 
 
 
1 Year Prevalence  5 Year Prevalence 10 Year Prevalence 
Cases (thousands) 31  128  181  
 
Figure 1.2. Prostate cancer prevalence rates in the UK at 31
st
 December, 2006. These 
statistics show that around 180,000 men are alive for 10 years following the diagnosis of 
prostate cancer reflecting improved healthcare interventions in the detection and management 
of Prostate Cancer in the UK. Table adapted from http://www.cancerresearchuk.org/cancer-
info/cancerstats/types/prostate/incidence/#source34  (CRUK 2010) 
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1.4.  Management of prostate cancer 
 
As per EAU guidelines on the management of prostate cancer (NICE 2008) diagnosis of 
prostate cancer is based on histopathological confirmation following which the mainstays of 
therapy include “active surveillance” for low risk cancers (Gleason histological grade not 
more than 7), radical prostatectomy and radiotherapy in younger patients; whilst hormonal as 
well as cytotoxic therapy is reserved for late stage cancers with metastasis (Heidenreich, Aus 
et al. 2008). Hormonal therapy in the form of androgen deprivation offers short-term 
symptomatic relief in around 70% cases until the tumour progresses to a hormone insensitive 
phenotype (Dorkin, Robson et al. 1997).  
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In the UK patients with prostate cancer are risk stratified to facilitate decision making into 
individual management strategies (Table 1):  
 
 PSA  Gleason 
score 
 Clinical 
stage 
Low risk < 10 ng/ml and Less than or 
equal to 6 
and T1-T2a 
Intermediate 
risk 
10-20 ng/ml or 6 or T2b-T2c 
High risk >20 ng/ml or 8-10 or T3-T4 
(locally 
advanced 
disease) 
 
Table.1. Risk stratification in localised prostate cancer patients (NICE 2008). 
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Men with low-risk, localised prostate cancer are first offered active surveillance which is 
particularly suitable for patients in clinical stage T1c, Gleason score 3+3, PSA density <0.15 
ng/ml and in patients with less than 50% malignant foci in the total number of biopsy cores; 
active surveillance however is not recommended for men with high-risk localised prostate 
cancer (NICE 2008) A recent survey showed that in the year 2010 80% of UK oncologists 
expressed their approval in favour of active surveillance (Payne, Clarke et al. 2012). It has 
also been recommended that active surveillance should be considered for men with 
intermediate risk localised prostate cancer but not for men with high-risk localised prostate 
cancer – high-risk localised prostate cancer must be managed by radical prostatectomy or 
radical (conformal) radiotherapy, those with a Gleason score of 8 and higher must be 
considered for a minimum of 2 years of adjuvant hormonal therapy and patients with 
metastatic prostate cancer should be offered bilateral orchidectomy as an alternative to 
continuous LHRHa therapy (Guidance 2008, NICE 2008).  
The benefits of screening strategies for prostate cancer and improvisation of therapeutic 
policies remains equivocal as of today and is a significant impediment faced by healthcare 
professionals across the UK (Lane, Hamdy et al. 2010). The ProtecT (Prostate testing for 
cancer and Treatment) trial and the CAP (Comparison Arm for ProtecT) study are two 
ongoing UK-based randomised controlled trials aim to measure prostate cancer mortality at 
10 years as the primary outcome and overall survival, financial expenditures and quality of 
life as secondary outcomes (Lane, Hamdy et al. 2010). The CAP study examines the 
effectiveness of prostate cancer screening while the ProtecT study evaluates the efficacy of 
active monitoring, radiotherapy and radical prostatectomy for localised prostate cancer. In 
addition both these trials underscore the need for improvising better diagnostic and 
pharmacotherapuetic development that will facilitate management of adavanced stage 
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prostate cancer (Lane, Hamdy et al. 2010). Androgen refractory cases remain the biggest 
challenge in advanced prostate cancer management (UK 2013). Hormone-refractory stages 
are currently treated with cytotoxic agents such as docetaxel alone (non-metastatic cancer) or 
in combination with prednisone (such as in cases of symptomatic osseous 
metastasis)(Heidenreich, Aus et al. 2008). However, relapse to chemotherapy is not 
uncommon. This underscores the relevance of improved models to study the mechanism of 
hormone-refractory prostate cancer. It is also important to scrutinise the molecular networks 
and signalling pathways that regulate hormone-refractoriness. Genome-wide association 
studies or GWAS identify common alleles that contribute to the risk of developing prostate 
cancer (Lane, Hamdy et al. 2010). This reflects that an understanding of the cancer genetics 
and relevant molecular signalling in androgen-refractoriness can be a powerful tool to 
clinicians and scientists in improvising competent and effective treatment for advanced 
prostate cancer.  
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1.2. Molecular pathology of prostate cancer 
The prostate relies on androgens such as testosterone and dihydrotestosterone for 
maintenance of its glandular structure and function. Androgen deprivation therapy offers 
symptomatic relief in prostate cancer until the emergence of hormone refractory disease - 
understanding the mechanism of hormone-refractoriness in this cancer is indispensable in 
elucidating the molecular pathogenesis of prostate cancer (Dorkin, Robson et al. 1997). 
Androgens bind to nuclear androgen receptor proteins which are then activated to further 
bind to androgen response elements that regulate transcription of specific target genes (Beato 
1989).  One such gene regulated by androgens is the prostate-specific antigen (PSA) gene 
which contains androgen responsive elements in its promoter region (Riegman, Vlietstra et al. 
1991).  Disruption in this signalling system contributes towards progression to hormone 
refractory disease  (Dorkin, Robson et al. 1997).  
A study using microarray profiling of prostate cancer xenografts concluded that a moderate 
increase in androgen receptor transcript was the only change that was constantly associated 
with the development of hormone-refractory disease and three major mechanisms have been 
identified behind resistance to antiandrogen therapy (Chen, Welsbie et al. 2004). 
Amplification of the androgen receptor gene promoting tumour growth at low serum 
androgen levels (Visakorpi, Hyytinen et al. 1995) and mutations of the androgen receptor 
gene that might provide a growth advantage following anti-androgen treatments have been 
reported in around 10% of prostate cancer cases (Taplin, Bubley et al. 1995, Taplin, 
Rajeshkumar et al. 2003). Elevated mitogen-activated protein kinase signalling such as those 
mediated by ERBB2 (HER-2/neu) or HRAS has also been incriminated in promoting 
hormone-refractory prostate cancer – forced expression of HER-2/neu results in ligand-
independent growth and the androgen-receptor pathway synergises with even modest doses 
of androgens to hyper-activate the pathway (Craft, Shostak et al. 1999, Gioeli, Ficarro et al. 
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2002, Chen, Welsbie et al. 2004). A third mechanism implicated in androgen-independent 
prostate cancer is the androgen receptor bypass mechanism wherein alternative signalling 
pathways drive hormone resistance (Chen, Welsbie et al. 2004). One such pathway involves 
the bcl-2 oncogene that is known for its anti-apoptotic actions – bcl-2 expression is reported 
to be elevated following anti-androgen treatment and this has been implicated in causing the 
emergence of androgen-independent prostate cancer (McDonnell, Troncoso et al. 1992). It 
has also been documented that bcl-2 overrides apoptosis in vitro in LNCaP prostate cancer 
cells and augments hormone-refractoriness in vivo (Raffo, Perlman et al. 1995). Persistent 
activation of the hedgehog signalling pathway is also implicated in hormone refractory 
disease, promoting conversion of prostate progenitor cells to cancer-initiating cells 
(Karhadkar, Bova et al. 2004).  
A study that used transplantation experiments demonstrated that conversion of a paracrine 
mechanism to an autocrine mechanism is instrumental behind malignant transformation of 
prostate epithelial cells (Gao, Arnold et al. 2001). In the normal prostate, androgen acts in a 
paracrine manner on different cell types – androgen receptors in prostate stromal cells 
produce growth factors or ‘andromedins’ which in turn diffuse across the basement 
membrane into the epithelial compartment and bind certain plasma membrane receptors 
thereby initiating epithelial cell growth and survival pathways (Litvinov, De Marzo et al. 
2003, Isaacs and Isaacs 2004). The prostatic epithelial compartment comprises the basal and 
the secretory luminal epithelium along with neuroendocrine cells- basal epithelial cells do not 
express androgen receptor and this layer is lost in prostate cancer; however in the nuclei of 
secretory luminal cells, the androgen receptor initiates transcription of genes such as the 
prostate specific antigen and human glandular kallikrein-2 (Isaacs and Isaacs, 2004). 
Nevertheless, the receptor in these secretory luminal cells do not augment proliferation but 
act to suppress the secretory-cell growth by inhibiting andromedin-induced proliferation 
 25 
 
(Isaacs and Isaacs 2004). In malignant cells, a switch in mechanism from stromal-cell-
dependent paracrine pathways to autocrine pathways means that androgen receptors in these 
cancer cells directly stimulate their growth and proliferation (Gao, Arnold et al. 2001). In a 
hormone-escape prostatic cancer environment, molecular alterations occur that reduce the 
threshold of the androgen receptor ligand otherwise needed for cell growth and survival, 
additionally elevated levels of the androgen receptor in hormone refractory cancers also 
super-sensitizes these cells to androgen (Chen, Welsbie et al. 2004, Isaacs and Isaacs 2004). 
Indeed reducing androgen receptor expression to a level that would slow the growth of 
prostate cancer cells as well as trigger apoptosis has been suggested as a prostate cancer 
therapeutic mechanism (Isaacs and Isaacs 2004). However, this concept has not yet been 
studied and detailed scrutiny of the androgen receptor pathway calls for a cell biology model 
that would mimic the   normal prostate physiology as accurately as possible.  
Prensner et al evaluated the role of non-coding RNAs in prostate cancer disease progression  
by means of transcriptome sequencing across a prostate cancer cohort comprising 102 
prostate tissues and cell lines. This group identified 121 un-annotated prostate cancer 
associated non-coding RNA transcripts (PCATS) of which PCAT-1 was characterised to be a 
prostate-specific regulator of cell proliferation as well as to be a transcriptional repressor 
implicated in prostate cancer (Prensner, Iyer et al. 2011).  More recently, several publications 
have reported whole-exome sequencing to decipher the mutational configurations of prostate 
cancer, with one study identifying SPOP, FOXA1 and MED12 mutations to be instrumental 
behind carcinogenesis (Barbieri, Baca et al. 2012) and another study identifying proteins 
interacting with the Androgen Receptor (AR) such as FOXA1, MLL2, UTX and ASXL1 to 
be mutated in castration-resistant prostate cancer (Grasso, Wu et al. 2012).  
The aim of this project has been to establish an ex vivo model that will eventually allow 
interrogation of signalling pathways that regulate the molecular pathology of advanced stage 
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prostate cancer. Furthermore the emerging significance of hormone-refractory prostate cancer  
underscores the relevance of prostate cancer stem cells which might be responsible for drug 
resistance (Collins and Maitland 2006).  
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The  Androgen Receptor in Prostate Cancer 
Prostate cancer progression is highly dependent on androgens, the actions of which take place 
through a functionally active Androgen Receptor (AR) (Linja and Visakorpi 2004). 
Functionally active androgen receptor signalling is critical in the development of prostate 
cancer since congenital syndromes such as androgen insensitivity and syndromes with 
reduced or absent AR signalling result in underdeveloped prostates that do not develop 
prostate cancer (Palmberg, Koivisto et al. 1999, Huggins and Hodges 2002). AR expression 
and signalling remains intact during development of androgen-insensitive disease where 
implications of genetic and epigenetic changes cause prostate cancers to be influenced by AR 
signalling (Taplin 2007).  
The gene for AR is located on X chromosome Xq11-12 (Chang, Kokontis et al. 1988, Evans 
1988, Taplin 2007). The AR molecule constitutes an amino-terminal activating domain  and a 
carboxy-terminal ligand-binding domain in addition to a DNA-binding domain in the mid-
region that contains two zinc-fingers (Feldman and Feldman 2001). Unligated AR molecules 
are cytoplasmic and remain bound to heat shock proteins 90, 70, 56 and 23, these chaperone 
proteins stabilize AR’s tertiary conformation so as to allow for androgen binding [35; 36]. 
The steroid hormone androgen regulates crucial phenomenon such as those involved in 
prostatic development and differentiation through the formation of hormone-receptor 
complexes with androgens [31]. Once androgen-binding to the AR occurs, heat shock 
proteins dissociate from the AR, causing dimerization of AR which is followed by kinase-
mediated phosphorylation – this causes AR to translocate to the nucleus [36]. AR belongs to 
the family of steroid-thyroid-retinoid nuclear receptor family, it is a phospho-protein where a 
conformational change in the ligand-binding domain occurs following androgen binding and 
consequent  phosphorylation of the AR causes it to interact with specific androgen response 
elements causing activated gene expression (Brinkmann, Blok et al. 1999). The activated 
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DNA-bound AR homo-dimer complex recruits co-regulators to the AR complex where the 
activated complex involves a shift in the AR helix 12 position to create a binding site for co-
activators (Feldman and Feldman 2001). These co-activators cause AR to interact with a 
certain complex of proteins that have the potential to either inhibit or stimulate gene 
transcription – this complex of proteins is known as the General Transcription Apparatus 
(McKenna, Lanz et al. 1999). Co-activators facilitate transcription by recruiting protein 
complexes to DNA which cause a change in the chromatin structure to a more activated form 
(Chang and McDonnell 2005). Examples of co-activators demonstrating histone acetyl 
transferase activity include NCOA1, NCOA2, NCOA3, PCAF, CBP, TIP60 and p300 (Dehm 
and Tindall 2005). Co-repressors silence transcription through chromatin condensation 
(Chang and McDonnell 2005), examples of such molecules include SMRT (silencing 
mediator of retinoid and thyroid) hormone receptors and NCOR (nuclear receptor co-
repressor) (McKenna, Lanz et al. 1999). Examples of AR-regulated genes include PSA 
(prostate specific antigen), CDK8 (cyclin-dependent kinase 8), PIK3R1 (p85 catalytic subunit 
of phosphatidylinositol 3-kinase) and RAB4A (Velasco, Gillis et al. 2004).  Prostate cancer 
growth and progression depends on the ratio of proliferating cells to the ratio of apoptotic 
cells – this is mediated by androgens and hence androgen ablative therapy works to control 
the disease progression in the initial stages by reducing cell proliferation rate and increasing 
rate of cell death eventually leading to elimination of prostate cancer cells (Denmeade, Lin et 
al. 1996, Feldman and Feldman 2001). It has also been documented that amplification of the 
AR gene at Xq11-q13 can account for androgen independence and consequent prostate 
cancer progression – Visakorpi.et al identified in vivo molecular mechanisms involving high-
level amplifications of the AR that were detected in 30% recurrent tumours through FISH 
studies with an AR-specific probe (Visakorpi, Hyytinen et al. 1995).  
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The development and progression of prostate cancer results from several alterations in the 
AR signalling pathway (Linja and Visakorpi 2004). AR signalling in the normal prostate is 
very different from the malignant prostate. In the normal prostate, androgen-stimulated 
proliferation of the epithelium is mediated through AR positive stroma. However, in the 
malignant prostate androgen-mediated signalling switches to the autocrine mode whereby no 
interaction with the stroma is required (Gao, Arnold et al. 2001). The hormone refractory 
state has also been attributed to an increase in multiple androgen regulated genes (Linja and 
Visakorpi 2004). A cDNA microarray study that was carried out on human CWR22 prostate 
cancer xenografts during hormone ablation indicated the global gene expression profiles to be 
distinct in primary, regressing and recurrent tumours and further identified a set of androgen-
responsive genes where expression levels were down-regulated initially with therapy but 
were later restored and up-regulated in recurrent tumours (Mousses, Wagner et al. 2001).  For 
recurrent tumours, alteration in gene expression profiles was also noted for known targets of 
rapamycin as well as those that converged on the PI3K/AKT/FRAP pathway.  The results 
from this study suggested that the combined effect of re-activation of androgen-responsive 
genes as well as the stimulation of rapamycin-sensitive signalling pathways could potentially 
lead to prostate cancer progression as well as contribute to androgen insensitive prostate 
cancer (Mousses, Wagner et al. 2001). Hara. et al established an androgen-insensitive MDA 
Pca 2b prostate cancer cell line in vitro from bone metastasis derived androgen dependent 
MDA PCa 2b human prostate cancer cells after 35 weeks of growth suppression through 
androgen depletion (Hara, Nakamura et al. 2003).These studies emphasize the relevance of 
androgens and the androgen receptor signalling in prostate biology. 
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2. Stem Cells in the Prostate 
2.1 Definition of a stem-cell 
Stem cells sit at the top of the lineage hierarchy and are characterised by their ability to self-
renew and generate one or many specialised cell types through differentiation (Donovan and 
Gearhart 2001, Reya, Morrison et al. 2001).  Stem cells can be embryonic or non- embryonic 
– whilst embryonic stem cells can differentiate into any of the three germ layers, the ability of 
non-embryonic stem cells to differentiate is much more limited (Tuch 2006). There are three 
types of embryonic stem cells – embryonal carcinoma cells derived from testicular tumours, 
embryonic stem cells derived from pre-implantation embryos and embryonic germ cells 
derived from primordial germ cells of post-implantation embryos (Donovan and Gearhart 
2001). Alternatively, stem cells can also be defined based on their differentiation potential – 
totipotent stem cells sit at the top of the lineage hierarchy and can differentiate to give rise to 
any cells of embryonic and extra-embryonic origin ; whilst pluripotent stem cells are next in 
the lineage hierarchy and can differentiate into any embryonic cell types but do not 
differentiate to any extra-embryonic tissue (Tachibana, Sparman et al. 2012). Multi-potent 
stem cells are descendants of pluripotent stem cells and differentiate into several cell types  
along specific lineage routes while unipotent cells refers to the terminally differentiated cell 
types that can maintain only a single cell type or cell lineage (Hochedlinger and Plath 2009). 
Testicular spermatogonial stem cells (SSC) are a self-perpetuating population of germ cells 
that bear embryonic stem cell like characteristics and have been shown to directly trans-
differentiate into reproductive as well as non-reproductive tissues of all germ layers (Simon, 
Ekman et al. 2009). Non embryonic stem cells also known as adults stem cells include 
haematopoietic stem cells and mesenchymal stem cells (Tuch 2006). A recently developed 
stem cell technology that enables generation of so-called induced pluripotent stem cells (or 
iPS) refers to stem-cells that are generated by overexpression of specific transcription factors 
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in somatic cells causing these cells to be reprogrammed into a pluripotent state which bears 
molecular and functional similarity to embryonic stem cells (Hochedlinger and Plath 2009).  
 
It has been shown that the inner cell mass isolated from normal murine blastocysts when 
cultured in embryonal carcinoma cell line-conditioned medium give rise to pluripotent cell 
clones – these cells resembled embryonal carcinoma cell lines in morphology and expressed 
SSEA-1, a marker common to mouse teratocarcinoma stem cells and early embryos but 
absent in murine differentiated cell types; furthermore these cells demonstrated in vitro 
differentiation into cells representing all the three germ layers by forming embryoid bodies 
and demonstrated their pluripotential characteristics in vivo by forming teratocarcinomas in 
mice (Martin 1981). It has also been reported that in vitro cultures of mouse blastocycts can 
result in formation of established pluripotent cell lines that possess al the characteristic 
features of embryonic stem cells; the success of derivation of these pluripotent lines were 
dependent on three factors – the stage of embryonic development when the blastocysts were 
used for pluripotent line derivation, the number of precursor cells available from the embryos 
and selection of appropriate in vitro conditions that would facilitate proliferation of these cell 
lines as stable undifferentiated pluripotent cell lines (Evans and Kaufman 1981). These cells 
were called embryonic stem cells based on their source as opposed to the teratocarcinoma-
derived embryonal carcinoma cell lines. The establishment of the first human embryonic 
stem cell lines defined characteristics of primate embryonal carcinoma cells to include the 
following: that these are derived from pre-implantataion or peri-implantation embryos, that 
these cells show continuous undifferentiated proliferation over long periods of time in culture 
and that these cells are capable of differentiating into cell types representing the endoderm, 
mesoderm and ectoderm irrespective of their time in culture as undifferentiated stable 
pluripotent cells (Thomson, Itskovitz-Eldor et al. 1998).  A total of 5 distinct embryonic stem 
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cell lines were established from fresh or frozen cleavage stage separate embryos during In 
Vitro Fertilisation (IVF) procedures, 3 of the lines possessed a normal XY karyotype while 
the other two showed a normal XX karyotype (Thomson, Itskovitz-Eldor et al. 1998).   
 
Pluripotent stem cells are identified by certain properties – morphologically they grow in 
colonies comprising small rounded cells with high nuclear to cytoplasmic ratio and large 
rounded nucleoli. They can be grown indefinitely in culture, a unique phenotype explained by 
high level of telomerase activity in these cells – telomerase expression is associated with 
immortality of cell lines in culture with high levels of telomerase expression detected in germ 
lines and in embryonic tissues (Wright, Piatyszek et al. 1996). On the contrary, diploid 
somatic cells with limited life span are marked by an limited telomerase activity and 
shortened telomeres that causes these cells to undergo replicative senescence following a 
restricted life-span in vitro (Allsopp, Vaziri et al. 1992, Counter, Avilion et al. 1992, Counter, 
Hirte et al. 1994). The pluripotent nature of these cells are further characterised by the 
expression of certain cell-surface antigens such as alkaline phosphatase, stage-specific 
embryonic antigens SSEA3, SSEA4, Tra-1-60 and Tra-1-81 (Thomson, Kalishman et al. 
1995, Thomson, Itskovitz-Eldor et al. 1998, Thomson and Marshall 1998). Consistent with 
human embryonic carcinoma cell lines, undifferentiated pluripotent cell lines did not stain for 
SSEA1 – the fact that SSEA1 defines differentiated embryonic stem cell cultures in humans 
but undifferentiated pluripotent states in murine pluripotent stem cell lines reflects the 
elementary species-specific differences in development between humans and mice (Thomson, 
Itskovitz-Eldor et al. 1998). The functional aspects of pluripotent stem cells are defined by 
their extremely limited lineage restriction in that they can differentiate into a wide repertoire 
of terminal cell types. This is demonstrated in vitro through formation of 3-dimensional 
embryoid bodies in the absence of b-FGF. These embryoid bodies when seeded onto gelatin-
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coated plates differentiate to give rise to a heterogeneous population of cell types including 
neuronal-like structures, myocytes (such as beating cardiomyocytes) and epithelial-like cells. 
Ideally, pluripotent cells such as those comprising the inner cell mass of the blastocyst and 
epiblast of post-implantation embryos as well as pluripotent stem cell lines should be able to 
contribute to chimerism in vivo (Trounson and Grieshammer 2012).  Unfortunately, given 
ethical constraints chimera-formation assays cannot be carried out in the human thereby 
limiting an extensive application of these pluripotent cell lines in regenerative and 
reproductive science. Pluripotent stem cell lines generated from blastomeres, inner cell mass 
of blastocysts and epiblasts of post-implantation pre-gastrulation embryos all form teratomas 
(Chung, Klimanskaya et al. 2006, Cockburn and Rossant 2010, Nichols and Smith 2011). 
However, epiblast stem cells do not form chimeras; this can be attributed to the fact that 
either they are not pluripotent and/or to incompatibility between the host and injected cells 
(Trounson and Grieshammer 2012). When mouse embryonic stem cells (ESC) are injected 
into inner cell mass deficient tetraploid embryos these form ESC-derived embryos  (Nagy, 
Gocza et al. 1990). This unique ability of pluripotent stem cells towards chimerism has seen 
this technology being extensively used to study mammalian gene function through transgenic 
knock-out mice (Capecchi 1989). However, very recently it has been shown that unlike 
murine embryonic stem cells, rhesus-derived embryonic stem cells and inner cell mass are 
not capable of chimera formation since they fail to incorporate into host embryos (Tachibana, 
Sparman et al. 2012). On the contrary, chimerism was demonstrated through monkey 
totipotent cells in the form of very early 4-stage embryos – raising the question whether the 
failure of chimera formation was due to the pluripotent cells being lineage restricted or  
whether they were unable to implant and utilise extra-embryonic support from the host, 
raising the issue of host-compatibility in such stem cell experiments (Tachibana, Sparman et 
al. 2012, Trounson and Grieshammer 2012).   
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2.2. Stem cells in the prostate - prostate epithelial stem cells and the epithelial stem cell 
niche 
The existence of stem cells in the prostate was first reported by Isaacs . when a study in 
rodents demonstrated that normal prostate regenerates following several cycles of androgen 
ablation and replacement (Isaacs 1985, Tsujimura, Koikawa et al. 2002). A different study 
demonstrated glandular epithelial induction with the help of tissue recombinants prepared 
using adult mouse urinary bladder epithelium and mesenchyme of embryonic urogenital sinus 
– suggesting the possible existence of a stem cell compartment in the adult urogenital tract 
(Cunha, Lung et al. 1980, De Marzo, Nelson et al. 1998). An in vivo study further established 
the existence of murine prostatic epithelial stem cells in the proximal region of prostatic ducts 
(Tsujimura, Koikawa et al. 2002). Another research paper established prostate regeneration 
using adult mouse prostate epithelial cells and embryonic urogenital sinus mesenchyme (Xin, 
Ide et al. 2003). An in vivo mouse-model study demonstrated that cells that are of the Lin
-
Sca-1
+
CD133
+
CD44
+
CD117
+
 phenotype are multi-potent and can generate an entire 
functional prostate (Leong, Wang et al. 2008). Recently it has been documented that p63 
expressing cells constitute the stem cells of the developing prostate as well as the bladder 
(Pignon, Grisanzio et al. 2013). Another in vivo study analysed prostate development by 
investigating genetic lineage tracing and concluded that postnatal prostatic development is 
regulated by basal multi-potent stem cells which differentiate into basal, luminal and 
neuroendocrine cells as well as by uni-potent progenitor cells (both basal and luminal) 
(Ousset, Van Keymeulen et al. 2012). Clonal analysis revealed that while prostate 
development in the adult is mediated by uni-potent luminal and basal cells; there are multi-
potent progenitor cells that regulate prostate development in the postnatal period (Ousset, 
Van Keymeulen et al. 2012). Lineage analysis of basal epithelial cells have further shown 
that tumour development through luminal or basal cells result in cancers that bear distinct 
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molecular profiles that can predict patient outcomes (Wang, Mitrofanova et al. 2013). It is the 
malignant transformation of basal cells which give rise to tumours with luminal phenotype; 
however cross-species bioinformatics analyses have shown that tumours of luminal origin are 
more aggressive and reflect poorer patient outcomes (Wang, Mitrofanova et al. 2013).  
Putative prostatic stem cells have also been isolated from human benign prostatic hyperplasia 
(BPH) specimens using flow cytometry-based side population sorting wherein stem cells 
preferentially express a multi-drug resistance protein that enables them to efflux the Hoechst 
dye (Bhatt, Brown et al. 2003, Tang, Patrawala et al. 2007).  
Functionally, the prostate gland can be divided into several stem cell units all of which arise 
from a single or reserve stem cell that is located in the basal epithelial compartment 
(Robinson, Neal et al. 1998, Litvinov, De Marzo et al. 2003). This reserve stem cell divides 
to form transit amplifying cells which in turn divide and differentiate into the secretory 
luminal layer - a subset of basal cells constitute stem cells while the remainder form transit-
amplifying cells (Hudson, O'Hare et al. 2000, Litvinov, De Marzo et al. 2003). The transit 
amplifying cell types have restricted ability to divide and ultimately differentiate to give rise 
to terminally committed and functionally active luminal secretory cells (Robinson, Neal et al. 
1998). Epithelial stem cells have been implicated in the aetiology of both BPH and prostate 
cancer by several research groups (Isaacs and Coffey 1989, Bonkhoff and Remberger 1996, 
De Marzo, Nelson et al. 1998, Hudson, O'Hare et al. 2000). There is substantial ambiguity 
behind the etiology of both BPH and prostate cancer; however they are both diseases of aging 
and are dependent on androgens for growth and development (Isaacs and Coffey 1989, 
Coffey and Walsh 1990, De Marzo, Nelson et al. 1998). Nevertheless, BPH and prostate 
carcinoma are very distinct clinical conditions – firstly benign prostatic hyperplasia rarely 
ever transforms into malignancy, unlike prostatic intraepithelial neoplasia (PIN) and cancer 
genomic instabilities are rarely associated with BPH (De Marzo, Nelson et al. 1998). A 
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characteristic feature of BPH is the variable stromal overgrowth which in turn can cause 
epithelial hyperplasia through mesenchymal-epithelial interactions (Cunha 1994).  One 
proposed model for development of prostatic intraepithelial neoplasia and eventually prostate 
cancer is an aberrant cell cycle effect that would cause certain cells in the secretory 
compartment to transiently proliferate and prevent them from differentiating into terminal 
cells (De Marzo, Nelson et al. 1998). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 37 
 
2.3. Cancer stem cell hypothesis 
The concept of cancer stem cells was first put forward in haematopoietic cells by Bonnet and 
Dick wherein they postulated that the leukaemic clone is organised in a hierarchy (Bonnet 
and Dick 1997). Further to this, cancer stem cells were identified in solid tumours, including 
breast cancer (Al-Hajj, Wicha et al. 2003) and in brain tumours (Singh, Clarke et al. 2003). 
Prostate neoplasms are heterogeneous in that the cells in a single tumour display variable 
phenotypic characteristics and distinct proliferative and malignant potentials (Heppner 1984, 
Collins, Berry et al. 2005). Tumour heterogeneity suggests two possible models behind 
tumuorigenesis - stochastic and hierarchical (Collins and Maitland 2006). The stochastic 
model explains that different cancer cells within a single neoplasm would have the ability to 
proliferate extensively, however the probability that any such cell would enter the cell cycle 
is low; the hierarchical theory explains that only a subset of cells would be enriched for the 
ability to self-renew and would thus initiate tumourigenesis (Reya, Morrison et al. 2001). In 
prostate cancer, a population of cancer stem cells have been identified with a 
CD44
+/α2β1
hi
/CD133
+
 phenotype – these cells show features of self-renewal, regenerate 
diverse populations of non-clonogenic cells that in turn express androgen receptor and 
prostatic acid phosphatase (Collins, Berry et al. 2005).   
 
Establishing a prostate cancer stem cell model will serve to demonstrate the cellular and 
molecular mechanisms behind tumour heterogeneity (Collins and Maitland 2006). This in 
turn will enable specific targeting of cancer stem cells whilst considering therapy for prostate 
cancer and might lead to improved therapeutic efficacy. 
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2.4. Animal models of prostate cancer 
Prostate cancer is a disease that is typically exclusive to man. The only other animal known 
to develop prostatic adenocarcinomas and PIN spontaneously is the dog (Waters, Sakr et al. 
1998).  There are several similarities between prostate cancer in humans and canines such as 
advanced age of disease onset, metastatic abilities of the primary tumour, apparent onset of 
androgen independence of advanced disease  and tumour heterogeneity (Waters, Sakr et al. 
1998). However, canine models are not a practical solution given that these models are 
economically prohibitive; the incidence of prostate cancer is incredibly low in dogs (Maini, 
Archer et al. 1997) and it is difficult to genetically manipulate a canine model and maintain 
such transgenic litters (Ghoniem and VandenBerg 1994).  
Several strains of rats have been shown to develop spontaneous prostate cancer (Pylkkanen, 
Makela et al. 1996, Maini, Archer et al. 1997) and murine xenograft models using 
immunodefficient mice has been popularly used to model prostate cancer. However there are 
considerable differences between the mouse and the human prostate. The human prostate is 
alobular with a distinct central, peripheral and transitional zone. Most cancers arise in the 
peripheral zone of the gland, the transitional zone is rarely involved and practically none arise 
in the central zone  (De Marzo, Platz et al. 2007). Most BPH lesions on the other hand arise 
in the transitional zone (De Marzo, Platz et al. 2007). The mouse prostate on the other hand  
has four lobes: dorsal, lateral, anterior and ventral and each lobe is divided into three regions 
relative to the urethra (Leong, Wang et al. 2008). Other notable differences include that the 
mouse prostate atrophies with advanced age while the human prostate hypertrophies with 
age, the mouse does not develop prostate cancer spontaneously and unlike humans the short 
life span of mice prevents the mouse prostate from accumulating cumulative genetic lesions 
(Sharma and Schreiber-Agus 1999) that may possibly be an important contributing factor in 
human prostate carcinoma . 
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2.5. Markers of “stemness” and differentiation in the prostate 
Epithelial cell differentiation pathways have been demonstrated through keratin and cell 
adhesion molecule expression (Murant, Handley et al. 1997, van Leenders, Dijkman et al. 
2000, Hudson, Guy et al. 2001) as well as through expression of androgen responsive 
proteins and cell proliferation (Maitland and Collins 2008).  Basal cells express high levels of 
keratins such as K5, K14, K15, K17, K19 and p63 but express low levels of AR (androgen 
receptor), PSA and keratins 8 and 18. In contrast, luminal cells lack p63, K5 and K14 but 
express high levels of K8, K18, AR and PSA with some luminal cells also expressing K19 
(Hudson, Guy et al. 2001, van Leenders, Aalders et al. 2001). Basal cells in normal, BPH and 
high grade intraepithelial neoplasia express p63 though this marker is rarely expressed in 
adenocarcinoma specimens (Parsons, Gage et al. 2001). This gene is known to play an 
important role in prostate development and has also been detailed as essential for normal 
stem-cell function in the prostate (Grisanzio and Signoretti 2008).   
A number of other markers have been described as ‘stemness’ markers in the prostate – α2β1 
integrin (Collins, Habib et al. 2001), CD133 (Richardson, Robson et al. 2004), CD44 
(Patrawala, Calhoun et al. 2006), CD117 (Leong, Wang et al. 2008) and Nkx3.1 (He, 
Sciavolino et al. 1997, Wang, Kruithof-de Julio et al. 2009). CD133 or AC133 is also known 
as prominin-1 (Shmelkov, St Clair et al. 2005) is expressed by 1% of human prostate basal 
cells that are also positive for α2β1 integrin – these cells are characterised by high in vitro 
proliferation capacity and have the ability to generate prostatic-like acini in immuno-
compromised male nude mice (Richardson, Robson et al. 2004). A study of CD44 using 
prostate cancer cells demonstrated that this marker is associated with increased proliferation 
as well as increased mRNA expression of other stem cell genes such as Oct-3/4, Bmi, β-
catenin and SMO. Furthermore these cells are also more clonogenic, tumorigenic, metastatic 
as well as undergo asymmetric cell division in clonal analyses (Patrawala, Calhoun et al. 
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2006). Nkx3.1 expression marks a luminal cell population that have bipotential, possess self-
renewal properties, can re-constitute prostatic ducts in renal grafts and are demonstrated by 
prostate regeneration assays to facilitate stem cell maintenance (Wang, Kruithof-de Julio et 
al. 2009) . CD117 along with Sca-1, CD-133 and CD44 has been demonstrated to mark a 
murine prostate stem cell population that are multi-potent and can self-renew - in fact a single 
such cell can reconstitute a prostate in vivo (Leong, Wang et al. 2008). 
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3. Lineage plasticity and Cell fate 
3.1. Pro-iPS model to study prostate tiussue differentiation and homeostasis  
The mechanism of differentiation of progenitor cells into different cellular lineages can be 
studied with the help of pluripotent cells. Pluripotency is defined as the ability of a cell to 
give rise to one of the three germ layers of the embryo. Examples of pluripotent cells include 
cells of the inner cell mass and its derivative, embryonic stem cells and the induced 
pluripotent cells. Embryoid body formation and chimera formation are characteristic features 
of pluripotency. Induced pluripotent cells refer to reprogrammed somatic cells by means of 
pluripotency factors. This was first demonstrated by Takahashi and Yamanaka when they 
reprogrammed mouse embryonic and adult fibroblast cultures by transducing these with Oct 
3/4, Sox2, c-Myc and Klf4 under embryonic stem cell culture conditions (Takahashi and 
Yamanaka 2006). These initial induced pluripotent stem (iPS) cells were not germline 
competent and showed aberrant DNA methylation patterns until selection for Nanog 
expression allowed for establishment of a germline competent iPS cell line with increased 
embryonic stem cell-like gene expression and DNA methylation patterns comparable with 
chimera generating Fbx15 iPS cells (Okita, Ichisaka et al. 2007). Later, Yu. et al successfully 
derived iPS cell lines from human somatic cells (Yu, Vodyanik et al. 2007). Using iPS cell 
lines avoids some of the ethical dilemma raised with using human embryo for embryonic 
stem cell generation. Studying prostate induced pluripotent cell differentiation to prostate 
cells would enable demonstration of the genetic alterations and epigenetic modification that 
occur during prostate development and differentiation (Nishikawa, Goldstein et al. 2008). 
The availability of a stable prostate iPS cell line would also obviate current technical 
difficulties associated with primary culture of prostate epithelia and stroma. The presence of 
well characterised limited iPS cell lines would further bypass clinical variations amongst 
tissue specimens encountered with primary tissue culture. 
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Deciding on a somatic source of iPS cells that will be best committed to differentiate into 
prostate is important as iPS cells from different origins have different propensities to 
differentiate (Yamanaka 2009).  Induced pluripotent stem cells generated from murine 
hepatocytes and murine stomach cells do not need any retroviral integration into specific sites 
and thus are spared of tumourigenic potential (Aoi, Yae et al. 2008). Additionally, 
reprogramming juvenile human primary keratinocytes is 100-fold more efficient and twice as 
rapid than the reprogramming of fibroblasts (Aasen, Raya et al. 2008).  The aim of this 
project is to ascertain if non physiological skin fibroblast derived iPS cells are as efficiently 
committed to differentiate into prostate cells as are the iPS cells derived from the prostate. 
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3.2. Nuclear re-programming – and introduction 
 
Nuclear re-programming is defined as a change in the gene expression of a cell  to a different 
unrelated cell type (differentiated) or to that of an embryo (Gurdon and Melton 2008). 
Development of a fertilised egg into an adult is marked by an irreversible progressive lineage 
restriction during differentiation into terminal cell types that confines these cells to their 
committed fate; the process of re-programming is achieved by several different technologies 
(Figure 1.3) such as mammalian somatic cell nuclear transfer, cell fusion, induced 
pluripotency through forced ectopic gene expression and direct re-programming of one cell 
type into another (Wilmut, Schnieke et al. 1997, Rodolfa and Eggan 2006, Takahashi and 
Yamanaka 2006, Gurdon and Melton 2008).  The process of nuclear re-programming is 
critical for several reasons – this technique reveals substantial information about the process 
of differentiation, development and about specialised gene expression and function. This 
process also provides an advance in cell-replacement therapy where defective cells can be 
replaced by ‘corrected’ cells of the same or a related kind but has been established from an 
entirely different type of cells. Fnally, nuclear re-programming allows for disease 
pathogenesis in a petri-dish in the sense that pluripotent cell types can be established from 
patients with different diseases and these cells harbour genetic information of the respective 
disease processes (Gurdon and Melton 2008). The different techniques used in nuclear re-
programming will now be described. 
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Figure 1.3. The experimental routes to nuclear re-programming: A. by means of nuclear 
transfer to eggs. B. By induction of pluripotency through transcription factor re-programming 
(iPS technology). C. By means of lineage switching back to a branch point and then again in 
a different direction. D. by direct conversion of one cell fate to the other. Schematic adapted 
from (Gurdon and Melton 2008). 
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3.3. Somatic cell nuclear transfer 
This technology exploits the role of the nucleus in embryonic differentiation. In the 1880s, 
August Weissmann formulated the ‘germ plasm theory’ where he hypothesised that in 
multicellular organisms cells would differ from each other through a series of asymmetric 
cellular division where different cells would come to inherit varying proportions of genetic 
material from their progenitors (Weismann 1893). This theory was further tested by Roux and 
colleagues and it was established that during embryonic differentiation different blastomeres 
receive different kinds of nuclei which further decide upon their consequent lineage 
specification and cell fate.hHowever, this school of thought was later challenged with the 
concept that cleaved nuclei are identical and differentiation is indeed attributed to specific 
areas of the egg cytoplasm (Briggs and King 1952). Morgan suggested that the nuclei 
differentiate as a consequence of variability between different regions of the cytoplasm and 
such nuclear differences can further affect the cytoplasm in a reciprocal manner (Morgan 
1934). The more recent studies have suggested that cytogenetic processes (Schultz 1947) 
and/or ciliate morphogenesis could account for nuclear differentiations (Weisz 1951). Briggs 
and King devised specific experiments to address these concerns by transplanting nuclei from 
advanced blastula cells into enucleated eggs of the amphibian Rana pipiens – this resulted in 
the production of swimming tadpoles and the study formed the earliest evidence of 
experimental reversal of embryonic cellular differentiation (Briggs and King 1952). These 
authors also concluded that the natural process of nuclear differentiation in an embryo is 
irreversible since nuclear transfer resulted in abnormal development when older gastrula 
stage cells were used in place of the blastula (Briggs and King 1957). These studies were 
carried forward by testing if nuclear transfer from fully differentiated cells would result in 
offspring.The first attempt at such a concept involved nuclear transfer from intestinal 
epithelium cells of feeding tadpoles where a certain proportion of transferred intestinal nuclei 
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gave rise to normal feeding tadpoles suggesting that at least a fraction of differentiated cells 
contain nuclei with pluripotent characteristics. However, 48% of intestinal nuclei failed to 
demonstrate cleavage following transplantation and irregular cleavage formation that resulted 
in abortive nuclear transfer was observed with many intestinal nuclei but with very few 
embryonic nuclei (Gurdon 1962). Many of the experiments also resulted in either partial 
cleavage and/or abnormal development (Gurdon 1962). Successful nuclear transfer from a 
fully differentiated ‘fertile’ intestinal cell into adult frogs provided conclusive evidence that 
during the course of differentiation processes that alter gene expression and function in 
directing cells to their specific fates as well as genetic mechanisms that are repressed during 
differentiation do not result in the irreversible alteration of genes that would be needed for 
differentiation of cells into other lineage/cell types.In other words, genetic information is not 
lost within all cells during the course of differentiation (Gurdon and Uehlinger 1966). It can 
therefore be deduced that during the process of embryonic differentiation there is a change in 
nuclear genetic expression but not in the content. Furthermore, although during the course of 
lineage commitment there is a change in phenotypic characteristics of a cell, its genome 
remains unaltered throughout lifetime (Gurdon and Melton 2008).  
 
The next major breakthrough in nuclear transfer saw cloning of the sheep ‘Dolly’, when it 
was shown that in vitro cell lines isolated from sheep embryos that had been forced into 
quiescence through serum starvation following 6-13 passages in culture resulted in viable 
offspring when the nuclei of these cells were transferred into enucleated oocytes (Campbell, 
McWhir et al. 1996). This study suggested that induction of quiescence in donor cells brought 
about alterations in chromatin structure that ultimately allowed for nuclear transfer and 
consequent embryonic development. The same technique was repeated to facilitate nuclear 
cloning from three different donor populations, including terminally differentiated adult 
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mammary gland cells and cells from the foetus (Wilmut, Schnieke et al. 1997). A major step 
forward from these experiments was the nuclear cloning of monkeys to generate rhesus 
macaque blastocysts from adult skin fibroblasts through the process of somatic cell nuclear 
transfer. This generated two stable embryonic stem cells lines from the thus derived primate 
embryos that  demonstrated all the characteristics of pluripotent cells such as the distinct 
morphology, expression of embryonic stem cell markers, exhibited transcriptional similarity 
to embryonic stem cell transcripts and differentiated into derivatives of all the three germ 
layers in vitro as well as in vivo (Byrne, Pedersen et al. 2007). This therefore allows us to 
conjecture that human cells also retain overall genomic fidelity during development and that 
this process can be reversed through specific genetic manipulations at the chromatin level 
(Gurdon and Melton 2008). Mechanisms accompanying nuclear re-programming include an 
increase in volume of the transferred nuclei  as well as decondensation of sperm chromatin 
which is mediated by nucleoplasmin, an acidic immuno-depleting nuclear protein in egg 
cytoplasm that demonstrates histone binding functions (Philpott, Leno et al. 1991). Nuclear 
re-programming is also facilitated by mechanisms of histone modifications  as well as 
through DNA demethylation on the Oct4 promoter sites (Simonsson and Gurdon 2004). Oct-
4 DNA demethylation is mediated by Gadd45a interacting directly with XPG mRNA 
(Barreto, Schafer et al. 2007). Chromatin protein exchange of the oocyte-specific linker 
histone H1 by histone variants B4 or H1 also play a critical role in nuclear re-programming 
suggesting that maternally expressed linker histones determine nuclear dynamics in the 
context of embryonic toti-potency (Saeki, Ohsumi et al. 2005). One of the hindrances to 
nuclear re-programming is the fact that epigenetic memory of the donor cell may not get 
completely erased during nuclear transfer suggesting that epigenetic memory stabilizes 
normal development and can also lead to inefficient nuclear reprogramming (Gurdon and 
Melton 2008). Overexpression of the histone H3.3 has been documented to enhance parental 
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memory in transplanted nuclei where it interacts with the myogenic gene MyoD in non-
muscle lineages. As a corollary, it has also been observed that the association of a mutated 
histone H3.3 (H3.3 E4) with the promoter region results in elimination of this memory (Ng 
and Gurdon 2008) suggesting that the mechanisms of cellular re-programming would be 
amenable to epigenetic manipulations. 
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3.4. Cell fusion and cell extracts 
Re-programming by cell fusion refers to the process of fusing two different cells to form a 
heterokaryon and then adding a cell division inhibitor would allow for the nuclei to remain 
separate. The net effect sees the dominant more actively dividing cell impart its pattern of 
gene expression on its partner (Gurdon and Melton 2008). This phenomenon has been 
demonstrated for erythrocytes where its fusion with a growing cultured cell saw reactivation 
of the red cell nucleus along with a massive increase in its volume. The increase in volume 
was suggested to be due to an increase in RNA and/or DNA synthesis and was regulated by 
specific localizations of the chromatin on which the genetic synthesis took place (Harris 
1967).  Blau.et al induced the expression of muscle genes in non-muscle cells by fusing 
human amniocytes with differentiated murine muscle cells by means of polyethylene glycol. 
This generated a cell known as a heterokaryon where the parental cell nuclei remain distinct, 
do not divide and these cells retain a full complement of chromosomes. On the other hand, 
syncaryons are interspecific hybrids in which parental nuclei are combined and chromosomes 
are lost during cell division (Blau, Chiu et al. 1983). Primary murine muscle cells were fused 
with primary keratinocytes (representing ectoderm derivatives), fibroblasts (representing 
mesoderm derivatives) and hepatocytes (representing endoderm derivatives) with the result 
that all the three different types of cells were capable of activating a number of previously 
silent muscle gene cells, indicating that the differentiated state of a cell is amenable to genetic 
modifications (Blau, Chiu et al. 1985, Pomerantz and Blau 2004). This nuclear activation is 
believed to occur through the cytoplasm where the activators remain existent even after 
differentiation and are recognized by nuclei of other species (Blau, Chiu et al. 1983). In 
another study , human fibroblasts and foetal lung were merged with differentiated mouse 
muscle cells and it was observed that the enzyme MM-creatine kinase (CK) and 5.1H11 were 
detectable at comparable levels, irrespective of the presence or absence of the DNA synthesis 
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inhibitor cytosine arabinoside. Furthermore, muscle gene expression was not restricted to the 
G1 phase. The study thereby concluded that differentiation re-programming in heterokaryons 
is not dependent on the phase of cell cycle or DNA synthesis (Chiu and Blau 1984). The 
appeal behind the use of oocytes lies in the fact that they have the natural ability to re-
programme sperm nuclei with 100% efficiency without the need for a permanent genetic 
change of the fertilising sperm cell or of the resultant re-programmed embryo-like cells 
(Gurdon and Melton 2008).  However, this process is limited by severe ethical and 
humanitarian restrictions.  
 
Mammalian development is marked by a unidirectional progressive loss of developmental 
potential that causes a unicellular zygote to differentiate to give rise to a wide repertoire of 
220 specialized cell types in the mammalian body (Hochedlinger and Plath 2009). The 
process of induced pluripotency refers to re-programming a terminally differentiated cell type 
against its differentiation gradient to an immature pluripotent phenotype. The newly re-
programmed cells now acquires the characteristics of an embryonic stem cell in terms of 
morphology and differentiation ability (Takahashi and Yamanaka 2006, Takahashi, Tanabe et 
al. 2007, Yu, Vodyanik et al. 2007, Hochedlinger and Plath 2009). Induced pluripotent cells 
are also known as ‘iPS’ cells and were first established from mouse tail fibroblasts by Prof. 
Shinya Yamanaka’s group in Tokyo. Genetic manipulation of these somatic fibroblasts with a 
cocktail of 4 out of 24 factors tested defined pluripotency transcripts – Oct4, SOX2, Klf4 and 
C-Myc (OSKM). This 4 factor combination saw fibroblast cells gradually lose their somatic 
phenotype in that the cells no longer demonstrated the distinct elongated phenotype and the 
characteristic gene-expression pattern of a fibroblast was lost (Takahashi and Yamanaka 
2006).  These results were later reproduced using human adult fibroblasts to generate human 
iPS cells that would have extensive applications in research as well as regenerative medicine 
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(Takahashi, Tanabe et al. 2007). Since these latter iPS cells were formed through selection 
using the factor Fbx15 these iPS cells were termed Fbx15 iPS cells.I Ironically, in spite of 
their ability to form embryoid bodies and teratomas these cells demonstrated certain 
differences to embryonic stem cells in terms of embryonic stem cell transcript expression and 
failure to produce chimeras. To address this issue, Nanog selection (a factor previously 
declared as redundant in pluripotency re-programming) was used to generate Nanog iPS cells 
that resulted in viable chimeras as well as being more identical to human embryonic stem 
cells with respect to gene-expression profiling and DNA methylation patterns (Okita, 
Ichisaka et al. 2007). Nanog is one of the three core transcriptional factors in the pluripotency 
circuitry of embryonic stem cells (Boyer, Lee et al. 2005). Nanog deficiency results in 
abortive epiblasts and Nanog-deficient embryonic stem cells lose their characteristic 
pluripotent phenotype and differentiate into extra-embryonic endodermal lineage (Mitsui, 
Tokuzawa et al. 2003).   In addition, all the transgenes of Oct4, SOX2, Klf4 and C-Myc were 
strongly silenced in Nanog selected clones. However, 20% of the Nanog iPS-generated 
offspring developed tumours that were attributed to the reactivation of C-Myc gene (Okita, 
Ichisaka et al. 2007, Okita, Nakagawa et al. 2008). Although C-Myc plays an important role 
in maintaining murine embryonic stem cell self-renewal and pluripotency through the 
LIF/STAT3 pathway (Cartwright, McLean et al. 2005) it has been documented in human 
embryonic stem cells that it adversely affects pluripotency by causing apoptosis and 
differentiation in a transcriptional activity dependent manner (Sumi, Tsuneyoshi et al. 2007). 
Therefore, attempts were made at the induction of pluripotency in human cells without C-
Myc (Nakagawa, Koyanagi et al. 2008) by using only Oct4, SOX2 and Klf4 (Wernig, 
Meissner et al. 2008) and by using a slightly different combination of transcription factors, 
namely – Oct4, SOX2, Lin28 and Nanog (Yu, Vodyanik et al. 2007, Nakagawa, Koyanagi et 
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al. 2008). Hence, iPS generation without C-Myc in humans has been described to be more 
specific although the process is less efficient (Nakagawa, Koyanagi et al. 2008).  
 
Transgene integration has been another major cause for concern in using the iPS cell 
technology. The first iPS cell lines were established by mean of retroviral transduction in 
mouse (Takahashi and Yamanaka 2006) as well as human fibroblasts (Takahashi, Tanabe et 
al. 2007, Huangfu, Osafune et al. 2008, Lowry, Richter et al. 2008). In vitro transduction of 
cells with retrovirus has been shown to result in subsequent mutations that lead to the 
formation of neoplastic clones.I It has also been observed that SCID patients cured by means 
of retroviral gene therapy have consequently developed leukaemia thereby  inducing 
genotoxicity associated with retroviral integration (Nienhuis, Dunbar et al. 2006). Lentiviral 
transduction protocols for iPS generation (Yu, Vodyanik et al. 2007, Stadtfeld, Brennand et al. 
2008, Sommer, Stadtfeld et al. 2009, Anokye-Danso, Trivedi et al. 2011) target both dividing 
and non-dividing cells and have not been associated with the slow kinetics that is often seen 
with retroviral transduction methods that can only transduce actively dividing cells (Robinton 
and Daley 2012). Lentiviral transductions however are also associated with genomic 
integration as well as inefficient proviral silencing (Yu, Vodyanik et al. 2007, Stadtfeld, 
Brennand et al. 2008, Sommer, Stadtfeld et al. 2009, Anokye-Danso, Trivedi et al. 2011, 
Robinton and Daley 2012). A study by Judson and colleagues showed that the introduction of 
microRNAs, miR-291-3p, miR-294 and miR-295 increase the efficiency of re-programming 
in mouse through all four of the OSKM factors, most specifically through C-Myc which 
binds the promoter of the miRNAs (Judson, Babiarz et al. 2009). The transcriptional 
activation of  Oct 4 and SOX2 regulated miR-302 and translational inhibition of its target, 
Cyclin D1 which is an important regulator of the G1 phase of cell cycle  suggests a putative 
role for Oct4 and SOX2 in pluripotent cell cycle regulation (Card, Hebbar et al. 2008). As 
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expected, miRNA (302/367)-mediated iPS induction is highly efficient and rapid. The 
efficiency of this miRNA iPS induction can be further improved in conjunction with addition 
of the small molecule valproate and suppression of HDAC2 (Anokye-Danso, Trivedi et al. 
2011). Efficiency of lentiviral transduction can also be improved by adapting an inducible 
transduction protocol, this further allows for controlled expression of factors (Maherali, 
Ahfeldt et al. 2008, Stadtfeld, Maherali et al. 2008). An inducible lentiviral transduction 
protocol enabled the scrutiny of iPS induction, demonstrating for the first time that following 
10 days of ectopic transcript expression the successfully re-programmed cells start producing 
their own endogenous pluripotent transcript and enter a stable pluripotent state when the 
exogenous transcripts become redundant (Stadtfeld, Maherali et al. 2008). The doxycycline-
inducible lentiviral system also proved that doxycycline addition to human-iPS-derived 
differentiated cells resulted in secondary h-iPS cell lines with a 100 fold increased frequency, 
with a more rapid induction in keratinocytes when compared to fibroblasts (Maherali, Ahfeldt 
et al. 2008). To address the issue of lentiviral integration, Okita and colleagues used an 
adenovirus mediated transduction protocol and were initially unable to generate iPS cells 
using the  OSKM factors in 4 separate adenoviral vectors. However, iPS cell lines were 
successfully generated in mouse embryonic fibroblasts through repeated plasmid 
transfections of two different vectors, one containing the transcription factors Oct4, SOX2 
and Klf4 in a single construct and the other containing C-Myc alone (Okita, Ichisaka et al. 
2007). iPS generation through adenoviral transduction was also shown to be successful using 
a varied source of starting cell types such as tail tip fibroblasts, foetal liver cells and 
hepatocytes (Stadtfeld, Nagaya et al. 2008).  Adenoviral iPS induction protocols and plasmid 
transfections are transient procedures and do limit exogene integration. However, they are 
associated with very low transduction efficiencies, a technical hindrance addressed by 
PiggyBac transposition re-programming (Robinton and Daley 2012). The piggyBac, host-
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independent transposon technology catalyses the insertion of doxycycline-inducible 
pluripotent exogenes through the transposase enzyme. This phenomenon is transient and is 
benefitted by the fact that the piggyBac transposons possess natural ability to be excised once 
the pluripotent lines have been generated  (Woltjen, Michael et al. 2009). Another excisable 
system saw use of a floxed lentiviral transgene construct that could be excised through Cre-
recombinase once the stable pluripotent cell lines expressing endogenous embryonic stem 
cell genes were established (Somers, Jean et al. 2010). Using this strategy several normal and 
disease-specific (cystic fibrosis and α 1-AT deficiency as well as from individuals suffering 
from scleroderma and sickle cell disease) iPS lines were established through a single 
lentiviral stem-transcript cassette that encoded all the four pluripotent transcripts (Oct4, 
SOX2, Klf4 and C-Myc). Both the piggyBac transposon and  the lentiviral floxed stem cell 
cassette resulted in iPS induction with much improved efficiencies (from 0.001% in 
adenoviral systems to 0.1-1% in both the excisable systems) as well as resulting in lines that 
are devoid of any genomic integration (Somers, Jean et al. 2010, Robinton and Daley 2012). 
However, a common problem with both the excisable systems is that the technique involves 
the industrious process of screening of the excised lines to confirm transgene removal 
(Woltjen, Michael et al. 2009, Somers, Jean et al. 2010, Robinton and Daley 2012). Yet 
another approach to iPS generation involves using viral-free vectors such as small molecules 
(Kim, Kim et al. 2009), protein particles (Zhou, Wu et al. 2009), synthetic mRNA particles 
(Warren, Manos et al. 2010) and mature microRNA particles (Miyoshi, Ishii et al. 2011). 
Proteins such as cell-penetrating peptides provide direct delivery of re-programming factors 
to target fibroblasts to generate stable iPS lines and this technique obviates the use of 
genome-integrating and/or mutagenic materials (Kim, Kim et al. 2009). Another study 
generated iPS lines from mouse embryonic fibroblasts by using recombinant cell-penetrating 
proteins; however the protein-based delivery techniques have been associated with low 
 55 
 
efficiency and requirements for generation of large quantities of pure proteins (Zhou, Wu et 
al. 2009, Robinton and Daley 2012). Synthetic mRNA molecules can also be used to re-
programme differentiated cells to RNA-iPS cells. The very same methodology can again be 
used to differentiate the RNA-iPS cells into desired lineage cell types (Warren, Manos et al. 
2010). To summarise, the traditional methods for iPS generation are DNA-based (retroviral 
(Takahashi and Yamanaka 2006, Takahashi, Tanabe et al. 2007, Huangfu, Osafune et al. 
2008, Lowry, Richter et al. 2008), lentiviral (Yu, Vodyanik et al. 2007, Sommer, Stadtfeld et 
al. 2009, Somers, Jean et al. 2010, Anokye-Danso, Trivedi et al. 2011) , piggyBac (Woltjen, 
Michael et al. 2009) as well as plasmid based induction methods (Okita, Nakagawa et al. 
2008)) ; DNA-free re-programming methods are mostly dependent on RNA-based delivery 
systems and include induction through cell-penetrating proteins (Kim, Kim et al. 2009, Zhou, 
Wu et al. 2009), synthetic mRNAs (Warren, Manos et al. 2010) , mature microRNA (Miyoshi, 
Ishii et al. 2011) and through the RNA-free Sendai virus (Fusaki, Ban et al. 2009).   
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3.5.Mechanism of lineage re-programming 
 
Early studies proved the process of re-programming to be a stochastic process whereby all the 
cells were amenable to being re-programmed to pluripotency on constant growth and 
transcription factor expression (Hanna, Saha et al. 2009). The other model demonstrating the 
re-programming mechanism comprised the elite model where only a small number of cells 
can be re-programmed either partially or to the fully re-programmed state, this can again 
either refer to the induced elite model or the pre-determined elite state (Yamanaka 2009).   
Evidence for the pre-determined elite state comes from studies that used un-differentiated 
stem-cells and showed that cells that were not yet lineage restricted were more amenable to 
the re-programming process. Specific examples include the study on nuclear re-programming 
where it was observed that higher re-programming efficiencies were obtained from the nuclei 
of immature cells (such as neural-stem cells and embryonic stem cells) than from terminally 
differentiated nuclei (such as from lymphocytes differentiated from neuronal progenitor cells) 
(Blelloch, Wang et al. 2006). Multi-lineage differentiating stress-enduring or ‘Muse’ cells 
were identified as a population of SSEA3+/CD105+ stress-resistant cells that can self-renew, 
grow in colonies that show a pluripotent stem cell gene expression profile, represent the three 
germ layers in vitro and in vivo these homed into damaged skin, muscle and liver cells to 
ultimately differentiate into cytokeratin 14+ (ectoderm), dystrophin+ (mesoderm) and 
albumin+ (hepatic-endoderm) cells respectively. In addition, these Muse cells were primarily 
isolated from cultured skin fibroblasts, bone marrow stromal cells or bone marrow aspirates 
(Kuroda, Kitada et al. 2010). Muse cells are more amenable to re-programming suggesting 
that human fibroblast cells contain a proportion of adult stem cells that show greater 
propensity towards being induced to a fully re-programmed state.I It has also been seen that 
iPS-like cells generated from the non-Muse cells were not fully re-programmed (Wakao, 
 57 
 
Kitada et al. 2011). The pre-determined elite model of re-programming also raises the 
question of whether during re-programming there is an actual re-setting of a terminally 
differentiated cell’s phenotypic and genotypic constitution to an embryonic state or whether 
the process simply involves mere de-differentiation of an already immature cell towards 
greater lineage-plasticity (Yamanaka 2009).  
 
However, it has been recently shown that re-programming in mouse comprises an early 
stochastic and a late hierarchical stage. The early stochastic stage comprises a marked 
variation between individual cells with respect to their gene expression profiles with Esrrb, 
Utf1, Lin28 and Dppa2 acting as markers that reliably predict cells most prone to the re-
programming process. This is followed by activation of Sox2 that initiates a later 
deterministic hierarchical phase marked by the up-regulation of factors not including Oct2, 
Sox2, Klf4, Nanog but involving a cohort of other genes , including Esrrb, Sall4 and Lin28. 
These downstream factors are sufficient to activate the pluripotent circuitry and result in 
stable iPS lines (Buganim, Faddah et al. 2012).  
 
Transcription factor-induced re-programming has been shown to involve epigenetic 
modifications whereby the epigenome of a differentiated somatic cell is altered to that of an 
embryonic stem cell-like state, X-chromosome reactivation was seen in female iPS lines 
which again showed random X-inactivation upon differentiation   (Maherali, Sridharan et al. 
2007). H3K4 trimethylation is associated with active transcription of genes (Bernstein, 
Kamal et al. 2005, Kim, Barrera et al. 2005) while H3K27 trimethylation   is associated with 
the silencing of genes  (Boyer, Plath et al. 2006, Lee, Jenner et al. 2006). Genome-wide 
analysis of these two key histone elements confirmed that successful iPS induction involves 
the epigenetics of the target cells to be reset to an immature state (Maherali, Sridharan et al. 
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2007). However, partially re-programmed cells show reactivation of only certain embryonic 
transcripts, incomplete suppression of lineage-specifying transcripts (which can be addressed 
by the use of RNA inhibitors) and DNA hypermethylation  at pluripotency-loci, suggesting 
that DNA methyltransferase inhibitors can be used to facilitate the re-programming process 
(Mikkelsen, Hanna et al. 2008). Furthermore, in partially re-programmed cells genes co-
occupied by C-Myc and any of SOX2, Oct4 and Klf4 factors show pluripotent cell binding 
pattern and the relevant expression profile. However,  genes that are co-bound by Oct4, 
SOX2 and Klf4 in embryonic stem cells and those that encode pluripotency regulators lack 
binding and are not transcriptionally activated in incomplete re-programming. It has been 
suggested that exogenous c-Myc acts before activation of the pluripotency determinants 
(Sridharan, Tchieu et al. 2009). Upon retroviral transduction, increased expression of SSEA1 
and down-regulation of Thy1 allowed identification of cells during the different phases of re-
programming.Whilst Thy1 down-regulation occurs in most of the cells, activation of SSEA1 
and other pluripotency regulators occurs at very low frequency suggesting the role of 
epigenetic barriers in the iPS induction protocol (Sridharan, Tchieu et al. 2009).  
 
The re-programming process in mice is marked by three phases – initiation, maturation and 
stabilisation with the initiation phase being chiefly dominated by a mesenchymal-epithelial 
transition (MET) phase (Samavarchi-Tehrani, Golipour et al. 2010).The initiation phase is a 
reversible phase marked by an up-regulation of epithelial genes such as Cdh1, Epcam, Crb3 
and Ocln  and a down-regulation in mesenchymal genes such as Snail, Slug, ZEB1 and ZEB2 
(Li, Liang et al. 2010, Samavarchi-Tehrani, Golipour et al. 2010). The MET phase in mice 
appears before SSEA-1 can be detected and is marked by a change in morphology of the cells 
from elongated spindle-shaped fibroblasts to rounded cobble-stone shaped clusters of cells 
that form well-defined intercellular junctions and express increased cytokeratin from day 5 
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post-transduction. The induction of MET in mouse fibroblasts was more rapid with OSKM 
than with Oct4, SOX2 and Klf4 combination (Li, Liang et al. 2010). Oct4, SOX2, Klf4 and c-
Myc also down-regulate miRNAs, miR-155 and miR-10b, which are associated with EMT 
(Ma, Teruya-Feldstein et al. 2007, Kong, Yang et al. 2008). The same transcription factors 
are associated with the down-regulation of miR-205 and -429 which bring about a MET by 
targeting transcription factors, Zeb1, Zeb2 and Sip1 (Gregory, Bert et al. 2008, Park, Gaur et 
al. 2008, Li, Liang et al. 2010). This transcript change was further reflected by a change in 
the behaviour of the cells that acquired a marked reduction in invasiveness following MET 
(Li, Liang et al. 2010). A well-known EMT inducer TGF-β, that partly acts through Snail 
(Peinado, Quintanilla et al. 2003) has been documented to act as an obstacle to nuclear 
reprogramming and iPS induction (Maherali and Hochedlinger 2009). As expected, it has 
also been proved that TGF-β 1, TGF-β 2 and TGF-β 3 all hinder the initiation phase of iPS 
induction by preventing MET. Activin-A however, which also belongs to the  TGF-β family 
was noted to have no effects on iPS induction (Li, Liang et al. 2010). TGF-β cytokines bind 
to TGFβR-2 leading to recruitment of TGFβR-1 to the complex , this ligand binding event 
causes autophosphorylation of the complex (Shi and Massagué 2003) and triggers a 
signalling cascade that activates Snail.I In this whole process TGFβR-3 acts as a co-receptor 
(Li, Liang et al. 2010). Yamanaka factors, OSKM brings about a reduction in levels of 
TGFβR-2 and TGFβR-3, although levels of TGFβR-1 remain unchanged. SOX2 and Oct4 
supress TGFβR-3. Oct4 and Klf4 supress TGFβ-3 and c-Myc supresses TGFβ-1 and TGFβR-
2. However, it has been seen that c-Myc is indispensable in the complete repression of the 
TGFβ pathway (Takahashi and Yamanaka 2006, Li, Liang et al. 2010). The initial 8 days of 
fibroblast re-programming is also marked by a reduction in fibroblast specific genes such as 
Thy1, following which there is a gradual increase in levels of SSEA1. However, the process 
of re-programming is not yet irreversible at this stage and very few of the Thy
low
SSEA1
hi 
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cells move on through maturation to the stabilisation phase (Stadtfeld, Maherali et al. 2008, 
Li, Liang et al. 2010). Reduction in levels of Thy1 is the earliest detectable change during re-
programming followed by an up-regulation in levels of SSEA-1 which increases once the 
cells become independent of the exogene. The transition phase in mouse is marked by re-
activation of embryonic transcripts Fbx15, Nanog, Oct4, Sox2, telomerase and also by X-
inactivation (Brambrink, Foreman et al. 2008, Stadtfeld, Maherali et al. 2008). Also, fully re-
programmed cells are dependent on the ectopic pluripotent transcripts during the first 12 days 
of iPS induction following which they start producing their own endogenous pluripotent 
genes and do not rely anymore on the exogenes.  The cells now enter the stabilisation phase 
(Brambrink, Foreman et al. 2008). The ‘pre-determined’ elite model however has been 
challenged by the fact that beyond fibroblasts, lineage-committed cells can also be re-
programmed to a pluripotent state (Yamanaka 2009). Skin keratinocytes have proved to re-
programme with higher efficiencies (Aasen, Raya et al. 2008) and it has also been shown that 
iPS cells can be derived from several types of adult somatic cells such as hepatocytes (Aoi, 
Yae et al. 2008, Lee, Seo et al. 2012), gastric mucosa cells (Aoi, Yae et al. 2008), pancreatic 
β cells (Bar-Nur, Russ et al. 2011) and terminally differentiated B lymphocytes (Hanna, 
Markoulaki et al. 2008). These models argue more in favour of the stochastic re-
programming phenomenon. The induced elite model hypothesises that several genes besides 
the 4 iPS induction factors need to be induced or silenced through viral integration into the 
host genome (Yamanaka 2009). However, this very clause defines viral integration to be a 
critical process for iPS induction which is controversial given  that iPS re-programming can 
be carried out through several non-genome-integrating transduction mechanisms such as 
through adenovirus (Stadtfeld, Nagaya et al. 2008, Zhou and Freed 2009), plasmids (Okita, 
Nakagawa et al. 2008), small molecules (Warren, Manos et al. 2010, Chen, Gulbranson et al. 
2011) as well as DNA-free RNA-based transcription-factor delivery systems (Fusaki, Ban et 
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al. 2009, Kim, Kim et al. 2009, Zhou, Wu et al. 2009, Warren, Manos et al. 2010, Miyoshi, 
Ishii et al. 2011) . Also, it has been shown that epithelial cell and other types of cells from 
liver, gastric mucosa and skin are less prone to viral integration (Aasen, Raya et al. 2008, Aoi, 
Yae et al. 2008). These cells did not show any common viral genome-integration sites 
diminishing kudos for the induced elite models. Furthermore, re-programming techniques 
that use episomal DNA vectors have seen the episomal DNA to disappear spontaneously over 
time (Yu, Hu et al. 2009) . Nevertheless, the high efficiency seen with retroviral transduction 
protocols (Robinton and Daley 2012) would suggest that viral genome integration does 
contribute towards accelerating the iPS induction process. Insertional mutagenesis does 
promote iPS induction possibly by affecting several other endogenous genes that ultimately 
lead to increased proliferation, decreased apoptosis as well as increased iPS induction rates 
(Hargrove, Kepes et al. 2008, Hawley 2008, Robinton and Daley 2012).   
 
The stochastic iPS induction model states that most cells in the body are susceptible to the re-
programming process given that the pluripotency re-programming transcripts collectively re-
set the epigenetics of the differentiated cells to an embryonic state (Hanna, Saha et al. 2009). 
During the process of development, normal cells roll down the slope of differentiation to their 
destined lineage. However, embryonic stem cells possess a special epigenetic status that 
prevents them from differentiating through specific epigenetic road-blocks that allow the 
cells to move from a totipotent to a pluripotent state but obstruct their journey further down to 
the multipotent and terminally differentiated unipotent states (Hochedlinger and Plath 2009). 
There are two critical factors for re-programming to be successful –firstly the expression of 
the four pluripotency determining transcripts must be at a level that is sufficient to move the 
cells towards the right direction and secondly that the epigenetic road-block is indispensable 
in confining the cells to the particular pluripotent state even after the expression of the 
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exogenes are silenced (Hochedlinger and Plath 2009). Both these events are however 
controlled stochastically as it is impossible to control the expression levels of the 
pluripotency transcripts as well as to achieve the necessary epigenetic road-block events 
through the re-programming factors (Hochedlinger and Plath 2009). However, this 
underscores the role that epigenetic mechanisms such as DNA methylation and histone 
modifications would play in the whole re-programming process (Hochedlinger and Plath 
2009).   
 
The next important rate-limiting step in the re-programming process is the stoichiometry 
between the different pluripotency transcripts during iPS induction. If the balance between 
the re-programming factors is not correct then this results in failed re-programming and/or 
formation of partially re-programmed cells (Carey, Markoulaki et al. 2011). Cells from 
different organs show varying plasticity with respect to the re-programming process. One of 
the reasons for this is that different cells carry different levels of endogenous pluripotency 
transcripts. For instance, excess levels of Oct4 and SOX2 are detrimental to the maintainence 
of pluripotency (Radzisheuskaya, Le Bin Chia et al. 2013). Furthermore, it has been observed 
in neural stem cells that already contain higher levels of endogenous SOX2, that iPS 
induction is a lot more efficient without the addition of SOX2 exogene transcript to the re-
programming cocktail (Eminli, Utikal et al. 2008, Kim, Zaehres et al. 2008). Improper 
balance between the different pluripotent factors leads to incomplete re-programming and 
senescence/apoptosis (Carey, Markoulaki et al. 2011). Another factor that influences the re-
programming process is the integration pattern following re-programming. This, along with 
the amount, stoichiometry, continuity and silencing of the exogenes can be controlled by the 
gene delivery system (Yamanaka 2009). Also a favourable integration pattern can be attained 
by using cells that would already contain a re-programming competent integration pattern 
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(Maherali, Ahfeldt et al. 2008, Wernig, Lengner et al. 2008). This was demonstrated by the 
observation that fibroblast cells obtained through differentiation of iPS cells were a lot more 
amenable to enable ‘secondary iPS’ cell line generation (Wernig, Lengner et al. 2008). 
Furthermore, the piggyBac system of iPS generation has shown the efficiency of re-
programming to be approximately 20%, further underscoring the relevance of attaining 
appropriate transgene integration for successful pluripotency re-programming (Woltjen, 
Michael et al. 2009).   
The various mechanistic steps in iPS-reprogramming is summarised in Figure 1.4  
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Figure.1.4. Flowchart summarising the mechanism of iPS reprogramming 
 
 
 
Target somatic cell: eg. Fibroblast cell  
Transduction with pluripotent transcripts Week 1 
Messenchymal to Epithelial transition (MET), reversible process 
 Downregulation of mesenchymal markers like TGFβ and TGF-β receptors, SNAIL , Slug 
 Upregulation of epithelial markers like E-Cadherin 
 Up-regulation/activation of endogenous pluripotent transcript such as NANOG, Oct-4 
and SOX2 
 Cells become independent of the added exogene  
Week 2 
iPS colonies  
Week 4-6 
 65 
 
3.6.Epigenetics of iPS re-programming 
Based on their epigenetic potential, stem cells have been assigned different names that reflect 
their differentiation abilities – each specific stem cell population (eg: totipotent cells, 
pluripotent cells, multipotent cells and unipotent cells) will have a distinct epigenetic pattern 
that will determine its lineage plasticity (Figure 1.4) (Yamanaka 2009). It is therefore 
absolutely essential that when moving from a differentiated epigenetic state to the embryonic 
state, the initial de-differentiated status is inactivated (Stadtfeld, Maherali et al. 2008, 
Hochedlinger and Plath 2009). Lineage specific genes include (although are not limited to) 
Gata6, SOX9 and Pax7 and failure to completely inactivate these genes results in partial re-
programming (Mikkelsen, Hanna et al. 2008). Knockdown of these lineage-specific genes 
results in efficient transition from the partial to the fully re-programmed state. Treating 
partially re-programmed cells with extra-cellular signal-related kinase (ERK) and glycogen 
synthase kinase-3 (GSK3)/ Wnt signalling cascades also promotes partially re-programmed 
cells to attain the fully re-programmed state (Silva, Barrandon et al. 2008, Ying, Wray et al. 
2008). Another critical factor is the repression of differentiation-associated HOX cluster of 
genes by the SET domain protein, Blimp1 for the maintenance of primordial germ cells in 
vivo. This further suggests the importance of silencing differentiation specific genes in 
attaining the fully re-programmed state (Ohinata, Payer et al. 2005). The fully re-
programmed iPS state can be only achieved once the endogenous loci of the relevant 
pluripotency factors are indefinitely activated through proper DNA methylation. Failing this, 
the cells would roll down the epigenetic slope back to their initial differentiated state 
(Yamanaka 2009). The promoter regions of most pluripotency genes are methylated in 
somatic cells but are hypomethylated in embryonic stem cells. DNA demethylation of these 
regions is very important for successful iPS re-programming (Imamura, Miura et al. 2006, 
Mikkelsen, Hanna et al. 2008, Yamanaka 2009). The OSKM/OSLN factors do not have 
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intrinsic demethylation properties and therefore iPS generation can be enhanced by using 
demethylation-promoting agents such as 5-azacytidine (Mikkelsen, Hanna et al. 2008). 
Histone modifications are also important in iPS reprogramming – in all pluripotent cells 
hsitones H3 and H4 are hyperacetylated in the promoter regions of pluripotency associated 
genes (Yamanaka 2009). Un-differentiated target cells must undergo critical histone 
modification from their initial hypoacetylated state to a hyperacetylated state (Imamura, 
Miura et al. 2006, Yamanaka 2009). This may be brought about by c-Myc which has the 
ability to recruit histone acetyltransferases to target genes (Knoepfler, Zhang et al. 2006). 
Valproic acid is also a histone deacetylase inhibitor which has been proven to enhance the 
efficiency of iPS generation (Huangfu, Osafune et al. 2008).  
Another important observation is the fact that silencing of the differentiation-related genes 
occurs prior to up-regulation of pluripotency genes. This suggests that the differentiation state 
of the cell does influence its susceptibility to iPS re-programming (Hanna, Markoulaki et al. 
2008, Hochedlinger and Plath 2009). One of the reasons why stem cells such as adult stem 
cells may re-programme with higher efficiency can be explained by the fact that they share 
transcriptional regulators such as Zinc finger protein X-linked (Zfx) and SOX2 with 
embryonic stem cells (Galan-Caridad, Harel et al. 2007, Hochedlinger and Plath 2009). Also, 
neural stem cells and keratinocyte stem cells give rise to cloned mice more readily than do 
mature fibroblasts, neurons and transit amplifying cells (Aasen, Raya et al. 2008, Eminli, 
Utikal et al. 2008, Kim, Zaehres et al. 2008). However, it has also been shown that in the 
haematopoietic system, nuclei of differentiated granulocytes are more competent donor cells 
for nuclear transfer than haematopoietic stem cells (Inoue, Ogonuki et al. 2006, Sung, Gao et 
al. 2006). The identity of the starting cell that gives rise to the iPS cell as yet remains 
ambiguous. To address this issue, two sets of experiments were cperformed in two different 
systems - in the pancreas and in the haematopoietic systems (Hochedlinger and Plath 2009).  
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Hanna et al. attempted to re-programme B-lymphocytes into iPS cells, B cells carry 
differentiation-associated DNA rearrangements that identify their differentiation state.  It was 
seen that expression of the OSKM exogenes alone was ineffective in re-programming the 
cells to an iPS state (Hanna, Markoulaki et al. 2008). This was even true for ‘secondary iPS’ 
lines that would have potentially contained at least competent integration sites for complete 
re-programming (Wernig, Lengner et al. 2008) . The only way iPS lines were generated was 
through either additional overexpression of Cebpα or by knock-down of Pax5 as an  addition 
to OSKM transduction (Hanna, Markoulaki et al. 2008). Ectopic expression of Cebpα leads 
to downregulation of Pax5 and reduced levels of Pax5 have been associated with 
multipotency in B cells (Nutt, Heavey et al. 1999). Pro-B cells were re-programmed with 
higher efficiency and this study showed that even in the haematopoietic system the 
differentiation state influences iPS re-programming (Hanna, Markoulaki et al. 2008). In a 
different study that used terminally differentiated pancreatic β cells as target cells for re-
programming, successful re-programming of the differentiated cells using 4 pluripotency 
transcripts was achieved. The authors concluded that de-differentiated cells are not 
selectively targeted during the re-programming process (Stadtfeld, Brennand et al. 2008). 
This latter result is consistent with Sung’s work where they asserted that their study 
unambiguously confirmed that contrary to conventional belief the differentiation state of a 
cell does not play any role in cellular re-programming (Sung, Gao et al. 2006). However, 
pancreatic β cells belong to the endodermal lineage and it has been suggested that cells of the 
endodermal lineage (including cells such as liver and gastric mucosa cells) are more 
susceptible to pluripotency re-programming than cells like fibroblasts and haematopoietic 
cells which are of mesodermal origin (Hochedlinger and Plath 2009). Also, systems with 
definitive cellular hierarchy are more difficult to re-programme as the cellshave to be pushed 
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through several tiers of the lineage before they can reach pluripotency, as opposed to cells 
that multiply through self-duplication (Hochedlinger and Plath 2009).  
 
During transcriptional activation transcription factors bind to the distal enhancer and 
promoter elements which lead to recruitment of co-activators that facilitate binding of the 
general transcriptional machinery and assembly of RNA polymerase-II-containing pre-
initiation complex (PIC) at the core promoter (Hochedlinger and Plath 2009, Yamanaka 2009, 
Robinton and Daley 2012). Packaging of DNA into nucleosomes also influences 
transcriptional events such as transcription factor binding, PIC formation as well as 
transcriptional elongation. Transcription factor binding is further affected by chromatin 
structure such as DNA methylation, histone modifications and variants as well as ATP-
dependent chromatin remodelling (Hochedlinger and Plath 2009). In differentiated cells, the 
loci for pluripotency remains in an unfavourable conformation for transcription factor 
binding (Hochedlinger and Plath 2009). However, it is believed that the reprogramming 
factors (most specifically OSKM) bind closed chromatin and induce favourable conformation 
changes before transcriptional changes are in place (Sridharan, Tchieu et al. 2009). 
Reprogramming is primarily a multistep process requiring cell division whereby target cells 
go through a number of transitional states to finally reach the pluripotent state (Samavarchi-
Tehrani, Golipour et al. 2010, Buganim, Faddah et al. 2013). Each transition is marked by a 
distinct gene-expression profile (Stadtfeld, Maherali et al. 2008, Robinton and Daley 2012). 
When dealing with heterogeneous cell populations it has been shown that the efficiency of re-
programing can be improved by selecting for cells that would be more poised to reach the 
‘ground state’ (Robinton and Daley 2012). This can be attained by selecting for cells 
expressing certain cell-surface marker-profiles and by selectively advancing these cells 
through to the final maturation and stabilisation phases (Robinton and Daley 2012). Markers 
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that become down-regulated include tissue-specific or differentiation-specific markers such 
as Thy1 (for fibroblasts). In the study herein, it has been shown that the prostatic marker, 
androgen receptor becomes down-regulated during the course of prostate-specific iPSC 
generation (Moad, Pal et al. , Stadtfeld, Maherali et al. 2008).  
 
The initial stages of iPS re-programming tend to be reversible and a majority of cells that 
pass through the initial transition tend to regress back through differentiation. A very small 
proportion of target cells attain the stable ‘pluripotent state’(Li, Liang et al. 2010). The fate of 
a cell through to the pluripotent stages is marked by distinct epigenetic changes and a 
characteristic gene expression profile. In murine cells, SSEA1 positive cells tend to be 
incompletely re-programmed in that they often tend to regress back to a Thy1 positive 
phenotype (Stadtfeld, Maherali et al. 2008). In human cells it has been reported that alkaline 
phosphatase, Gdf3, hTERT and NANOG do not identify with the fully re-programmed state 
(Chan, Ratanasirintrawoot et al. 2009). The initial stage of iPS induction in fibroblast cells is 
marked by a mesenchymal-epithelial transition that is identified by a down-regulation in 
mesenchymal transcripts such as SNAI1, SNAI2, Zeb1 and Zeb2 and an up-regulation in 
epithelial markers such as E-Cadherin, EpCam and Ocln (Li, Liang et al. 2010, Samavarchi-
Tehrani, Golipour et al. 2010).  These changes are accompanied by morphological alterations 
such as reduction in cell size, increase in nuclear-cytoplasmic ratio, increased proliferation 
and formation of cell clusters (Moad, Pal et al.). TGF-β is also known to play an important 
role in the initiation phase whereby TGF-β inhibition promotes the initiation phase in iPS 
induction by replacing SOX2 and cMyc. E-616452 (RepSOX or replacer of SOX2), a small 
molecule inhibitor of TGFbR1/alk5 kinase inhibitor has been shown to promote iPS induction 
by replacing SOX2 through NANOG induction (Ichida, Blanchard et al. 2009, Maherali and 
Hochedlinger 2009). This MET (mesenchymal-epithelial transition) phase is then followed 
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by a gradual up-regulation in embryonic stem cell genes. In mice, NANOG and Sall4 are up-
regulated at a later stage while Utf1 and endogenous SOX2 are induced right at the end of the 
iPS re-programming process (Samavarchi-Tehrani, Golipour et al. 2010, Buganim, Faddah et 
al. 2013). In humans, the first step of iPS re-programming involves down-regulation of the 
differentiation marker CD13 on day 2 of the induction protocol. This is followed by an up-
regulation in SSEA-4 on day 2 to day 6 and up-regulation of Tra-1-60 and NANOG on day 6-
13 (Chan, Ratanasirintrawoot et al. 2009) . In human cells it has been noted that an up-
regulation of nuclear NANOG as well as SSEA4 does not denote a completely re-
programmed state, in fact the majority of SSEA4
+
Tra-1-60
+
 cells tend to either undergo 
senescence or apoptosis or remain in an incompletely re-programmed state. It has also been 
shown that pro-viral silencing as well a Hoerscht
dim
 cell phenotype identifies more strongly 
with complete re-programming. This is in addition to the cells up-regulating three other 
pluripotency markers – Tra-1-60, DNMT3b and REX1 (Chan, Ratanasirintrawoot et al. 2009).  
 
Pro-viral silencing is an important step in the re-programming process. Once cells are 
completely re-programmed they start producing their own endogenous pluripotency 
transcripts; this usually occurs at around day 14 of re-programming when exogene 
dependence is no longer important, and exogene silencing is critical at this stage (Chan, 
Ratanasirintrawoot et al. 2009). Another crucial step in iPS re-programming to the fully 
embryonic ground state is reactivation of the silent X chromosome. This occurs late in the 
iPS induction process and is identifiable with fully re-programmed cells (Maherali, Sridharan 
et al. 2007, Stadtfeld, Maherali et al. 2008). 
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Figure 1.4. The development potential of stem cells at different stages of development. The 
natural tendency for cells is to flow downwards along their differentiation gradient. Hence, it 
is very difficult to arrest cells when pushed up against their natural differentiation gradient. 
This can be achieved only once some sort of epigenetic road-block has been applied that 
would retain the re-programmed cells in their de-differentiation state. Figure adapted from 
(Hochedlinger and Plath 2009) . 
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3.6.Applications of iPS technology  
 
The iPS technology has found wide-spread applications in both research and clinics. In 
research, it has contributed significantly to the understanding of developmental biology most 
specifically with regards to transcriptional and epigenetic events that regulate development in 
human and murine-based models. It has greatly expanded our knowledge in analysing certain 
canonical signalling pathways, for example the Wnt pathway (Menendez, Yatskievych et al. 
2011), TGF-β signalling and epithelial-mesenchymal-transition signalling pathways, p53 
signalling, role of Oct4, SOX2 and NANOG as the core pluripotency network, activin/nodal 
signalling (Vallier, Touboul et al. 2009), role of SMAD signalling in directing differentiation 
towards a neural route (Chambers, Fasano et al. 2009, Menendez, Yatskievych et al. 2011) as 
well as elaborating the role of several transcriptional factors (such as Oct4, NANOG, Lin28, 
c-Myc, Klf4, Fbx15, EpCam, E-Cadherin and hTERT to name a few. The iPS technology 
also serves as a model to evaluate epigenetic events regulating normal development. For 
example, it suggests that all somatic cells in principle retain considerable developmental 
potential. The inherent ability of a cell to be returned to a primitive lineage-unrestricted state 
is further dependent upon several criteria such as its inherent plasticity, its molecular make-
up with respect to endogenous transcripts as well as its in vitro robustness against apoptosis 
and senescence.  Re-programming somatic cells to an embryonic stem cell state reveals 
critical information with regards to DNA methylation patterns, chromatin remodelling in 
cellular development and lineage plasticity. Also, it has now been shown that most somatic 
cells retain developmental potential not only to a generic embryonic phenotype but 
intercellular transitions are also possible through direct trans-differentiation-based 
reprogramming. This would hint that perhaps there is an alternative pathway in the 
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developmental hierarchy that can lead a differentiated cell type to a very different cell type 
without having to first go through embryonic lineage plasticity (Ieda, Fu et al. 2010). 
However, recently fibroblast cells have been directly re-programmed to an angioblast-like 
stage by first pursuing a state of intermediate plasticity when the cells have been transduced 
by the traditional OSKM factors but have absent pluripotent marker expression and are 
identifiable with a mesodermal progenitor-like state. These CD34
+
 cells are then able to 
directly give rise to functional endothelial and smooth muscle cells (Kurian, Sancho-Martinez 
et al. 2013). There are several papers demonstrating direct conversion of fibroblasts cells into 
cortical excitatory neurons through Ascl1, Brn2 and Myt1l (Vierbuchen, Ostermeier et al. 
2010) , direct conversion of pancreatic exocrine cells into insulin-producing endocrine cells 
(Zhou, Brown et al. 2008) and conversion of fibroblast cells to macrophage cells by means of 
PU.1 and C/EBPα/β (Feng, Desbordes et al. 2008). Another study demonstrated that by 
means of three combinations of two transcription factors, namely Hnf4α and either of FoxA1, 
FoxA2 or FoxA3 mouse embryonic and adult fibroblasts can be directly converted into 
hepatocyte-like cells (Sekiya and Suzuki 2011). Also, cardiac as well as dermal fibroblast 
cells can be directly trans-differentiated into functional cardiomyocytes by a combination of 
merely three transcriptional factors – Gata4, Mef2c and Tbx5 (Ieda, Fu et al. 2010). A very 
recent development to the lineage-re-programming technology has been in vivo re-
programming of cells, the re-programming of non-cardiomyocytes into functional 
cardiomyocytes in vivo (Hansson and Chien 2012, Song, Nam et al. 2012) with one study 
demonstrating this through only three transcription factors GMT or Gata4, Mef2c and tbx5 
(Qian, Huang et al. 2012). 
 
A critical application of the iPS technology has been in the field of clinical and translational 
research where these cells have been used to model several disease states. Disease-specific 
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iPS models potentially provide information on the natural history and progression of diseases 
(Robinton and Daley 2012). They reveal a substantial amount of information on the genetic 
and signalling aberrations instrumental in pathogenesis of disease states and thereby provide 
in vitro models for drug modelling as well as drug screening (Park, Arora et al. 2008, Somers, 
Jean et al. 2010, Robinton and Daley 2012). They further serve as tools on which therapeutic 
efficacy as well as potential toxicities can be evaluated in the first instance. These cells also 
serve as suitable models to test potential gene therapies since genetically faulted cells can be 
re-programmed, the gene defect can be corrected and the modified cells can then be 
differentiated to study molecular effects of gene therapy. Figure 1.5 describes the various 
disease-specific iPS models. These cells also have immense value in regenerative medicine 
where they can be used for tissue regeneration in disease-states such as organ failure as well 
as tissue reconstruction following injury and following surgical resection in malignancies 
(Soldner, Hockemeyer et al. 2009) .  
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System Disease Molecular defect of donor 
cell 
Cell type differentiated 
from iPS cell 
Neurological 
Disease 
Amyotrophic lateral 
saclerosis 
Heterozygous Leu144Phe 
mutation in SOD1 
 Motor neurons 
 Glial cells 
Spinal Muscular 
Atrophy 
Mutations in SMN1 
 
 Neurons 
 Astrocytes 
 Mature motor 
neurons 
Parkinson’s Disease Mutations in 
 LRRK2 
 SNCA 
Dopaminergic neurons 
Huntingtons disease 72 CAG repeats in the 
Huntington gene 
None 
Down’s syndrome Trisomy 21 Teratoma with tissue from 
each of the three germ 
layers 
Schizophrenia Complex trait Neurons 
Haematological 
Disease 
Fanconi’s Anaemia FAA and FAD2 corrected Haematopoietic cells 
Sickle Cell Anaemia Homozygous HbS mutation None 
Β-thalassaemia Homozygous deletion in the 
β-globin gene 
 
 
Polycythemia Vera Heterozygous Val617Phe Haematopoietic 
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mutation in JAK2 progenitors 
(CD34
+
CD35
+
) 
Metabolic Disease Type I diabetes Multifactorial, unknown β-Cell-like cells (express 
somatostatin, glucagon 
and insulin; glucose-
responsive) 
Gaucher’s disease, 
type III 
Mutation in GBA None 
Α1-antitrypsin 
deficiency  
Homozygous mutation in the 
α1-antitrypsin gene 
Hepatocyte-like cells 
(foetal) 
Type1 Long QT 
syndrome 
Dominant mutation in 
KCNQ1 
Cardiomyocytes 
Cardiovascular 
Disease 
Type II Long QT 
syndroma 
Dominant mutation in 
KCNH2 
Cardiomyocytes 
SCID or leaky SCID Mutation in RAG1 None 
Primary 
Immunodefficiency 
Herpes Simplex 
Encephalitis 
Mutation in STAT1 or TLR3 Mature cell types of CNS 
Duchenne 
musculodystrophy 
Deletion in dystrophin gene None 
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Other category Becker Muscular 
Dystrophy 
Unidentified mutation in 
dystrophin 
None 
Cystic fibrosis Homozygous deletion in 
CFTR 
None 
Friedreich’s Ataxia Trinucleotide GAA repeat 
expansion in FXN 
 Sensory neurons 
 Peripheral neurons 
cardiomyocytes 
Retinitis Pigmentosa Mutations in 
 RP9 
 RP1 
 PRPH2 OR 
RHO 
 Retinal progenitors 
 Photoreceptor 
precursors 
 Retinal-pigment 
epithelial cells 
 Rod photoreceptor 
cells 
Scleroderma  Unknown  None 
Prostate Prostate cancer associated 
fibroblasts 
None 
 
 
Figure 1.5. Suumary of the different disease-specific iPS models. iPS cells have the ability to 
arguably retain some  disease-specific characteristics during the course of reprogramming. 
This feature of the technology finds use in creating in vitro as well as in vivo models for 
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various disease pathogenesis. These models also have clinical relevance as they highlight the 
possibility of disease genotype correction through gene therapy. Table and date adapted from 
(Robinton and Daley 2012, Vêncio, Nelson et al. 2012). 
3.7.Tissue-specificity in iPS re-programming 
Several studies have documented that immature cell types with increase lineage plasticity are 
easier to re-programme than their more differentiated counterparts (Eminli, Utikal et al. 2008). 
It has also been widely suggested that during the course of re-programming iPS cells retain 
the memory of their original tissue type of origin or in other words the relevant somatic 
epigenetic memory remains intact in very low-passage iPS cells (Kim, Doi et al. 2010, Polo, 
Liu et al. 2010). There is evidence to suggest that during the course of re-programming adult 
mouse cells from various somatic sources retain the DNA methylation changes characteristic 
of the parental tissue of origin and this in fact makes the derived iPS cells more prone to 
differentiate back to the original cell of origin (Moad, Pal et al. , Kim, Doi et al. 2010). In a 
study that used distinct cell types from genetically matched individuals it was concluded that 
iPS cells from the different cell types are transcriptionally distinct, demonstrate 
distinguishable epigenetic patterns and show varied predelictions towards differentiation. 
These molecular properties, transcriptional and epigenetic patterns and functional 
characteristics however get erased with higher passages (Polo, Liu et al. 2010). However, the 
differentiation and methylation patterns of pluripotent cells derived by means of nuclear 
transfer have been noted to be closer to embryonic stem cells than iPS cells. This epigenetic 
memory can nevertheless be erased and modified through treatment of iPS cells with 
chromatin-modifying drugs (Onder, Kara et al. 2012). It has also been seen that embryonic 
tissues are more easily re-programmable to an embryonic stem cell state than cells that are 
more lineage committed. Cells from aged donors have higher levels of Ink4/Arf (Li, Collado 
et al. 2009). The Ink4/Arf is a tumour suppressor locus that encodes p16
INK4a
, p15
INK4b
 and 
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Arf and these three molecules are expressed by differentiated cells and are potent inhibitors 
of cellular proliferation and are critically regulated by in vitro culture conditions as well as 
being up-regulated in response to abnormal mitogenic signals (Li, Collado et al. 2009). The 
INK4/Arf locus is up-regulated in ageing organisms (Krishnamurthy, Torrice et al. 2004) and 
acts as an impediment to iPS induction in aged cells. The re-programming efficiency in these 
circumstances can be improved by  inhibiting the locus with the relevant shRNA (Li, Collado 
et al. 2009). Incidentally, it has also been noted that senescent cells are impossible to re-
programme with the traditional 4 factor re-programming cocktail.I Instead, a cocktail of six 
factors (Oct4, SOX2, Klf4, c-Myc, NANOG, Lin28) is essential in re-programming these 
aberrant cell types (Lapasset, Milhavet et al. 2011). 
 
Heterogeneity in iPS induction is also well-noted based on the tissue of origin. For example, 
keratinocytes re-programme with faster kinetics than fibroblasts (Maherali, Ahfeldt et al. 
2008). It has also been noted that stomach and liver cells when re-programmed to iPS cells 
show lower pro-viral integration thereby demonstrating that these cells need lower levels of 
pluripotency transcripts for re-programming purposes (Aoi, Yae et al. 2008). Another study 
that used mouse cells noted a variation in teratoma forming abilities of secondary 
neurospheres that were derived from varying tissue sources (Miura, Okada et al. 2009, Kim, 
Doi et al. 2010). Neurospheres from tail tip fibroblasts showed highest propensity towards 
teratoma formation, whereas iPS derived from MEF cells and gastric epithelial cells were 
least inclined towards teratoma generation while hepatocyte iPS cells showed an intermediate 
tendency towards teratoma generation (Miura, Okada et al. 2009). It was also observed that 
embryonic fibroblast derived neurospheres behaved similarly to embryonic stem cells in 
forming teratomas (Miura, Okada et al. 2009).  
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One of the explanations behind the persistence of such an epigenetic memory has been the 
fact that demethylation is inefficient and slow in factor-based re-programming. This 
persistent, tissue-based methylation signature is believed to impart iPS cells with the 
epigenetic imprint characteristic of the cell of origin (Kim, Doi et al. 2010). A study carried 
out exclusively on hepatocytes, saw iPS induction in three different lineage states – 
hepatoblast derived iPS cells, adult hepatocyte derived iPS cells and embryonic fibroblasts 
(Lee, Seo et al. 2012). It was observed that at low passages that hepatocyte-derived iPS cells 
showed a transcriptional pattern that was very similar to embryonic stem cells but 
nevertheless was also characteristic of the respective parental lineage state (Lee, Seo et al. 
2012). This hierarchical-specific hepatocyte memory may have been potentially responsible 
for the tendency of these low-passage lineage-specific iPS cells to differentiate into the 
parental cell type with greater propensity than the MEF-iPS cells (Lee, Seo et al. 2012). The 
hepatocyte-specific-transcriptional imprint does however gets erased in iPS cells at higher 
passages when they apparently seem to lose their lineage fidelity towards differentiation 
(Polo, Liu et al. 2010, Lee, Seo et al. 2012). It has been further suggested that variation 
between the different types of iPS cells towards hepatic differentiation can be modulated by 
donor differences where the genetic make-up of the individual patient can be more influential 
than the specific cell type and route of re-programming (Kajiwara, Aoi et al. 2012). 
 
Based on previous literature, it was decided that prostate development could potentially be 
modelled through a prostate-derived iPS model. Genetic changes during prostatic 
development reflect the aberrant signalling mechanisms that result in prostate cancer. There 
are no existing models that describe the genetic landmarks of prostatic differentiation and the 
cellular hierarchies in the human prostate remain as yet open to conjecture. Currently, stem 
cell models that represent prostatic development are confined to the murine prostate and there 
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are significant deviations of the mouse prostate from the human prostate, especially given 
mice never develop prostate cancer. Human stem cell models are derived through stem cell 
enrichments by means of certain putative stem cell markers. These cells are sparse, not 
sustainable in culture, laborious to grow and the properties of the resultant cells heavily vary 
between patients, quality of primary tissue as well as in vitro culture techniques. Furthermore, 
these cells are subject to in vitro genetic drifts and prove difficult to disentangle, based on 
their ambiguity with respect to stem markers. Although there are several stem cell markers 
that identify stem cell populations, this process is not deterministic. 
 
This thesis presents the establishment of a prostatic iPS cell (iPSC) model that de-
differentiates prostate stroma into an embryonic phenotype through a mesenchymal-epithelial 
transition state. These cells have been derived through a lentiviral transduction protocol that 
involved the use of 4 different pluripotent transcripts in a single polycistronic construct. The 
cDNA was further ‘Floxed’ by LoxP sites to ensure deletion of the viral genome once the 
cells attained their ‘ground-state’. Following transduction, the first 7 days of the re-
programming process was marked by a mesenchymal-epithelial transition phase. The cells 
were then subjected to an optimized protocol involving the use of pluripotent-cell as well as 
feeder cell-conditioned media. A total of 14 different cell lines have been generated that 
represent de-differentiation of the human prostate to an embryonic state. The resultant cells 
have been substantiated with a diploid 46 XY karyotype and their credibility were further 
corroborated by means of ‘paternity’ tests showing an identical DNA identity match between 
parent and the resultant ‘Pros-iPSC’ cells for a panel of microsatellite markers, including sex 
marker Amelogenin.  
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All the Pros-iPS cells expressed embryonic stem cell characteristics. The cells were checked 
for endogenous stem transcript expression and expression of these transcripts was confirmed 
to be at a similar level or higher than that of human embryonic stem cells. Next, these cells 
were differentiated through conventional differentiation protocols in vitro to embryoid bodies 
which were further differentiated to give cells representing all the 3 germ layers. When 
injected in mice, Pros-iPS cells formed teratomas confirming their ability to differentiate into 
ectoderm, mesoderm and endoderm in vivo. It was also shown that these prostate-iPSC 
possess a greater propensity towards prostatic differentiation suggesting that a tissue-specific 
molecular and epigenetic imprint may be inherent during iPSC re-programming. This would 
imply that certain canonical pathways in prostate-specific metabolism may well persist 
during adult life. There may be certain transcriptional and epigenetic patterns that get 
silenced in adult life, which nevertheless retain the ability to become activated under distinct 
stimuli and/or niches and aberration of these canonical signals may be detrimental potentially 
leading to carcinogenesis.  
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Hypothesis, Aims and objectives: 
Hypothesis 
Prostate-derived induced pluripotent stem cells (Pro-iPSC) will show a greater predilection 
and commitment towards lineage-specific differentiation than the conventional skin-derived 
iPSC (skin-iPSC). 
Aims and Objectives 
The objectives of this project are: 
1. To establish novel iPS cell clones from the prostate (termed Pro-iPSC) and to compare 
these with skin-iPSC. 
2. To validate differentiation and tumourigenic potential of Pro-iPSC and skin-iPSC. 
3. To establish a prostate-specific stem cell model that will accurately mirror mechanisms 
instrumental in prostatic differentiation and carcinogenesis. 
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Chapter 2.  
General Methods 
1. Cell biology techniques 
1.1. Cell line culture – prostate cancer cell lines 
Four different prostate cancer cell lines were used (Figure 2.1) – LNCaP (from lymph node 
metastasis of prostate cancer); an androgen-independent LNCaP subline (LNCaP-AI); PC3 
(derived from prostate cancer metastatic deposits in the vertebrate)  and DU145 (derived 
from brain metastatic lesions in prostate cancer) (van Bokhoven, Varella-Garcia et al. 2003). 
LNCaP, PC3 and DU145 cell lines were obtained from ATCC (Rockville, MD, USA) and 
were cultured in 75cm
2
 and 150 cm
2  
polystyrene tissue culture flasks with canted neck and 
0.2 µm vented-caps (430641, 431079, Corning Incorporated, New York, USA). The cells 
were maintained  in RPMI-1640 medium with Hepes Modification (R5886, SIGMA®, 
Steinheim, Germany) supplemented with 10% foetal bovine serum (FBS) (F7524, Sigma 
Chemical Co., USA) and 2mM L-Glutamine (G7513, SIGMA®).  Androgen-independent 
LNCaP subline, LNCaP-AI was generated by culturing LNCaP cultures for approximately 20 
passages in regular RPMI-1640 medium where regular FBS was substituted with 10% 
dextran-charcoal-treated steroid-depleted FBS (SH30068.03, HYCLONE, Utah, USA). This 
cell line represents an in vitro model of androgen-independent prostate cancer (Gustavsson, 
Welen et al. 2005, Wiltshire, Singh et al. 2010). Tissue culture conditions were optimised at 
37°C with 100% humidity and 5% CO2. Cells were frozen at relatively early subcultures in 
culture media supplemented with 5% FBS (F7524, Sigma Chemical Co.) and 5% DMSO 
(D2650, SIGMA®) to ensure cell line stocks between passages 2-50. Cells were sub-cultured 
in a split ratio of 1:4 at 75% confluence by means of trypsinisation with 1XTrypsin-EDTA 
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(T4174, SIGMA®). Cultures were regularly monitored for adherence and bacterial 
contamination and maintained as mycoplasma negative.  
The main purpose for culturing cell lines was to study stem cell and prostate-specific markers 
in these cell lines, with the ultimate aim to optimise primer sets as well as conditions for real 
time RT-PCR. LNCaP, DU145 and PC3 are regarded as the three ‘classical’ prostate cancer 
cell lines. LNCaP cells are known to express androgen receptor as well as multiple androgen 
regulated genes (eg. PSA) at both the mRNA and protein level. Both PC3 and DU145 serve 
as negative controls for AR and PSA mRNA expressions (van Bokhoven, Varella-Garcia et al. 
2003). 
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Figure 2.1. Light microscopy images for LNCaP, PC3, DU 145 and LNCaP-AI cells. At X10 
magnification 
LNCaP cells 
PC3  cells 
DU 145 cells 
LNCaP-AI  cells: right picture at higher magnification 
 87 
 
1.2.Cell line culture : Feeder cell lines 
1.2.1. Mouse STO cells 
Murine STO embryonic fibroblast cells were used as feeder cells in order to provide 
mechanical as well as paracrine support to prostate epithelial cultures. Murine STO 
(embryonic fibroblast) cells were obtained from Dr. Stuart Williamson and were maintained 
in culture in DMEM medium with Hepes Modification (R5886, SIGMA®, Steinheim, 
Germany) supplemented with 10% FBS (F7524, Sigma Chemical Co., USA) and 2mM L-
Glutamine (G7513, SIGMA®).  Cells were routinely monitored for adhesion and 
contamination and were passaged every 48-72 hours at 75% confluence in a 1:10 ratio. These 
cells were maintained as mycoplasma negative. 
Cells were irradiated prior to use at 310 Amps 10kV for 20 minutes (4000 rads) or were 
inactivated by means of Mitomycin C. Mitomycin C (SIGMA®) was reconstituted in STO-
culture media at a concentration of 10µg/ml. Cells were incubated with the Mitomycin C 
containing media for 2 hours at 37˚C , 5% CO2 and 100% relative humidity following which 
they were washed three times in 1X PBS and trypsinised. The pellet was again washed a 
further 3 times in 1X PBS to ensure near-complete removal of any traces of Mitomycin-C. 
These cells were then seeded onto prostate primary epithelial culture at an initial confluence 
of ~65% or 100,000 cells per 75cc flask. After 5 days, once the prostate primary epithelial 
cells were seen to proliferate in a stable manner, the confluence of feeder cells was increased 
to ~75% or 500,000 cells per 75 cc flask. The reason for maintaining a moderate initial STO 
density was to prevent any potential competition from these freshly inactivated feeder cells 
during the early days of establishing epithelial cultures. 
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1.2.2. Mouse Embryonic Fibroblast cells 
1.2.2.1. Preparing gelatin coated plates 
These cells were seeded onto 0.1% Gelatin coated plates to improve adhesion and attachment 
of these cells. To prepare the gelatin solution, 10 grams of gelatin was added to 1L distilled 
sterile water. This was autoclaved for 30 minutes, following which this 1% stock was stored 
at -20oC in 50 ml aliquots. To make 0.1% Gelatin, 50 ml of 1% Gelatin was dissolved in 450 
ml sterile distilled water. 2ml of this 0.1% gelatin was added to each well of a 6 well plate 
and the plates were incubated overnight at 37oC. Immediately prior to use, the gelatin was 
completely aspirated from the plates and MEF cells were seeded. 
1.2.2.2. Culturing MEF cells 
Mouse Embryonic Fibroblast cells or MEFs were used as feeder cells for pluripotent stem 
cell cultures. CF-2 (mouse strain) irradiated mouse embryonic fibroblast cells were purchased 
from VhBio and were directly seeded onto 0.1% Gelatin coated plates in DMEM medium 
with Hepes Modification (SIGMA®) supplemented with 10% FBS (Sigma Chemical Co.) 
and 2mM L-Glutamine (G7513, SIGMA®).  Non-inactivated cell lines were also maintained 
in culture so as to generate feeder-conditioned media. These cells were routinely monitored 
for adhesion and for any potential mould and/or bacterial contamination and were maintained 
as mycoplasma negative. 
Irradiated cells were seeded at a density of 50,000 cells/cc and used immediately (within a 
maximum of 24 hours). In cases where there were unforeseeable delays in using the MEF 
cells within 24 hours of seeding, the DMEM media described above was removed from the 
adherent cultures and the cells were washed twice with 1XPBS. Following this, Embryonic 
Stem Cell Media was added onto the MEF cultures. This conditioned the media with the 
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MEF cells secreted factors, however in all circumstances the seeded MEF plates were used 
within a maximum of 48 hours. Irradiated cells were used as a feeder layer for a maximum of 
7-10 days. Unlike with the STO cells, iPS cells were seeded onto these cells. it was observed 
that adding irradiated MEF cells onto established iPS cultures failed to offer appropriate 
support and resulted in death and/or differentiation of the pluripotent cells. In all 
circumstances the iPS cultures were transferred onto freshly seeded MEF-plates every 7 to 10 
(maximum) days. 
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1.3. Culturing cell lines: Normal Human Dermal Fibroblast (NHDF) cells 
NHDF cells were kindly donated by Prof. Majlinda Lako and were cultured in DMEM 
medium with Hepes Modification (SIGMA®) supplemented with 10% FBS (Sigma Chemical 
Co.) and 2mM L-Glutamine (G7513, SIGMA®). They were split in a 1:10 ratio every 5-7 
days and were given a media change every 48 hours. These cells were used as the control cell 
line for iPS induction and cells were used at very low passages. Hence they were frozen 
down at very low passages and were not propagated in culture beyond passage 20. The cells 
were routinely monitored for adhesion and for any potential mould and/or bacterial 
contamination. The cells were maintained as mycoplasma negative cells. 
 
1.4. Freezing and thawing cell lines. 
Freezing media was prepared fresh and to do so the respective growth media was 
reconstituted with an additional 10% FBS (Sigma Chemical Co.) and 10% Dimethyl 
Sulphoxide (D2650, DMSO Hybri-MAX®, Sigma®). Cells were counted trypsinised and 
resuspended in the freezing media at 2 million cells / ml and stored at -80˚C for short-term 
storage. 
To retrieve frozen cells, thawed cell vials were immediately reconstituted in the respective 
culture media and centrifuged at 1500 rpm X5 minutes. The cells were washed once more in 
their respective media and were then plated out in T75 culture flasks. After 24 hours, cells 
were monitored for adherence and potential mould and/or bacterial contamination. The cells 
were washed with 1X PBS and fed with fresh media. 
 
 
 91 
 
1.4. Primary tissue culture in the prostate 
In total, human prostatic tissue was collected from more than 60 anonymised patients (aged 
50-85 years) who underwent trans-urethral resection of the prostate (TURP) for  BPH or 
cystoprostatectomy for bladder cancer.  All samples were obtained with patient consent and 
after conforming to ethical guidelines and ethical permission.  
I. Collagenase I digestion of prostatic tissue  
Collagenase I digestion was performed to release epithelial structures and stromal organoids 
(Collins, Robinson et al. 1996, Robinson, Neal et al. 1998, Heer, Robson et al. 2007).  All 
tissue samples were washed in PBS to reduce operation theatre contaminants. Each sample 
was dissected into small cubes measuring 3mmX3mmX3mm so as to ensure increased 
surface area for digestion. Samples were incubated in 200 IU/ml strength Type I Collagenase 
(LS004196, Worthington, Lorne Laboratories, Reading, UK) solution for a period of 20 hours. 
Collagenase I solution was prepared by dissolving appropriate amount of Collagenase IV 
powder in RPMI 1640 media supplemented with 5% FBS (Sigma Chemical Co.,USA), 2mM 
L-Glutamine(SIGMA®) and 1% Penicillin-Streptomycin (SIGMA®). Tissue digestion was 
performed overnight in an oven at 37°C.  
II. Separating prostate epithelia from prostate stroma  
Following collagenase digestion, the digest was passed through a 21 gauge needle to 
homogenise and increase yield. Cells were then washed at least five times in PBS. Epithelial 
cells were separated from their stromal counterparts through repeated differential gravity 
centrifugation at 800rpm for 1 minute – this alone has been reported to yield epithelial 
fractions to 98% purity (Robinson, Neal et al. 1998, Heer, Robson et al. 2007). Epithelial 
acini were further treated with 1X trypsin (SIGMA®) at 37°C for 30 minutes to disaggregate 
 92 
 
organoids and release single cells (Collins, Habib et al. 2001, Heer, Robson et al. 2007). Cells 
from the epithelial fraction were further sorted using magnetic separation with the help of 
MACS microbeads linked to an antibody against the HEA (Human Epithelial 
Antigen/CD326/EpCAM/) antigen (Miltenyl Biotech Ltd., Surrey, UK).  
III. MACS sort 
Epithelial cell adhesion molecule (EpCAM) or CD326 is expressed by epithelial cells as well 
as by epithelial-tumour cells (Moldenhauer, Momburg et al. 1987).  Cells were magnetically 
labelled with CD326 microbeads at 4°C for an hour, and then made to pass through a MACS 
column placed in a magnetic field. Epithelial antigen expressing cells bind to these ferritin 
labelled microbeads and are retained in the column when made to pass through. The labelled 
cells were subsequently collected in MACS buffer (2mM EDTA in PBS and 0.25% FBS) and 
cultured as epithelial cells. 
IV. Culturing prostate epithelia 
Prostate epithelial cells were routinely cultured in 25 cm
2
 Collagen I coated flasks (BD 
Biosciences, Oxford, UK) in serum-free, low-calcium containing keratinocyte basal medium 
(17005, GIBCO®, Invitrogen Ltd., Paisley, UK) supplemented with 25mg of bovine pituitary 
extract (13028, GIBCO®) and 2.5µg of recombinant epidermal growth factor (10450, 
GIBCO®). The medium was further supplemented with 100ng/ml of cholera toxin (C8052-
1MG, SIGMA-ALDRICH®, Steinheim, Germany), 0.2 ng/ml of LIF (L5283, SIGMA-
ALDRICH®), 0.1 ng/ml of GM-CSF (G5035, SIGMA-ALDRICH®), 0.2 ng/ml of SCF 
(S7901, SIGMA-ALDRICH®). Presence of bovine pituitary extract, low calcium 
concentration, cholera toxin and other growth factors have been demonstrated to facilitate 
proliferation as well allow for higher serial passages of these epithelial cultures (Chaproniere 
and McKeehan 1986). 
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A ten minutes rapid adhesion and a twenty-minutes adhesion was used to enrich for stem cell 
populations and viable cell populations, respectively (Collins, Habib et al. 2001, Heer, 
Robson et al. 2007). Mitomycin C inactivated murine STO cells (mouse embryonic fibroblast 
cell line) were used as feeder cells in epithelial culture. These cells provided mechanical 
support and provided stromal-derived factors which are both essential for epithelial culture 
(Collins, Habib et al. 2001, Lang, Stark et al. 2001). It was noted in this study that since the 
initial yield of epithelial cells was most often very low, culturing in 25 cm
2 
flasks in place of 
previously used 75 cm
2
 flasks ensured that the epithelial cells were in close proximity which 
in turn increased culture success rate. 
Epithelial cells were washed with 1XPBS (GIBCO) and fed with epithelial culture medium 
every 48 hours. Mitomycin C inactivated feeder cells had to be replenished at least once a 
week. These cells were split once colony formation was observed, cell clusters containing > 
32 cells were designated as colonies (Collins, Habib et al. 2001).  Cells were split using 
1Xtrypsin-EDTA (SIGMA®) and the trypsin was neutralised using 10% FBS (Sigma 
Chemical Co.) in place of regular medium. Using 10% FBS in place of conventional culture 
medium prevented occurrence of stromal contamination in epithelial cultures as well as 
facilitating epithelial growth (Chaproniere and McKeehan 1986). 
V. Culturing primary prostate stroma  
Prostate stromal cells were separated from their epithelial counterparts by first washing the 
cells from the prostate collagenase I digest (please refer Step I) in 1X PBS (GIBCO) and then 
re-suspending the cells in stromal culture medium comprising RPMI 1640 media 
supplemented (SIGMA®) with 5% FBS (Sigma Chemical Co.), 2mM L-Glutamine 
(SIGMA®) and 1% Penicillin-Streptomycin (SIGMA®). This suspension was then 
centrifuged at 800rpm for 1 minute – the resultant supernatant was enriched with stromal 
 94 
 
cells (Lang, Stark et al. 2001) and was cultured in 75cm
2
 regular tissue-culture flasks 
(Corning Incorporated).  Cells were regularly monitored for adherence and fed thrice a week 
with stromal culture medium. Cells were split by means of trypsinisation at 75% confluence 
in a split ratio of 1:5. 
1.3. 3-D culture of prostate primary cells 
It has been observed that development of a functional and anatomical appropriate prostate 
relies on the presence of extracellular matrix (Lang, Stark et al. 2001). To culture primary 
cells in 3-dimensional structures, a total of 2000 cells were re-suspended in 100 µl of BD 
Matrigel 
TM
 basement membrane (35428, BD Biosciences, Bedford, UK). BD Matrigel is 
stored frozen at -20°C and has to be thawed overnight at 4°C before use. Re-suspended cells 
were incubated in 24 well tissue culture plates (Corning incorporated) at 37°C in a tissue 
culture incubator for 30 minutes. Once the Matrigel had set, 50 µL of appropriate culture 
medium was added. 
For stromal cells, stromal culture media was used whilst for epithelial cells epithelial culture 
media was further enriched with stromal-derived factors. The latter was obtained by culturing 
inactivated mouse STO cells in epithelial growth medium for 2 hours following which the 
stromal factors-enriched media was aspirated and filter sterilised to remove dead STO cells. 
For 3-D culture, cells were fed with respective media every 48 hours. 
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1.4. Pluripotent Stem Cell Culture 
1.4.1. Culturing Pro-iPS cells 
Human pluripotent stem cells were grown on MEF cells at 50,000 MEF cells/cc and 
maintained in 6-well plates. These cells grew in colonies and the colonies were monitored 
daily for evidence of death, differentiation as well as fungal and/or bacterial contamination.  
The health of the surrounding MEF cells were also regularly monitored as considerable 
variation was observed between different batches of MEF cells. Depending on the health and 
density of the surrounding MEF cells, Pro-iPS colonies were passaged every 5-7 days.  
A healthy Pro-iPS colony would be denoted by a tight compact morphology lacking any 
evidence of central umbilical differentiation and/or peripheral fibroblast-like differentiation. 
Cells were maintained in pluripotent stem cell culture media that comprised the following:  
1. 80% Knockout™ D-MEM (10829-018, GIBCO, Life Technologies, Paisley, UK) 
2. 20% Knockout™ Serum Replacement (10828-028, GIBCO, Life Technologies, 
Paisley, UK) 
3. FGF-basic Recombinant Human (13256-029, GIBCO, Life Technologies, Paisley, 
UK) at 8ng/ml 
4. 100mM MEM non-essential amino acids (11140-035, Life Technologies, Paisley, UK) 
5. 200 mM GlutaMAX™-I Supplement (35050-038, Life Technologies, Paisley, UK) 
6. 1% Penicillin-streptomycin (Sigma, Germany)  
7. 0.1 mM β-mercaptoethanol (Sigma, Germany) 
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Differentiation at the centre of the colonies were identified and removed with the help of 
P20/200 sterile plastic Gilson tip. If peripheral differentiation causing irregular ill-defined 
colony borders were observed then the colonies were passaged and healthy areas of each 
colony was broken into small cells clumps of 50-60 cells and transferred onto fresh MEF 
cells. In this case, the colonies were subjected to mechanical and enzymatic dissociation. 
1.4.2. Passaging Pro-iPS cells 
To detach the Pro-iPS colonies from the surrounding MEF cells, the colonies were treated 
with Collagenase IV solution (Gibco, Life Technologies, Paisley, UK) at 1mg/ml for a 
maximum of 5 minutes. This resulted in curling of the colony-borders. At this point the 
Collagenase IV solution was removed from the cells and fresh pluripotent stem cell culture 
media was added. The cells were observed under a dissection microscope and were dissected 
on a stage heated to 37˚C. 
Firstly, any areas of differentiation (this appeared as brown discoloration while the healthy 
pluripotent cells looked like translucent areas) were removed manually with the help of a P20 
Gilson pipette. Next the tip of the P20 was run over the remainder colony to break it up into 
small bits of 50-60 cells and these were gently sucked up in the pipette and transferred onto 
fresh MEF feeder plates which were placed in the incubator for 24-48hrs before changing the 
media. The colonies were split in a ratio of 1:8 every 5 days.  
It was essential to ensure that the colonies were broken into appropriate sized cell clusters – 
pluripotent stem cells do not survive as single cells and therefore if colonies are too small 
then they will fail to grow. However, failure to dissect a colony into cell clusters smaller than 
60 cells would result in excessive and early differentiation of the transferred colonies. Also, 
excessive precaution must be taken during Collagenase IV treatment since this does not get 
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neutralised by serum. Complete removal of the Collagenase IV solution is essential as 
otherwise this will cause death of pluripotent cells.  
Improper maintenance and passaging of pluripotent cells result in karyotypic abnormalities. 
Enzymatic digestions through Trypsin-EDTA as well as through Collagenase IV treatment 
can result in cytogenetic aberrations. Such anomalies can be minimised through mechanical 
dissociation whereby no enzymatic processes are involved and the colonies are exclusively 
removed manually with the help of a firepolished sterilised glass pipette tip.    
1.4.3. Freezing Pro-iPS cells 
Pro-iPS cultures were frozen at 85% confluence. Cells were collected as clumps through 
Collagenase IV digestion, cell pellet was collected after centrifuging the cells at 200g X 5 
minutes. Freezing media was made up in media constituting equal volumes of pluripotent-
stem cell culture media and cryopreservation media. Cryopreservation media was made up 
with 60% pluripotent stem cell culture media, 20% FCS and 20% DMSO. 1 6-well plate 
containing ~300 healthy pluripotent colonies were collected in 200 µL of the freezing media, 
to this 10µM Y-molecule (Stemolecule ™ Y27632, Stemgent, MA, USA) was added and the 
cells were frozen at -80˚C for short term storage and were later transferred to liquid nitrogen 
for long term storage.  
1.4.4. Thawing Pro-iPS cells and recovering them back to culture 
Pro-iPS cells were thawed onto MEF feeders on BD Falcon™ 4 well In Vitro Fertilization 
(IVF) Plate (353654, BD Biosciences, Oxford, UK). Contents of 1 6-well plate were thawed 
onto 4 wells of a 4 well IVF plate. The cells were allowed to stick down onto MEF cells for 
48 hours following which their growth was monitored every 24 hours. Recovery was around 
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80% and colonies were transferred onto 6-well plates (from 1 4 well IVF plate to 15 wells of 
a 6 well plate) after one week. 
1.4.5. Embryoid Body (EB) formation and differentiation 
Pro-iPS cell clumps were collected in EBformation media (Knockout-DMEM 80%, 
Knockout Serum Replacement 20%, GlutaMAX™-I Supplement 200 mM, 1% MEM non-
essential amino acids, 1% Penicillin-streptomycin) and cultured on low-adhesion plates for 7 
days. Once embryoid bodies were formed these were subsequently differentiated to test the 
pluripotency of the Pro-iPS. 
To differentiate the embryoid bodies, these were transferred onto 0.01% Gelatin-coated plates 
(each plate contained around 10-20 embryoid bodies) and were allowed to differentiate in 
EB-formation media for a further 10-15 days.  
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2.1. Lentiviral transduction using OSKM and OSLN factors 
Several transduction protocols and Lentiviral kits were tried and the most efficient human-
iPS specific generation methodology was optimised through repeated attempts at the process. 
Two different types of lentiviral constructs were used - individual Oct4, SOX2, Lin28 and 
NANOG lentiviral vectors (all from ST000005, STEMGENT, San Diego, USA) in one 
system and the use of a 4-in-1 Floxed lentiviral system (ABP-SC-LVI4in1, Allele 
Biotechnology, San Diego, USA)  in another protocol. Two different iPS reprogramming 
cocktails were tried – the traditional Yamanaka OSKM factors and the Thomson OSLN 
factors. As per literature, the Yamanaka OSKM factors have been associated with faster 
kinetics and higher efficiency (Robinton and Daley 2012). Although they have been used to 
re-programme human cells, the sustained activation of c-Myc is known to cause death and 
differentiation in human pluripotent cells (Sumi, Tsuneyoshi et al. 2007, Yu, Vodyanik et al. 
2007). Therefore, it was decided that the transduction protocol would be optimised initially 
using Thomson’s OSLN factors. Incidentally, two different protocols were followed with the 
two different re-programming cocktails. A range of MOI (Multiplicity of Infection) was 
tested from 2 to 10 so as to optimise the maximal efficiency at minimal toxicity. For both the 
transduction protocols, Polybrene (TR-1003-G, Millipore, Massachusetts, USA) was used to 
aid entry of the lentivirus into the cells.  
For all transductions the transduction media was made up fresh and used immediately. Cells 
were transduced for 48 hours and from week 1 onwards they were cultured in embryonic 
stem cell-like culture conditions. 
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2.2. Analysis of optimal transduction efficiency 
The optimal transduction efficiency was regarded as the MOI that would be sufficient to 
transduce the majority of the target cells. Given that iPS induction is a multi-step process, the 
number of cells passing from one transition to the other progressively reduces with a very 
small proportion of the initially transduced cells reaching the ultimate ‘ground state’. Due to 
certain epigenetic events that are as yet equivocal, very few cells progress beyond the initial 
MET (or mesenchymal-epithelial transition) phase. Many transduced cells that have acquired 
an epithelial phenotype are still prone to either perish or revert back to the mesenchymal 
phenotype (Buganim, Faddah et al. 2013). Also, it is essential that the amount of virus used is 
kept to a minimum so as to prevent multiple integral sites and to ensure silencing of the 
transgene.  
Target cells were seeded at 75% confluence in a 96-well plate. A range of MOI was tested: 
0.5, 1.0, 2.5, 5.0, and 10.0. Cells were transduced with mWasabi GFP empty lentiviral vector 
(Allele Biotech., USA) in their respective growth media for 48 hours after which GFP 
expression was analysed and compared against a polybrene-only control (or MOI = 0). All 
FACS analysis was done on the FACS Calibur using Fl1-H channel for GFP detection and 
Cyflogic for analysis and interpretation of results.   
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3. Cytogenetics: Karyotyping 
Karyotypic analysis was carried out so as to ensure that Pro-iPS cells did not suffer from any 
aneuploidies. Pro-iPS cell lines were karyotyped at passage 18-20. Karyotyping was done 
through the following three steps: 
3.1. Harvesting cells and Metaphase arrest – protocol courtesy, Mr. Arman Esfandiari 
3.1.1. Growth and Harvest of Pro-iPS cells 
Pro-iPS cells were grown on irradiated MEF feeder cells and were harvested for analysis only 
at 85% confluence. 6 wells of a 6 well plate full of Pro-iPS colonies were treated with  the 
mitotic spindle poison Colcemid (kindly donated by Mr. Arman Esfandiari and Prof. John 
Lunec) for a period of 120 minutes. The duration of Colcemid treatment is dependent on the 
cell cycle of the relevant cell lines. Cells that multiply quickly and have short cell cycles 
(example: embryonic stem cells and other pluripotent stem cells) need shorter Colcemid 
treatment while cells with longer cell cycles need longer Colcemid treatment to facilitate 
appropriate Metaphase arrest. It is important to treat the cells for the correct duration of 
Colcemid ; lengthy incubations with Colcemid will result in the generation of tightly 
compacted chromosomes on G-banding which in turn would complicate inspection for 
interchromosomal and subchromosomal aberrations. The incubation period for Pro-iPS cells 
was optimised to 2 hours of treatment which resulted in a well-spread out metaphase with 
precise G-banding of the chromosomes. 
Following Colcemid treatment, Pro-iPS colonies were collected by means of collagenase 
treatment. Collagenase treatment exclusively allows for lifting of pluripotent stem cell 
colonies while the feeder MEF cells remain mostly unaffected. Once the colonies were 
collected, the suspension was allowed to stand for another 10 minutes which further ensured 
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the separation of any accompanying MEF cells from the Pro-iPS colonies. The iPS colonies 
were then washed in 1XPBS and subjected to a brief 1% trypsin digestion for 5 minutes at 
37˚C after which the trypsin was neutralised with 10% FCS-PBS.  This was then centrifuged 
at 1500 rpm X 5 minutes following which most of the FCS-PBS was aspirated from the cell 
pellet leaving behind 200 µl. The pellet was gently flicked to resuspend the mitotic cells. 
3.1.2. Addition of hypotonic solution 
To lyse the cells, 1ml of hypotonic solution (1:1 0.4% KCl + 0.4% Sodium Citrate) was 
added against the side of the tube to the mitotic cells, at this stage the cells were resuspended 
and then the total final volume was made up to 2ml with the hypotonic solution. This was 
incubated at 37˚C for 7 minutes following which the cells were centrifuged at 1500 rpm X 6 
minutes.  
3.1.3 Fixation 
5 drops of fixative (3:1 Methanol and Acetic Acid) was added along the sides of the tube to 
the cell pellet to make up a final volume to 2 mL. The cells were resuspended in the fixative 
and were fixed at room temperature for 30 minutes. This was centrifuged as before and the 
pellet obtained was again resuspended in fresh fixative made up to 2 mL and the solution was 
incubated at room temperature for a further 20 minutes. The cells were then dropped onto 
slides or frozen at -20˚C. 
3.1.4. Dropping cells and preparing slides 
Slides were rinsed with ice cold water and were then rinsed with the fixative. Appropriate air 
humidity in the room for this step is 50%-60% (in a dry day this can be achieved by placing 
the slide over a beaker of water). In case frozen cells were used, these were washed once in 
the fixative. Using a plastic transpipet, 2-3 drops of the cells were dropped at 45˚ angle onto 
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the slides following which a tongue-shaped smear was attained. The optimal cell density was 
ascertained by observing each smear under the phase contrast microscope – the best cell 
density would be the one showing appropriate lysis of the cell and a well-spread out 
chromosomal pattern immediately next to the cell body. The slides were then aged at room 
temperature for at least 24 hours. 
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3.2. G-banding of chromosomes and generation of Karyogram, protocol courtesy Dr. Claire 
Schwab 
3.2.1. G-banding 
Pots were arranged in the following order (reagents kindly provided by Dr. Claire Schwab): 
a. 1ml Trypsin in 25 ml saline/25 ml Leishman’s buffer , pH 6.8  
b. 50 ml Saline 
c. 50 ml Saline 
d. Staining solution: Giemsa and Leishman’s staining solutions, 0.4 ml Giemsa Staining 
solution added to 8ml Leishman’s stain and 40 ml Leishman’s buffer 
e. 100+ ml pot of cold distilled water 
One slide was processed at a time. The slide was placed in trypsin solution (a) for 15 seconds 
and then transferred immediately to the saline solution (b). This was then rinsed in the third 
saline pot (c). The slide was next placed in the Staining solution (d) for 5 minutes and then 
thoroughly rinsed in distilled water (e). The stained slides were then mounted with coverslip 
using DPX and analysed using the Kario software or Cytovision®. 
3.2.2. Analysis and generation of Karyogram 
A brightfield image was opened on the software and an appropriate human cell, based on the 
lysis, metaphase spread and G-banding pattern was chosen. Human chromosomes were 
specifically and exclusively chosen for analysis, this was confirmed through morphology 
with the help of a cytogeneticist (Dr. Claire Schwab). Extrachromosomal objects such as cell 
debris were disregarded. Next, the chromosomes were separated from each other when 
overlapped; this was most specifically common nearer the centromeres. This procedure was 
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continued until the software read each chromosome as a single entity. The total number of 
chromosomes was recorded. Next, the chromosomes were aligned with the help of a 
standardised normal human karyogram and these were labelled. Any interchromosomal 
and/or subchromosomal re-arrangements and/or aberrations were noted.  
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4. DNA fingerprinting 
DNA fingerprinting was carried out to corroborate authenticity of the Pro-iPS cells and to 
rule out any possibility that these could have been generated as a result of cross-
contamination with other pluripotent cell lines. Cell pellets were collected from both the 
parental fibroblasts and from the generated Pro-iPS cells. These samples were sent off to 
Northern Molecular Genetics Service, UK and were fingerprinted for a set of 16 different 
microsatellites including the sex-marker Amelogenin through the Promega PowerPlex® 16 
system. The kit was specific for human cells alone and would not amplify murine DNA. 
The PowerPlex® 16 is a STR (Short Tandem Repeat) analysis technology whereby a set of 
different loci are co-amplified and detected through a three colour system. One primer for 
each of the loci Penta E, D18S51, D21S11, TH01 and D3S1358 is labelled with fluorescin 
(FL); one primer for each of the loci FGA, TPOX, D8S1179, yWA and Amelogenin is 
labelled with carboxy-tetramethylrhodamine (TMR) and one primer for each of the loci Penta 
D, CSF1PO, D16S539, D7S820, D13S317 and D5S818 is labelled with 6-carboxy-4’5’-
dichloro-2’, 7’-dimethoxy-fluorescein (JOE). All the loci are then then amplified 
simultaneously in a single tube and analysed in a single gel lane. The results were analysed 
using the ABI377 sequence detector using Genotype software (Applied Biosystems), 
courtesy Dr. Helen Powell. 
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5. Live cell staining and Imaging 
hESC colonies were stained with  1:100 dilutions of Anti-TRA-1-60, Clone TRA-1-60-FITC 
conjugate (Millipore) and Anti-SSEA-4, Clone MC-813-70-PE conjugate (Millipore). The 
hESC colonies were incubated with these antibodies at 37oC for 2 hours following which the 
anitibody-containing hESC media was removed and hoercsht hESC media solution was 
added at a final concentration of hoercsht at 0.5µg/ml. After 10 minutes incubation, the 
respective wells were washed twice with hESC media to ensure that all traces of the toxic 
hoercsht dye were removed completely. The colonies were then imaged in hESC media under 
an Nikon eclipse TE2000U inverted microscope using the software ‘NIS elements – BR 3.0’ 
(Figure 2.2 demonstartes the exposure time for the different filters).  
Filter (the light that 
you actually see) 
Staining 
colour(your colony 
will show this 
colour) 
Exposure time Marker 
green red 1s SSEA4 
Blue(cobalt - like) green 600-800ms Tra-1-60 
Purple (Prussian 
blue like) 
Blue 60-80ms Hoercsht  
  
Figure 2.2  Exposure times as optimised for the three laser filters. Following acquisition of 
the images, the media was replaced with fresh hESC media containing 10µM Y-molecule 
(Stemolecule ™ Y27632, Stemgent, MA, USA).  
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6. Alkaline phosphatase staining 
Pros-iPS cells were cultured for 5 days and were analysed for alkaline phosphatase activity at 
50-70% confluence. The cells were fixed in 10% formalin for 2 minutes and were then rinsed 
with 1XTBST buffer (20mM Tris-HCL, pH 7.4, 0.15 NaCl, 0.05% Tween-20). The cells 
were then treated with Fast Red Violet, AS-BI phosphate solution and distilled water in a 
2:1:1 ratio for 15 minutes in the dark at room temperature after which they were washed in 
1XTBST Buffer. The numbers of colonies expressing alkaline phosphatase were counted in 
1XPBS. 
7. Immunofluorescence staining fixed cells 
4% PFA fixed cells were blocked in appropriate blocking agent and incubated with respective 
primary antibody overnight at 4˚C. Next, the cells were washed in 1XPBS and incubated with 
the respective Alexa-Fluor conjugated secondary antibody. The cells were mounted in 
VECTASHIELD® Hard-set mounting media with DAPI and analysed through confocal 
microscopic imaging (for antibody details see supplementary information). 
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8. Teratoma assays 
 Teratoma assays were carried out using NOD/SCID mice. This procedure wasconducted 
using the following steps. 
8.1. Preparation of cells for injection 
The day before injection, BD Matrigel 
TM
 basement membrane (35428, BD Biosciences, 
Bedford, UK) was defrosted on ice. Matrigel was defrosted overnight below 3˚C. Syringes, 
needles as well as tips were also kept on ice to ensure that while handling Matrigel the 
temperature was maintained below 3˚C since higher temperatures would cause Matrigel to set.  
Pro-iPS colonies were collected through Collagenase digestion and were separated from the 
surrounding MEF cells by letting the disrupted colonies sediment through gravity instead of 
centrifuging the cells. The supernatant containing MEF cells was carefully aspirated and the 
Pro-iPS colony pellet was washed once in 1XPBS and then trypsinized to single cells. The 
cells were counted and made up to a concentration of 5 million cells per ml in the pluripotent 
stem cell media. This was placed on ice and brought down to a temperature of ???. For the 
injection, aliquots were prepared with 100ul of the cell suspension (100ul of cell suspension) 
and 100ul of thawed Matrigel. 
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8.2. Injecting cells and measuring tumours 
Cells were injected subcutaneously in the right thigh of each mouse. One cell line was used 
per mice and in total each cell line was replicated through three mice. All injections were 
performed by Dr. Lyle Armstrong. Each mouse was identified through ear notches. Prior to 
injecting the mice it is recommended that the respective areas are shaved as this results in a 
greater precision for the injections. Failure to maintain precision can result in intra-abdominal 
injections in place of subcutaneous injections and this can cause intra-abdominal growths 
which fail to mature into teratomas and can result in improperly differentiated teratomas. 
Tumours were looked out for and they were measured every week commencing from Week 3 
following injection. Measurements were taken in both vertical and horizontal dimensions and 
the mice were euthanized based on the following guidelines: 
1. 1-1.5 cm
2
 
2. If any dimension exceeds 15mm 
3. Tumours reach 5% body weight 
4. Weight loss reaches 20% of initial body weight 
8.3. Harvesting the tumours 
Mice were euthanized by Mrs. Shirley Dodd by cervical dislocation. The tumours were then 
provided to be harvested. Any overgrown hair was clipped and the skin over the tumour was 
lifted with the help of forceps. A small nick was made which was then extended to expose the 
tumour. The tumour was dissected away after dissecting it away from surrounding tissues 
including vascular supply. The tumours were measured, weighed and collected in formalin. 
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8.4. Fixation and dehydration of teratomas 
Tumours were fixed in both Bouins fluid and 4% paraformaldehyde (PFA). Bouin’s fluid 
fixation was used for trichrome stains while 4% PFA was used for immunohistochemistry. 
Accordingly, the tissues were either fixed in 20X volume of Bouins fixative for 24 hours, or 
in 20X volume of PFA for 12 hours at 4˚C. Next, the fixative was removed from the samples 
and the tissue was washed three times in water. 30-40ml of 70% ethanol was added to the 
tissue and this was left on for two hours. The procedure was repeated with 80%, 90% and 
then 95% ethanol. Tissues were stored in 95% ethanol until ready for processing.  
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3. General Molecular biology techniques 
3.1.Optimising real time PCR primers for 12 stem-cell and prostate-specific differentiation 
genes 
12 genes were selected based on their ability to demonstrate ‘stemness’ and prostate-specific 
differentiation. These included four pluripotency genes – Oct-4, SOX-2, NANOG, LIN28; 
four prostate stem cell genes – CD133, CD44, CD117, PSCA; and four androgen responsive 
genes – AR, PSA, Nkx3.1 and p63. Expression of these genes was used to characterise in 
vitro inherent plasticity in prostate primary samples. The aim here was to optimise the PCR 
technique and primers in terms of appropriate standard curves and primer specificity. LNCaP 
cell line was used a positive control for androgen responsive genes and both PC3 and DU 145 
were used as negative controls for AR and PSA (van Bokhoven, Varella-Garcia et al. 2003).  
All experiments were performed in triplicates. 
3.2. RNA isolation  
RNA was isolated from four different prostate cancer cell lines using RNeasy® Micro-kit 
(Qiagen, West Sussex, UK) (Figure 2.3 demonstrates an example of RNA extraction from 
three replicates of each cell line tested. Samples were ensured for purity through their 
260/280 ratio) . The protocol followed was as described in the manufacturer’s handbook 
(RNeasy® Micro Handbook, Qiagen). Cells were trypsinised and 100,000 cells were 
collected for RNA isolation.  The first step involved disrupting cells in guanidine-thiocyanate 
containing RLT Lysis buffer which was further supplemented with 10µl of β-
mercaptoethanol per ml of lysis buffer used. This step was performed in a fume hood and 
appropriate face protection was used. Following this, an equal volume of RNase-free 70% 
ethanol was added to the lysate and the sample was directly transferred to an RNeasy 
MinElute spin column placed in a 2 ml collection tube. Ethanol facilitates selective binding 
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of RNA to the silica membrane found in the spin columns. Following a sample-wash with 
RW1 wash buffer the cells were treated with DNase I for 15 minutes at room temperature to 
degrade DNA contaminants and ensure purity of resultant RNA.  The sample was washed 
again in RW1 buffer and following this step another wash with buffer RPE was performed. 
The spin column was subsequently washed with RNase-free 80% ethanol after which the 
column was carefully removed from the collecting tube and placed in a new collecting tube. 
Care was taken for the column not to touch the flow-through from the earlier step since 
carryover of ethanol affects down-stream reactions steps. The spin columns were centrifuged 
at full speed for 5 minutes to ensure complete removal of any traces of ethanol. RNA from 
the columns was eluted using 14 µl of RNase-free water. 
All the above steps were performed using RNase-free products and frequent change of gloves 
during the procedure minimised occurrence of contamination as well as improved yield by 
eliminating contaminant-RNases. RNA concentration was measured using a nano-drop 
spectrophotometer and RNA preparations that demonstrated 260/280 ratios  close to 2were 
regarded as suitable for downstream analysis. Resultant RNA was either used immediately or 
stored at -80°C for future use. Storing at -80°C is essential to minimise degradation and 
maintain RNA integrity. Each RNA extraction experiment was repeated thrice with three 
different samples harvested on different days to account for variations in cell cycle events. 
All cells were harvested at 75% confluency. 
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Cell Line sample RNA concentration (ng/µl) 260/280 ratio 
LNCaP 1 1963.94 2.08 
LNCaP 2 2132.28 2.08 
LNCaP 3 1958.45 2.05 
LNCaP-AI 1 2810.20 2.04 
LNCaP-AI 2 1784.53 2.05 
LNCaP-AI 3 1504.48 2.07 
PC 3 2950.93 2.03 
PC 3 1925.23 2.05 
PC 3 1743.45 2.07 
DU 145 1011.71 2.01 
DU 145 2138.29 2.04 
DU 145 964.86 2.08 
 
Figure 2.3. RNA concentrations and 260/280 ratio of samples harvested from prostate cancer 
cell lines.  A 260/280 ratio of 2 indicates good quality RNA with high purity. 
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2.1.2. Reverse  transcriptase PCR 
mRNA was converted to cDNA using reverse transcription PCR. 1µg of RNA was made up 
to a volume of 12.7µl using RNase-free water. This RNA solution was then incubated at 
65°C for 5 minutes to remove any secondary structure following which it was incubated at 
37°C for two minutes. 7.3 µl of reverse transcriptase cocktail (see below for ingredients) was 
added next and the mixture was incubated at 37°C for one hour. At the end of an hour the 
reaction was stopped by inactivating enzyme activity by incubating at 95°C for five minutes. 
Resultant cDNA was either used immediately or stored at -20°C for future use. 
Reverse transcription cocktail: 
1. 0.3 µL of MMLV Reverse Transcriptase(Promega, Madison, USA) 
2. 4µl of 5X MMLV RT buffer(Promega), 
3. 2 µl of 4mM dNTPs(Promega)  
4. 1µL of 50µM Oligo dT15(Promega) 
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2.1.3. Real time PCR 
SYBR green (Platinum®Sybr®Green qPCR supermix-UDG with ROX, Invitrogen) reporter 
was used wherein Sybr green dye binds to the minor groove of double-stranded DNA and the 
fluorescence emitted is directly proportional to the amount of amplicons produced. 9µl of 
Sybr green mixture and 1µl of respective cDNA was loaded into wells of a 384 well plate.  
The Sybr green mix consisted of 5 µl Sybr green, 0.4 µl each of forward and reverse primers 
( see table for primer sequences). The mixture was made up to a volume of 9µl using RNase-
free water. The plates were sealed and centrifuged at 1000 rcf for 1 minute and loaded in a 
7900 HT real time PCR system (Applied Biosystems, California, USA) with predefined PCR 
programme. Gene expression profiles were analysed using ABI 7900 HT SDS 2.2 software 
(Applied Biosystems, Copyright 2003). All transcript levels were normalised to the 
housekeeping gene GAPDH (Figure 2.4 depicts an amplification curved for the house-
keeping gene GAPDH). No variation in GAPDH levels were noted between different samples. 
In samples with equal RNA concentration, the cycle time of GAPDH was unchanged 
(between 16-17 cycles). Measurements for each gene was evaluated with the help of a 
standard curve (Figure 2.5) 
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Figure 2.4. Amplification curve for housekeeping gene GAPDH for the different cell lines. 
mRNA expression for all other genes were normalised to GAPDH. Plot depicts amplicon 
accumulation against the number of amplification cycles. Quantitation of amplicon in real-
time PCR occurs in the exponential phase of the PCR cycle as opposed to traditional PCR 
methods (such as quantitation by agarose gels) that use PCR end-point product for analysis. 
Exponential phase in PCR amplification is the optimal point for analysing data, hence real-
time PCR is more precise than Agarose-gel PCR methods. 
 
Exponential phase 
Linear phase 
End-point/Plateau phase 
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Figure 2.5. An example of the standard curves used to determine gene expression levels. An 
R
2
 value of around 1 and a slope of around -3.2 were aimed for in each experiment. Standard 
concentrations were prepared such that unknown samples would fall closely within the ranges 
of values for known samples. This reduced possible errors that might arise due to 
extrapolation of the curve.  
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2.1.4. Designing primers 
Primers were designed through the primer designing software Primer Express. They were 
then checked for specificity on NCBI Nucleotide BLAST and through NCBI Primer BLAST. 
Sequences are enlisted in Figure 2.6 
SOX-2 F = 5’-CCCGGCGGAAAACCAA-3’ 
R=5’-CGGGCAGCGTGTACTTATCC-3’ 
Oct-3/4 F = 5’-GCAGCGCAACGCCCT-3’ 
R = 5’-GAATGTTGGCTCCCATGCC-5’ 
NANOG F = 5’-CATGAGTGTGGATCCAGTTTG-3’ 
R = 5’-CCTGAATAAGCAGATCCATGG 
LIN 28 F = 5’-CTGCACCTTGGGTCCCAC 
R = 5’-CACACAGCTAGTGCAGTTGGC 
CD 133 F = 5’-AACAGCGATCAAGGAGACCAAA-3’ 
R = 5’-AAGGTGCTGTTCATGTTCTCCA-3’ 
CD117 F = 5’-CCAGCCTTCAAAGCTGTGC-3’ 
R = 5’-AAGATAGCTTGCTTTGGACACA-3’ 
CD 44 F = 5’-AGAAGGTGTGGGCAGAAGAA-3’ 
R = 5’-AAATGCACCATTTCCTGAGA-3’ 
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PSCA F = 5’-CAGGTGAGCAACGAGGAC-3’ 
R = 5’-GTTCTTCTTGCCCACGTAGT-3’ 
Nkx3.1 F = 5'- AGCCAGAAAGGCACTTGGG-3' 
R = 5'-GGCGCCTGAAGTGTTTTCA-3 
P63 F = 5’-GCAGCGCAACGCCCT-3’ 
R = 5’-GAATGTTGGCTCCCATGCC-3’ 
AR F = 5’-CTGGACACGACAACAACCAG-3’ 
R = 5’-CAGATCAGGGGCGAAGTAGA-3’ 
PSA F = 5’-CAATGACGTGTGTGCGCAA-3’ 
R = 5’-CGTGATACCTTGAAGCACACCA-3’ 
GAPDH F = 5’-CGACCACTTTGTCAAGCTCA-3’ 
R = 5’-GGGTCTTACTCCTTGGAGGC-3’ 
 
Table 2.6.  Primer sequences for real-time RT-PCR. Primer sequences were designed using 
Primer Express 2.0 (Applied Biosystems) software. All sequences other than that for LIN 28  
and Nkx3.1 were obtained from Dr. S. Williamson; Nkx3.1 was provided from Dr. K. Coffey; 
Primer sequences for LIN28 were designed in this project.  All other primer sequences were 
verified using the primer design software.  
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2.1.5. Statistical analyses 
All experiments were performed at least in triplicates and the average was considered. All 
graphs plotted show the respective standard error. Relevant statistical significance was 
evaluated through T-Test analysis. 
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Chapter 3. 
Establishing and characterising primary cell culture of prostate stroma and epithelia 
3.1 Introduction 
Prostate primary cultures were established for both stroma and epithelia. Healthy and robust 
cells are absolutely essential for successful lentiviral transduction and for pluripotency 
reprogramming. In addition, the re-programming protocol is a long procedure spanning 
between 2-4 weeks before cells become fully re-programmed. Hence, the culture protocols 
were optimised so that healthy primary cell cultures could be established that could further be 
propogated in culture over longer periods of time. It was also absolutely essential to establish 
pure populations of stroma and epithelia. With stromal cells it was seen that the initial 
cultures were heavily contaminated with blood cells and haematopoietic cells. However, 
purity of cultures was established with higher passages. Epithelial cells were purified by 
means of the EpCAM (CD324) MACS sort and purity was subsequentlysubsequently 
confirmed through transcript studies.   
3.2 Aims 
a. To establish robust primary cultures of prostate stroma and epithelia 
b. To ensure that cultures were devoid of endothelial and haematopoietic contaminants 
prior to transduction 
c. To characterise endogenous levels of pluripotency transcripts in prostate primary cells  
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3.3 Results 
 
3.3.1 Primary culture in the prostate – culturing prostate stroma and prostate 
epithelia 
 
Primary tissue culture was attempted on at least 50 independent samples. Benign prostate 
samples were obtained from either TURP or cysto-prostatectomy specimens. All samples 
were obtained following patient consent and as per ethical approval. Single cell suspensions 
were harvested from these samples which were further separated for stromal and epithelial 
cell fractions.  
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3.3.2 Culture of the prostate epithelia 
 
A total of 55 samples were processed for derivation of prostate epithelial cultures. Out of all 
the samples tried, a total of 8 samples failed to grow and were regarded as “abortive” 
thereby giving a success rate of 85% for growing and culturing primary prostate epithelia. 
The success rate for epithelial primary culture in the author’s hands has varied between 
75%-85% (Figure 3.1). All cultures were grown for at least 4 weeks after which they were 
regarded as either successful or ‘abortive’. Cultures showing epithelial cell colonies with at 
least 32 cells were considered successful and were further sub-cultured. However, the 
fraction of samples that reached higher subcultures was limited indicating that the survival 
and proliferation of primary prostate epithelial attenuated with increased time and passage 
in vitro (Figure 3.1). This reflects the tedious nature of primary epithelial culture of the 
human prostate and emphasises on the need for a simplified in vitro model system that will 
facilitate the study of biology of the prostatic epithelium. Figure 3.1. demonstrates the 
success rates of culturing primary prostate epithelium at the different passages. 83% of 
samples grew such that they could be harvested at least at passage 1. Higher subcultures 
were attained with difficulty with only 2% of cultures reaching beyond passage 4. Only 1 
out of all the 55 samples that were cultured reached passage 6. 
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Figure 3.1. This figure demonstrates the success of primary prostate epithelia in the author’s 
hands. The success rate of epithelial cultures is indicated against the respective passage number. 
Higher subcultures refer to passage numbers beyond P4 and up to P6 (highest passage number 
that was obtained by the author). 17% of total samples failed to grow in vitro; these cultures 
contained less than 32 cells and were regarded as ‘aborted cultures’. 
 
Out of the attempted culturing of the 55 samples, epithelial cell fractions from 35 samples were 
further purified through MACS separation using CD326 microbeads (see Chapter 2). It was 
observed that following CD326 enrichment the cultures survived higher passages better (Figure 
3.2). In addition more than twice the number of purified samples reached higher passages as 
compared to the unsorted samples (Figure 3.2 and Figure 3.3). Furthermore, unsorted samples 
showed a failure rate three-fold higher than that of the enriched samples (Figure 3.4). 
83% 
15% 
9% 
2% 
17% 
0
10
20
30
40
50
60
70
80
90
P1 P2 P3 Higher
subcultures(P4 and
beyond; tried till p6)
Aborted
Number of  successful 
epithelial 
cultures(expressed as %) 
Number of passages 
Primary culture of prostate epithelial cells 
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Figure 3.2. Table demonstrating the success rate of primary prostate epithelial culture with 
and without CD326 EpCAM sort. 20% of sorted samples could be cultured in vitro beyond 
the first passage. 11% of sorted cultures did not grow in culture. Only 1 of 20 unsorted 
cultured could be maintained beyond passage 1 and 25% of unsorted cultures abortedA 
summary of sorted and unsorted primary epithelial cultures. Y-axis shows the anonymised 
patient-ID; HEA+ = Samples sorted for Human Epithelial Antigen 
0 1 2 3 4
11665
11696
11699
11598
11610
11632
11685
Passage No. 
Anonymised prostate 
samples 
EPITHELIAL SAMPLES (UNSORTED) 
0 1 2 3 4 5 6 7
11662(HEA+)
11674(HEA+)
11425 (HEA+)
11473(HEA+)
11478(HEA+)
11480(HEA+)
11514(HEA+)
11518(HEA+)
11552(HEA+)
11621(HEA+)
11632+11634+11636(HEA+)
11664(HEA+)
11682 (HEA+)
11515(HEA+)
11542(HEA+)
11494(HEA+)
11503(HEA+)
Passage no.  
Anonymised prostate 
samples 
EPITHELIAL SAMPLES SORTED FOR EpCAM (CD326/HEA) 
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Figure 3.3. Effects of EpCam (CD326) sort on epithelial cell culture. Sorting cells with the 
CD326 antibody through MACS allows for enrichment of prostate epithelial cells. It is 
possible that pure populations of epithelia survive better than when they have not been 
enriched due to contaminating cell types not overtaking the culture. It is also possible that 
CD326 sort enriches for a stem-cell population that tends to survive better in culture 
(Sundberg, Jansson et al. 2009). 
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Figure 3.4. Figure showing abortive colonies without CD326 sort and after CD326 sort. 
CD326 sorting allows for better cell survival and the number of abortive colonies is 
reduced by half (from 17% to 6%). 
Overall, it was noticed that epithelial cultures struggled to reach higher subcultures.In 
addition it was noted that Human Epithelial Antigen played a crucial role in facilitating 
robustness of epithelial cultures. One explanation for this might be that although 
differential gravity centrifugation yields an epithelial purity of >95% (Robinson, Neal et al. 
1998, Heer, Robson et al. 2007); the cultures at that point are contaminated with blood 
cells as well as endothelial cells. It is possible that these contaminants compete with 
epithelial cells for nutrition and possibly outgrow them and cause these epithelial cultures 
to die out. 
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3.3.2.1 Morphology of epithelial cells 
 
Prostate epithelial cells grew as colonies and demonstrated a characteristic cobble-
stone morphology (Figure 3.1-3.9) . Cells started to cluster and showed colony 
formation from week 1 of culture (Figure 3.5 and 3.6). Well established colonies were 
observed by week 4 (Figure 3.7 and 3.8). The colonies demonstrated variable 
morphology with some colonies depicting a distinct border and densely clustered cells 
and some others depicting irregular borders and loosely-clustered cells (Figure 3.7 
and 3.8). Cultures were most often passaged at this point. Colony size did not increase 
beyond week 6. At this point un-passaged colonies started to demonstrate an altered 
morphology. The compact borders started to become irregular and indistinct and the 
cells started to disperse and die out within the colony (Figure 3.10).  Cells showed 
altered morphology with an increase in cell size and altered cytoplasmic-nuclear ratio. 
Irregularity in cell shapes and vacuolation was also noted. Cultures that were not 
subcultured at this point detached off the floor and eventually perished. Cells rarely 
grew as monolayers. Subculture before attainment of maximal-density has been 
documented as an essential factor favouring successful serial passages (Chaproniere 
and McKeehan 1986). 
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Figure 3.5. Epithelial cells immediately following extraction and prior to addition of 
feeder cells. a. The cells are initially not very confluent, are relatively sparse and do 
not yet form colonies. b. However at week 1 epithelial cells start to aggregate in 
clusters  
 
 
 
a 
b 
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Figure 3.6. Epithelial cells at week1 – a. cells start to cluster and b. gradually form 
colonies. Cells have been seeded on a layer of inactivated STO feeder cells  
 
 
 
a 
b 
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Figure 3.7. Figure demonstrating epithelial cell colonies at week 3. a. Epithelial 
colony with irregular borders and dispersed morphology. b. Epithelial colony that is 
comparatively more densely packed and demonstrates distinct border.  
 
 
 
a 
b 
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Figure 3.8. Epithelial cell colony at week 4. a. The colonies start to acquire a more 
compact morphology although some of them depict irregular borders. X4 
magnification. b. Epithelial cell cultures grow in a cobble-stone morphology at higher 
magnification . X10 magnification  
 
 
 
a 
b 
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Figure 3.9. Primary prostate epithelial cells showing cobble-stone morphology. 
Magnification X40 
 
It was also noted that epithelial cultures were not sustainable over higher subcultures. 
Cultures did not show any overt phenotypic variation till passage 1. However cultures 
beyond P1 showed an increased tendency towards differentiation and cultures were 
increasingly difficult to establish (Figures 3.10-3.12). This suggests that primary 
culture of epithelia from solid tissues is difficult to establish and maintain over longer 
time intervals thereby underscoring the need for a more robust and convenient in vitro 
model that will simulate prostatic environment and physiology as accurately as 
possible.  
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Figure 3.10. Epithelial cells at P0 (a. and b.) and P1 (c. and d.), colonies tend to get more and 
more differentiated with increase in passage number. 
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Figure 3.11. Morphology of prostate primary epithelia beyond passage 1. a. Altered 
morphology of epithelial cells at P2. b. and c. At higher magnification the cells look 
senescent and vacuolated and start to lose their cobble-stone morphology.   
 
 
a 
b 
c 
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Figure 3.12. Epithelial cell morphology over long time periods in culture. Healthy 
epithelial cell culture (a. b. and c.). Figures d. e. and f. shows cultures that were not 
sub-cultured beyond week 6, cells here show altered morphology with increased cell 
size and vacuolation.  
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3.3.2.2  Epithelial cell colonies 
 
Three types of colonies were identified with primary epithelial cell culture namely the 
holoclones, paraclones and the intermediate meroclone-type colonies (Figure 3.13). 
Holoclones are described as large colonies with smooth rounded perimeters; 
paraclones are smaller colonies with an irregular perimeter. Meroclones are an 
intermediate variety with serrated borders (Barrandon and Green 1987). Distinct 
colony formation based on individual proliferation abilities was first described in 
keratinocytes (Barrandon and Green 1987); a similar description of prostate epithelial 
colonies has also been described prostate epithelial culture (Collins, Habib et al. 2001).  
Holoclones are regarded to have the highest growth potential and contain small 
rapidly multiplying stem-cell like cells whilst paraclones show limited proliferation 
and rapid terminal differentiation (Barrandon and Green 1987).  Meroclones or type II 
colonies demonstrate heterogeneity and contain both small and terminally 
differentiating cells (Barrandon and Green 1987, Collins, Habib et al. 2001).  
 
In our cultures, all the three colony types were noted. Culture by means of rapid type I 
collagen adhesion highly selected for holoclones comprising stem-cell like cells as 
compared to a 20 minutes type I collagen adhesion which selected primarily for viable 
cells. Also, cultures following rapid-adhesion resulted in higher success rates survived 
higher subcultures better than the ‘viable’ cells.  
 
 
 
 
 139 
 
 
 
 
 
Figure 3.13. Colony architecture in prostate stem epithelial cell types. Holoclones, 
meroclones and paraclones in epithelail cell culture. a. Holoclones are circular 
colonies with a relatively tight border and compact colony architecture. Holoclones 
mostly comprise undifferentiated cell types. b. Meroclones are an intermediate colony 
type between the holoclones and paraclones. c. Paraclones are colonies that are 
dispersed and lack definitive cell border, these colonies contain the largest number of 
differentiated cell types.  
Holoclones – tightly packed 
colonies containing small cells 
Meroclones – an intermediate 
colony type with irregular 
borders, cells are not as tightly 
packed as in holoclones 
Paraclones – Highly 
irregular cell colonies; do 
not survive long in cultures 
c 
b 
a 
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3.3. Culture of prostate stroma 
A total of 40 stromal cultures were grown and success was nearly 100%. These cells 
are distinct from their epithelial counterparts in terms of cell size, shape and culture-
type. Primary prostate stromal cultures grew as monolayers rather than colonies and 
demonstrated in vitro formation of whorl-like structures (Figure 3.14.a.). Individual 
stromal cells showed elongated and spindle-shaped cell morphology (Figure 3.14 b). 
Lamellae formation between cells was also noted.  Stromal cultures survived higher 
serial passages better than their epithelial counterparts and were a lot more durable. 
These cultures have been split upto at least 13 times and there has been no visible 
change in morphology with higher subcultures (Figure 3.15).  
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Figure 3.14. Primary prostate stromal culture. a. These cells grow in monolayers. X4 
magnification b. Individually prostate stroma are elongated spindle shaped cells that 
grow in whorl-shaped patterns. X40 magnification. 
 
 
Primary prostate stroma 
showing whorl-like 
patterns 
Less confluent culture of 
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showing lamellae-like 
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Figure 3.15. Primary prostate stromal cultures at different subcultures. The cells tend 
to grow well in culture and do not show any aberrant morphology over long time 
culture. 
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3.3.4. 3-D culture of prostate primaries 
In vitro cell culture studies are two-dimensional whilst in real life tissues and organs 
are three-dimensional. 3-D studies bridge the gap between conventional in vitro 
studies and whole-animal physiology. Some of the advantages of 3-D cultures include 
preservation of epithelial cell polarity and cell shape, gene expression profiles that 
more closely simulate in vivo systems and 3-D matrix induced modulation of cell 
growth, gland branching and cell differentiation (Yamada and Cukierman 2007). 3-D 
culture systems have been established in the prostate in the hope of establishing a 
model that would better emulate prostate microenvironment and physiology (Lang, 
Stark et al. 2001, Lang, Smith et al. 2006).  
In the 3-D cultures established by us, we noticed distinct 3-D epithelial and stromal 
morphologies. Firstly, it was observed that in general prostate primary cells grew and 
proliferated more rapidly in Matrigel than in 2-D. Prostate primary cells when seeded 
into Matrigel  three dimensional formed spheroids (Figure 3.16). In contrast, primary 
stromal cells grew as lamellar matrices that apparently formed mesh-like structures 
and seemingly resembled a 2D-layered morphology (Figure 3.17).  Epithelial cells 
showed increased commitment towards 3-D cultures compared to stromal cells which 
failed to show a typical 3-D morphology.   
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Figure. 3.16 Primary prostate epithelial cells in 3-D Matrigel culture. Cells grow in 
spheroid shaped structures. 
   
 
 
Figure 3.17 Prostate epithelia and prostate stroma in Matrigel cultures. Prostate epithelia form 
spheroids while prostate stroma grow in lamellar matices that seem to disperse through he 
entire matrigel plug 
 
Epithelial spheroid 
bodies – clustering to 
form spheres 
Prostate stromal cells grow in 
Matrigel as lamellar matrices 
and do not show spheroid 
formation 
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Prostate cancer cell lines are not comprehensive with respect to prostate cancer phenotypes – 
they do not represent primary prostate adenocarcinomas (Peehl 2005). Also cell lines do not 
represent the full breath of prostatic differentiation and thus do not serve as ideal models to 
study prostate growth and development. Furthermore, long-term culture of cell lines results in 
alteration of their biological properties (Peehl 2005) which adversely affects quality of 
research. Most of the limitations seen with cell line culture are resolved by means of primary 
culture which can be regarded as the gold-standard technique for studying development and 
differentiation in organ-systems. Although prostate primary culture techniques have been 
significantly optimised by several studies (Chaproniere and McKeehan 1986, Robinson, Neal 
et al. 1998, Collins, Habib et al. 2001); this technique is met with several hurdles such as 
tedious handling and low yield. Furthermore, this study observed variations between cultures 
as well over long durations of the same culture. Clinical variations between patients account 
for differences between cultures thereby hindering standardisation of experimental techniques. 
3-D cultures are a development on primary 2-D cultures – however experimentation that can 
be performed with these cultures is limited. 
In this study it has been observed that factors that facilitate primary prostate epithelial culture 
growth and proliferation are: 
1. Sorting with the help of Human Epithelial antigen 
2. Presence of cell-cell contact and  
3. Use of extracellular matrix supplemented with stromal-derived factors. While comparing 
epithelial cell culture to stromal cell culture it was observed that although stromal cells 
proliferated rapidly in 2-D cultures, they did not show significant 3-D anatomy in matrigel 
cultures.  
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3.3.5 Optimisation of primers for stem-cell and prostate-specific-differentiation gene 
expression profile in prostate cancer cell lines  
Real time RT-PCR was used to evaluate mRNA expression of 12 different genes in 
four different prostate cancer cell lines – LNCaP; LNCaP-AI; PC3 and DU 145 
(Figure 3.18). The primer sets for all the genes were thus optimised and confirmed to 
have been working. Non-specific binding and possibility of primer-dimers were ruled 
out through analysis of the dissociation curves. A single melt peak in the dissociation 
curves ruled out possibilities of primer-dimers and ensured that a single product was 
being amplified. Gene expression profiles defining three levels of plasticity were 
studied – those defining pluripotency, those defining adult stem cells with restricted 
differentiation and those that are terminally differentiated.  
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Figure 3.18. The dissociation curves for all the different primers showing a single 
melting point curve for all samples. Plot shows amplification against temperature. 
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3.3.7.Optimisation of prostate stem cell gene primers 
CD133 mRNA transcript was not detected in DU 145 cells. Both PC3 and DU 145 cells 
showed higher levels of CD 44 expression. Similar to pluripotency genes, relative mRNA 
expression was lower in androgen-independent LNCaP cells (Figure 3.19). 
 
 
Figure 3.19 Prostate stem cell gene expression in prostate cancer cell lines. Expression of the 
various stem-cell markers are variable across the different cancer cell lines 
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1.3.8. Expression of Androgen responsive elements in prostate cancer cell lines 
DU 145 and PC3 cell lines serve as negative controls for AR and PSA; these genes were not 
expressed in these two cell lines. Also it was noticed that though AR mRNA transcripts were 
relatively upregulated (as compared to LNCaP cells) in LNCaP-AI cells, these cells did not 
show any expression of PSA (Figure 3.20). 
 
 
Figure 3.20 Expression of androgen regulated genes in prostate cancer cell lines. Note, no 
expression of AR and PSA in cell lines PC3 and DU145.  
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3.3.9. Characterisation of prostate primaries 
3.3.9.1. Characterisation of prostate primary stroma  
Prostate stroma was cultured in monolayers and was analysed at initial and late passages. 
Initial passages showed evidence of endothelial contamination (through presence of CD 146 
+ve cells), epithelial contamination (through presence of CD24 +ve cells) and haematopoietic 
cells (through presence of CD45 +ve cells) (Figure 3.21-3.23). However as these cells were 
passaged, it was noted that the contamination level was significantly reduced at passage 1 
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Figure 3.21. Prostate primary stroma at p0, p1 and p2 showing absence of endothelial 
contamination at p1 passage 
 
 
Figure 3.22. Prostate primary stroma at p0, p1 and p2 showing significant reduction of 
haematopoietic contamination at p1 passage 
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Figure 3.23. Prostate primary stroma at p0, p1 and p2 showing significant reduction of 
epithelial contamination at p1 passage 
 
 
Next, the cells were analysed for levels of endogenous pluripotent transcript (Figure 3.24). It 
is well reported in literature that the expression of certain pluripotent transcripts is not 
confined to pluripotent and stem cells; varying levels of pluripotent transcript expression is 
seen in certain cancer cells (Gu, Yuan et al. 2007, Rodriguez-Pinilla, Sarrio et al. 2007, 
Chiou, Wang et al. 2010, Rajasekhar, Studer et al. 2011) and somatic cells . It is important to 
know the levels of endogenous pluripotent expression since re-programming factor 
stoichiometry is critical in the achievement of a pluripotent status (Carey, Markoulaki et al. 
2011).   
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Figure 3.24 Endogenous expression of Oct4, SOX2, NANOG and Lin 28 in prostate stroma 
at different passage numbers. 
Transcript analyses revealed that basal expression of pluripotency transcripts is observed in 
prostate primary cells; however the expression levels went down at higher passages. There 
was very high expression in the cells at harvest, but given the high levels of contamination 
seen with cells at p0 it is possible that the high levels of expression can be explained by the 
contaminating cells as opposed to the prostate cells themselves. P1 cultures were chosen for 
transduction since at this passage the cells were relatively pure and demonstrated moderate to 
high relative levels of pluripotency transcripts. These experiments were later re-considered 
after comparing them against pluripotent transcript expression levels in H9 human embryonic 
stem cells . 
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Next, these prostate cells were studied for expression of AR and PSA (Figure 3.25). P0 
stroma expressed both AR and PSA suggesting that these cells contain functionally active 
AR. However, this data is against current literature which suggests that AR in prostate stroma 
is not functional and that these cells do not express any PSA. This discrepancy in PSA 
expression seen with p0 stroma can again be explained by the fact that these cells contained 
fractions of epithelial cells that are known to express functionally active AR and thus PSA. 
Reduction in AR levels with higher passage is unexpected and this cannot be explained at this 
stage of this study.  
 
 
  
 
Figure 3.25 AR and PSA expression in prostate primary stroma at initial harvest and at higher 
cultures. 
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1.3.9.2. Characterisation of prostate primary epithelia  
Endogenous embryonic stem-cell transcripts were also analysed in prostate primary epithelia 
(Figure 3.26). Epithelial cells were purified with the help of EpCAM (CD324) MACS sort 
prior to culture and analysis. MACS separation through EpCAM antigen has been established 
as a robust method towards establishment of pure epithelial cultures (Williamson, Hepburn et 
al. 2012). Hence p0 epithelial cultures have been confirmed to be pure epithelial fractions and 
any transcript expression seen in these cells is attributed to prostate epithelia alone. Like 
prostatic stroma, these cells did show endogenous expression of embryonic transcripts and 
the levels here decreased with increasing passage number. Once again the exact reason 
behind this remains equivocal.  
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Figure 3.26. Endogenous expression of Oct4, SOX2, NANOG and Lin 28 in prostate stroma 
at different passages 
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AR and PSA expression was also measured in epithelia cells (Figure 3.27 and 3.28). Since 
the epithelial cells had been EpCAM sorted, only p1 cultures were analysed and compared 
against the prostate stroma. 
 
  
Figure 3.27. AR expression in prostate primary stroma and epithelia 
 
  
 
Figure 3.28. PSA expression in prostate epithelia and stroma. PSA was expressed only by 
prostate epithelia thereby corroborating the presence of functional AR in our epithelia. 
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As expected, epithelial cells showed AR and PSA expression but only AR expression was 
observed for their respective stromal counterparts. This is consistent with the current 
literature and corroborates that the epithelia used in this project expressed functionally active 
AR as is the case with prostate-specific epithelia. PSA expression was absent at very high 
passage. This may be explained by the fact that the epithelial cultures were established 
through an EpCAM sort and were further subjected to the rapid adhesion assay. Both the 
techniques specifically enrich for stem cell populations. It has also been shown that AR and 
PSA expression is reduced in prostate stem cells (Williamson, Hepburn et al. 2012).   
 
3.4 Conclusion 
Robust and healthy cells are critical for successful iPS re-programming. Hence, a great deal 
of emphasis was given to this part of the project in optimising the protocol so as to ensure 
healthy and sustainable cells in culture. Furthermore, it was absolutely essential to confirm 
quality control in terms of cell characterisation and purity. The main purpose of establishing 
the Pro-iPS model was to study prostate-specific growth and development; given the 
containment of a tissue-specific epigenetic memory in iPS cells it was important to ascertain 
the prostatic quality of the initial target cells. 
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Chapter 4 
4. Lentiviral transduction of prostate primary stroma and epithelia 
4.1. Introduction 
This chapter will describe the protocol that was adapted to re-programme primary prostate 
stroma and epithelia by means of lentiviral transduction. Two different protocols were tested. 
Both protocols involved lentiviral transduction. One system was based on the Thomson re-
programming cocktails, namely OSLN (Oct4, SOX2, Lin28 and NANOG) and used the four 
different pluripotency factors in four independent lentiviral constructs. The other system was 
more sophisticated and used a single polycistronic construct that contained all the 4 OSKM 
transcripts in one element. Each of the different transcripts is released as individual 
polypeptides through the ‘2A’ peptide cleavage sites. Furthermore, this system also 
incorporated a Cre-recombinase technology that allowed for manual removal of the exogene 
following iPS transduction. Both the OSKM and OSLN systems have their own advantages 
and disadvantages as discussed below. However, the most important factor that best describes 
the suitability of the two different re-programming manoeuvres was their ability to 
successfully introduce the pluripotent transcripts at the appropriate level into the target cells. 
This conclusion is based on the fact that neonatal foreskin was used as positive control. These 
cells are relatively easy to re-programme and were used alongside prostate cells to decide 
upon the most suitable iPS-induction protocol.  
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4.2. Aims 
1. To induce iPS-phenotype in prostate primary stroma 
2. To induce iPS-phenotype in prostate primary epithelia 
3. To re-programme human neonatal foreskin fibroblast cells into skin-iPS cells 
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4.3. Specific methods and Results 
4.3.1. iPS induction – OSLN factors 
4.3.1.1. Transduction Media  
This protocol used 4 separate iPS-induction viral vectors - Stemgent® Reprogramming 
Lentiviruses: Human SOX2 (ST070012, Stemgent®, USA), Human Oct4 (ST070013, 
Stemgent®, USA), Human Nanog (ST070017, Stemgent®, USA) and Human Lin 28 
(ST070016, Stemgent®, USA). The concentrations of each of the different viruses are: 
1. Human SOX2 = 2.4 x 106 TU/mL 
2. Human Oct4 = 7.2 x 106 TU/mL 
3. Human Nanog = 4.4 x 106 TU/mL 
4. Human Lin 28 = 4.1 x 106 TU/mL 
Transduction media contained the respective parental media in 10% FCS and 1% Pen-Strep 
and the relevant amount of virus so as to target an MOI of 10.  Multiplicity of infection refers 
to the ratio of infectious agents (in this case virus) to the number of cells. MOI depends on 
the transducibility of different cell lines/cell types and must be optimised accordingly. While 
very low MOI would result in inefficient transduction and thus a failed iPS induction, a very 
high MOI can result in multiple integration sites and persistence of the exogene. The volume 
of virus to be added to the transduction media was calculated using the following formulae: 
Transduction units (TU) = MOI X Number of target cells. Eg. To re-programme 100,000 
cells using an MOI of 10 (10 viral particles will target 1 primary cell) 1x10
6
 transduction 
units (TU) of the respective virus will be needed.  
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Volume of each virus = TU ÷ concentration of each virus 
100,000 cells were transduced with an MOI of 10. For each of the 4 virus constructs the 
number of transduction units worked out to be 1x10
6
. The volume of each virus used was 
thus: 
1. hSOX2 (Lot 1722):  
1x10
6
/2.4 x 10
6
 = 417 µl  
2. hOct4 (Lot 1608): 
1x10
6
/7.2 x 10
6
 = 139 µl 
3. hLIN28 (Lot 1611): 
1x10
6
/4.1 x 10
6
 = 244 µl 
4. hNanog (Lot 1612): 
1x10
6
/4.4 x 10
6
 = 228 µl 
 
Appropriate viral volumes were added to 2mL of transduction media, for this example the 
calculations were: 
2000 + 417 + 139 + 244 + 228 = 3028 µl of total transduction media 
Lastly polybrene was added to a final concentration of 0.6ug/ml. Again for the given example 
the volume of polybrene required was: 
(0.66x3028)/(1000) = 1.8 µg of polybrene 
The transduction media was made up fresh and was used immediately 
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4.3.1.2. Transduction of primary prostate stroma 
100,000 prostate stroma cells were seeded onto each well of a 6-well plate. Patint (aged ~ 60 
years) sample was collected following consent and ethical approval. The patient’s 
histoptaholigical analysis report showed no evidence of malignant foci in the sample. 24 
hours later, the cells were washed once in 1XPBS and the freshly prepared transduction 
media was added onto the cells. The cells were kept in transduction media for 48 hours. One 
well containing polybrene in media alone was used as a control well. After 48 hours, the 
viruses were removed and the cells were fed with 10% FCS-containing RPMI 1640. The 
plates were incubated for 7 days at 37˚C. No change in morphology was noticed. The cells 
grew to confluence without showing evidence of any obvious apoptosis when compared to 
the polybrene control.  
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24.3.1.3. Culturing prostate stroma cells post-transduction 
The first 7 days following transduction is detailed as the initial phase of re-programming 
when the cells go through the first transition phase and acquire a more epithelial phenotype 
(Li, Liang et al. 2010). A fraction of these cells would then be expected to move on to 
producing their own endogenous pluripotency factors and therefore become independent of 
the exogene(s). However, when using the OSLN system no change in morphology was 
noticed, the cells retained their mesenchyme phenotype and grew to confluence. On the 7
th
 
post-transduction day, 6-well plates were coated with Matrigel as described below. 
Materials: 
BD Matrigel
TM
 hESC-qualified Matrix, 5ml Vial 
Method:  
Dilution factor: dilution is calculated for each lot based on the protein concentration. Aliquots 
are prepared according to the dilution factor provided on the Certificate of Analysis. Aliquots 
were stored at -70
o
C for up to 6 months, freeze-thaw cycles were avoided. One day before 
use, Matrigel aliquots were thawed overnight on ice. The solution was made up to the 
appropriate dilution and 1ml was used per well of a 6-well plate. Plates were incubated 
overnight at 4
o
C. Matrigel was aspirated immediately prior to use, the plates were incubated 
for 30 minutes with 2ml of the relevant cell culture medium. 
On the 8
th
 day post-transduction, the stroma fibroblasts were trypsinised and seeded at a 
density of 10,000/well onto gelatin coated plates in Nutristem™ XF/FF Culture Medium 
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(Stemgent Cat. No. 01-0005). Nutristem media is a pluripotent stem cell specific media 
recommended by the manufacturer (Stemgent) and is detailed to contain all the factors 
required for stem cell culture and proliferation. The cells were allowed to adhere for 24 hours 
following which the media was changed and 2ml of fresh Nutristem media was added. Media 
was changed every 48 hours for the next 3-4 weeks.  
Around week 3-week 4 post transduction, colony-formation was noticed. Small irregular 
shaped colonies started to appear and these were transferred onto MEF-feeder plates and 
cultured for another 4-6 weeks. Although it was expected that these colonies would grow and 
multiply to generate iPS cell-lines, no such proliferation was noted. The colonies did however 
grow in size, but demonstrated only a 20% increase in their size over 4 weeks. When these 
were divided into smaller clumps they they did not show any significant proliferation, the 
individual clumps failed to grow significantly. Given the irregular shape of the colonies, it 
was decided that these would be categorized as either partially re-programmed or abortive 
colonies. Consequently, this protocol using the OSLN re-programming factors was 
discontinued. 
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4.3.2. iPS induction using OSKM factors 
Although c-Myc is a well characterised oncogene and is known to cause death and 
differentiation in human pluripotent stem cells (Sumi, Tsuneyoshi et al. 2007) the OSKM 
factors are more efficient in re-programming human fibroblasts and also offer faster kinetics 
of iPS induction (Robinton and Daley 2012). Hence, it was decided that the OSLN cocktail 
would be replaced with the OSKM cocktail for Pro-iPS generation. The new kit used 
contained all the 4 OSKM factors in a single construct separated by a self-cleaving 2A 
peptide (Figure 4.1) – this helps to ensure that all successfully transduced cells would receive 
equal amounts of each of the four transcription factors, thereby improving the stoichiometry 
between the 4 re-programming factors. This in turn would improve the efficiency of iPS-
induction (Carey, Markoulaki et al. 2011). Furthermore, the construct was floxed at both ends 
by LoxP sites that would further enable removal of the exogene through a Cre-recombinase 
technology. Hence, this system offered the capacity for cMyc removal in case excessive 
death and apoptosis was noticed in the Pro-iPS.  
 
 
Figure 4.1. OSKM 4 in1 construct used to generate Pro-iPS. All the four pluripotent 
transcripts are present in a single construct. The construct is flanked by two LoxP sites at 
either ends to facilitate removal of the exogenous transcript through Cre-recombinase 
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technology. Courtesy Allele biotechnology: http://www.allelebiotech.com/4-in-1-lentiviral-
particles-for-ipscs-generation-human-oskm/   
 
The initial step was to optimise the transduction efficiency by means of a GFP-tagged empty 
vector control (Figure 4.2). The mWasabi GFP virus stock was transduced into prostate 
fibroblast cells at different MOIs.  
 
 
Figure 4.2. Optimising MOI for the iPS induction in prostate. Primary prostate stroma was 
used at passage 2. Cells were transduced with the mWasabi GFP-tagged empty viral vector 
and the percentage of GFP positive cells was determined through FACS analysis.   
It was noted that at an MOI of 10, the net transduction efficiency was near to 20% (Figure 
4.2). MOI is defined as the number of infective particles (in this case virus containing OSKM) 
per target cell. Hence, in theory an MOI of 10 would mean that each of the target prostate 
fibroblasts is being aimed with 10 viral particles. It would also indicate that in theory all 
transduced cells would contain more than 1 integration site since the number of integrations 
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sites is also dependant on the MOI.For example an MOI of 0.3 would predict that 3% of the 
total target cell population may contain multiple integration sites. Hence, transduction 
efficiency should potentially be 100% for MOI 10. Nevertheless, the poor transduction 
efficiencies observed even at higher MOI suggested that these fibroblast cells were not easily 
amenable to the transduction protocol and with this system very few cells were getting 
successfully transduced. This may have been due to several reasons, including general 
resistance of the cells to lentiviral transduction, poor health of the target cell cultures or it is 
also possible that the viral titres were not as potent as described on the stock vials. However, 
the prostate fibroblast cells were never sorted for enrichment nor were they analysed to assess 
presence of varying phenotypes within the general population. It is possible that the stroma 
cell cultures contained cell fractions within them that were more amenable to the transduction 
procedure and these cells were transduced more successfully than the others. It has been well 
documented that stem cells and/or cells with a primitive de-differentiated phenotype are more 
amenable to iPS induction than more mature differentiated cells (Wakao, Kitada et al. 2011). 
If this is indeed the case then multiple exogene integration sites would be a limitation, but 
this can be tackled by monitoring transgene expression and by manually removing the 
exogene once stable Pro-iPS lines have been established.  
 
The iPS cell induction protocol with the OSKM 4 in 1 construct was then subjected to certain 
alterations. In the OSLN protocol, cells were seeded onto Matrigel-coated plates on Day 7 of 
transduction. It is more difficult to grow human pluripotent stem cells in the absence of MEF 
feeder cells and thus it was decided that on Day 7 of transduction the prostate fibroblasts 
would be directly seeded onto MEF feeder plates. Further, the pluripotent stem cell culture 
media was changed from Nutristem to a KO-DMEM-based pluripotent stem cell culture 
media. Hypoxia is known to regulate stem cell renewal and it also activates signalling 
 169 
 
pathways such as Notch and increases the expression of Oct4 (Keith and Simon 2007). 
Keeping this in mind, it was decided that in the absence of a hypoxic incubator, a reducing 
agent such as β-mercaptoethanol would be added to the media that would act to mop up any 
oxygen free radicals and thus potentially reduce the likelihood of oxidative stress.  
In the first 7 days following transduction the cells were closely monitored for evidence of 
altered morphology as well as cell death. No significant cell death was seen and the cells 
grew to confluence. However, a change in morphology was noted at this time. In certain 
regions, cell clusters started to aggregate and these cells showed a reduction in cell size, they 
started acquiring a rounded shape and also demonstrated a cobble-stone like morphology. 
This suggested that a mesenchymal-epithelial transition (MET) was potentially occurring in a 
fraction of the transduced cells. Details of this MET-like phase during iPS re-programming in 
the prostate has been described in details in Chapter 5. The cells were maintained on the 
feeder plates for a maximum of 14 days and were fed with fresh pluripotent stem cells media 
(Chapter 2)  every 48-72 hours. After 14 days of culture, the cells were trypsinised and 
transferred onto fresh MEF feeder plates and weret maintained in such a manner for 6-8 
weeks. No iPS colony formation was seen, but small irregular colonies started to appear 
which were picked and cultured for another 4-8 weeks. These are described in Chapter 5. 
It was decided that the protocol would be modified to include the use of conditioned media  
since this has been shown to improve the efficiency of iPS generation (Tilgner. K. 2010). For 
this purpose, two types of conditioned media were generated, a MEF feeder conditioned 
media and a human pluripotent stem cell conditioned media. MEF feeder media was 
generated by treating MEF cells at a density of 50,000/ml with pluripotent stem cell culture 
media and by collecting this media every 48 hours and by filter-sterilising it before use.  
Pluripotent stem cell culture media was generated in a similar fashion, by treating skin iPS 
cells with pluripotent stem cell culture media and by collecting the media every 48 hours. The 
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skin iPS conditioned media was then centrifuged at 1500 rpm X 5 minutes to precipitate any 
floating skin iPS cells and the supernatant media was collected and passed twice through a 
0.2 µm filter.  
The conditioned media were collected after treating the relevant cells for 24-48 hours at 37˚C. 
Given that the pluripotent stem cell culture media is stable only at 4˚C, some of the 
components of the media would likely have been depleted or degraded at 37˚C. Hence, it was 
decided that the conditioned media would be used in conjunction with freshly prepared 
pluripotent stem cell culture media. This way it  was possible to utilise the paracrine factors 
secreted by pluripotent stem cells that may putatively contain growth factors that are critical 
in promoting pluripotent stem cell maintenance and enhanced transition of transduced cell 
fractions into iPS cells by means of a positive loop mechanism (Tilgner. K. 2010).  It has 
been documented that during iPS transduction in human neonatal foreskin fibroblast cells, 
cultures treated with hES-conditioned media and MEF-conditioned media in a 1:1 ratio 
results in an increase in iPS colony generation that is 6-fold higher than in cultures that were 
treated with MEF-conditioned media alone (Tilgner. K. 2010).  For Pro-iPS generation, 
freshly prepared pluripotent stem cell culture media was used in conjunction with MEF-
conditioned media and pluripotent stem cell culture media in a 1:1:1 ratio. Cells were treated 
with this reprogramming media from Day 10 post-transduction until stable Pro-iPS cell lines 
were generated. Stable Pro-iPS cell lines were established between weeks 4 and 6 post 
transduction (Moad, Pal et al.). In this manner a total of 14 cell lines were generated and were 
expanded for characterisation.  
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4.3.3. Morphological description of Pro-iPS  
Pro-iPS cells were similar to hES cells in morphology. At early passages, the colonies were 
not as compact and had irregular borders (Figure 4.3.b and 4.3.c.). They showed an 
inclination to rapidly differentiate at the centre and around the borders and were difficult to 
culture. This may be explained by the fact that iPS induction forces cells against their 
differentiation gradient and during the initial stages there would be a tendency for the newly 
re-programmed cells to roll down the epigenetic gradient to their original differentiated state 
(Hochedlinger and Plath 2009). However, it was noticed that with a few more passages and 
with increased culture time the cells gradually adapted to culture conditions and started 
showing a morphology characteristic of human embryonic stem cells (Figure 4.4, 4.5 and 4.6) 
(Moad, Pal et al.).  
 
                     
 
Figure 4.3. iPS induction in human primary fibroblast cells. a. Prostate primary fibroblast 
cells showing the characteristic spindle-shaped mesenchymal morphology. b. Pro-iPS 
colonies at P0, irregular-shaped colonies with poor morphology and tendency to undergo 
spontaneous differentiation at the centre and around the borders. c. Pro-iPS colony at P6, 
morphology is more similar to embryonic-stem cells, borders look more well-defined and 
cells are more compact than at early passages. 
a. b. c. 
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Figure 4.4. Pro-iPS cultures at higher passages. Between P8-P15 these colonies adapt better 
in culture and demonstrate greater resemblance to the human embryonic stem cell 
morphology (Moad, Pal et al.). a. At p10 and b. at p15. 
 
 
   
Figure 4.5. Pro-iPS colony morphology compared to H9 ES cells a. (X20), b.(X20), c.(X20) 
and d. (X40) morphology of Pro-iPS colonies against e. H9 human embryonic stem cell 
colony morphology. Human embryonic stem cell-colony image have been adapted from 
(Thomson, Itskovitz-Eldor et al. 1998).  
a. b. 
a. b. 
c. d. 
e. 
 173 
 
 
 
 
 
 
    
 
Figure 4.6. Pro-iPS colony and cellular morphology   a. and b. at X40 and X60 magnification, 
respectively (Moad, Pal et al.) display similar morphology with c. H9 human embryonic stem 
cell-morphology (Thomson, Itskovitz-Eldor et al. 1998). Both the colonies comprise small 
round cells with high nuclear-cytoplasmic ratio. 
 
 
 
 
 
 
a. b. c. 
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 4.3.4. DNA fingerprinting of Pro-iPS 
DNA fingerprinting was essential to confirm authenticity of the cell lines and to confirm the 
absence of cross-contamination between the Pro-iPS with any other pluripotent cell line. In 
order to do this, 11 different satellite markers were tested and an identical match was 
confirmed between the parental fibroblast cells and resultant Pro-iPS cells thereby 
corroborating the Pro-iPS cells were derivative of primary prostate fibroblasts and were not  
due to cross-contaminaton (Table 4.1). 
  MARKERS 
TESTED 
Pro-iPSC Prostate parent 
fibroblast  
1 Amelogenin XY XY 
2 THO1 9.3 - 9.3 9.3 - 9.3 
3 D21S11 30 - 31.2 30 - 31.2 
4 D18S51 15 - 17 15 - 17 
5 D13S317 8 - 12 8 - 12 
6 D7S820 9 - 11 9 - 11 
7 D16S539 11 - 13 11 - 13 
8 PentaD  9 - 11 9 - 11 
9 D8S1179 13 - 14 13 - 14 
10 TPOX 8 - 11 8 - 11 
11 FGA 21 - 25 21 - 25 
 
 
Table 4.1. DNA fingerprinting results confirm an identical match between parental prostate 
fibroblast cells and Pro-iPS clones for the 11 microsatellites tested. Amelogenin is a sex 
marker and the presence of two bands denotes the sample being male XY. 
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4.3.5. Karyotyping 
 
Pro-iPS colonies were karyotyped between P10-P15 passage numbers and were tested 
for the presence of any aneuploidies. 26 karyograms were analysed and the average 
result was considered. No major aneuplodies were noted and the karyotype was 
confirmed to be 46 XY (Figure 4.7). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.7. Karyogram of human Pro-iPS showing a diploid 46 XY karyotypic status 
(Moad, Pal et al.). No major chromosomal aneuploidies were noted.  
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4.4. Discussion and Conclusion 
 
In this chapter, the optimisation of the iPS-induction protocol has been described 
along with the initial characterisation of the generated Pro-iPS cell lines. These cell 
lines were genotyped to corroborate authenticity and eliminate redundancy and were 
karyotyped to rule out any aneuploidies. The initial characterisation suggested that the 
Pro-iPS model thus generated would potentially present an appropriate model for non-
diseased prostate growth and development. The next step was to corroborate these cell 
lines in terms of their pluripotency. To this end, two series of characterisation 
experiments were undertaken – phenotypic characterisation by means of expression-
marker and transcript analyses and functional characterisation. These will be 
described in Chapters 6 and 7.  
 
An important question that remains as yet equivocal is the mechanism of iPS 
induction. It has been documented that iPS induction chiefly occurs in three stages – 
initiation, maturation and stabilisation with fewer cells transiting from one stage to the 
other so as to finally reach the ‘ground state’ or the fully re-programmed state 
(Samavarchi-Tehrani, Golipour et al. 2010). Chapter 4 looks at this aspect of re-
programming in the prostate and particularly at the role of epithelial to mesenchyme 
transition in prostatic de-differentiation.   
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Chapter 5. 
Mechanisms of prostate de-differentiation and formation of partial -iPS colonies in the human 
prostate 
5.1. Introduction 
In this chapter, the molecular changes at each of the different steps during iPS re-
programming in the prostate will be described. The changes observed in prostate fibroblast 
re-programming is characterised by an initial induction phase marked by a mesenchymal-
epithelial-transition phase. Prostate epithelia did not survive the transduction process, and 
failed to form iPS colonies and therefore induction of pluripotency could not be evaluated. 
However, when primary prostate epithelial were seeded onto MEF-feeder plates in 
pluripotent stem cell media they expressed an arguable de-differentiated status. 
5.2. Aims 
1. To analyse the different mechanisms of iPS-induction in prostate 
2. To re-programme prostate epithelia 
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5.3. Specific methods and results 
5.3.1. Transduction of prostate epithelia 
Prostate epithelia were cultured as described in Chapter 3. Once confluent, they were 
trypsinised and seeded onto MEF feeder plates and cultured in pluripotent stem cells media. 
Colonies started forming on the MEF feeders at 7 days after seeding them out. Once 
substantial sized colonies were noticed these were transduced with the OSKM 4 in 1 
construct (Allele Biotech., USA) and 0.6 µg/ml of polybrene. After 48 hours of transduction, 
the media was replaced with fresh pluripotent stem cell media and the cells were cultured in 
this media for another 4 weeks. No iPS colonies were noted. 
An alternative strategy of transducing prostate epithelia in KSFM media (see Chapter 3) for 
48 hours followed by culturing these prostate cells in KSFM media for the first 7 days was 
also tried. However, when using this method the prostate epithelial cells either seemed to die 
out and/or seemed to undergo a senescent and/or mesenchymal-like morphology. 
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5.3.2. MET in prostate re-programming 
5.3.2.1. MET changes in prostate primary fibroblasts 
Prostate fibroblast cells were transduced with the 4 in 1 OSKM virus and 48 hours after 
transduction they were maintained in their original RPMI-1640 media (see chapter 3) for a 
total of 7 days. On the 7
th
 day post-transduction the cells were collected and analysed for any 
change in gene expression profile.  The cells demonstrated an altered morphology following 
Day 7 of transduction. Prostate stroma fibroblast cells are spindle shaped in morphology and 
grow as monolayers (Chapter 3 and Figure 5.1.a and 5.1.b.) . Following transduction, it was 
noted that the cells started to acquire a rounded morphology with each cells depicting a high 
nuclear-cytoplasmic ratio and a cobble-stoned patter reminiscent of epithelial cells (Figure 
5.1.c. and d.) 
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Figure 5.1. MET transition in prostate fibroblast cells is noted in the first 7 days following 
transduction. a. Prostate fibroblast cells X10. b. Prostate fibroblast cells X 40. c. Prostate 
fibroblast cells post transduction X10. d. Prostate fibroblast cells post transduction X40   
 
 
 
a. 
c. 
b. 
d. 
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A number of mesenchymal and epithelial mRNA transcript levels were examined in these 
cells. The first step was to evaluate the TGF-receptor status in the two cell types. Inhibition of 
TGF-β signalling enhances iPS re-programming in mice by facilitating a higher efficiency of 
iPS induction and by also promoting a faster kinetics. The activation of the TGF-β receptor 
does the opposite (Maherali and Hochedlinger 2009). Also, the inhibition of the TGF-β 
receptor allows for the replacement of exogenous c-Myc and SOX2 in the re-programming 
cocktail (Maherali and Hochedlinger 2009). 
TheTGFf-receptor (TGF-R) status was evaluated in prostate primary cells and in LNCaP 
prostate cancer cells (Figure 5.2). As expected, the highest level of expression was observed 
in primary prostate stroma. TGF-R1 and TGF-R2 can only be differentiated by peptide 
binding and both these receptors have high affinity for TGF-β 1 (Cheifetz and Massagué 
1989) while TGF-R3 binds TGFβ 1 and TGFβ2 with high affinity (Cheifetz, Andres et al. 
1988). It has been documented that an increase in the levels of TGFβ1 and TGFβ2 reduced 
efficiency of iPS colony formation from 0.017% to 0.0013% (Maherali and Hochedlinger 
2009). Levels of TGF-R3 were similar in prostate epithelia and LNCaP cells. However, TGF-
R1 and TGF-R2 expression levels were a lot higher in prostate epithelial cells than LNCaP 
cells. This would suggest that compared to LNCaP cells the cultured prostate epithelia 
potentially possess more mesenchymal properties. This may be due to the fact that these cells 
are prone to an epithelial to mesenchymal transition in the current culture conditions. This 
aspect of research needs further overhaul but is beyond the scope of this project. These results 
suggested that prostate stroma may be more resistant to iPS induction than prostate primary 
epithelia. 
 
 182 
 
 
 
 
 
 
 
Figure 5.2. Expression of TGF-receptor (TGF-R1, TGF-R2 and TGF-R3) in prostate stroma, 
epithelia and in LNCaP cells.   
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The total levels of the pluripotency transcripts (endogenous and exogenous transcripts) were 
checked in the prostate primary fibroblasts so as to ensure that the cells were being 
transduced. An increase in all three transcription factors, Oct4, SOX2 and NANOG further 
suggested that these cells were indeed being successfully transduced (Figure 5.3-5.5). Since 
the re-programming cocktail did not contain any NANOG, an increase in NANOG levels re-
assured that the cells were beginning to induce their own endogeneous transcription factor 
mRNA expression. Confirmation of an increase in  endogenous transcripts for the other 
pluripotency factors were later monitored through primers encoding the 3’UTR end of the 
respective genes (see Chapter 6) . Three more players in EMT were subsequently analysed, 
namely mesenchymal markers SNAIL, SLUG and E-Cad these have been known to play a 
role in the MET phase of iPS induction (Li, Liang et al. 2010, Samavarchi-Tehrani, Golipour 
et al. 2010). Prostate primary stroma cells were analysed 7 days after transduction and it was 
seen that there was a significant decrease (p<0.05) in levels of SNAIL and SLUG following 
transduction with the iPS-re-programming cocktail (Figure 5.6) (Moad, Pal et al.). In 
addition, it was observed that levels of E-Cadherin were up-regulated in the prostate stroma 
following transduction (Figure 5.6).This indicated that the OSKM re-programming factors 
were inducing a mesenchymal-epithelial-transition (MET) in prostate stroma within the first 
7 days post-transduction.  
In this project, no tracking methods were employed hence it cannot be ascertained whether 
the cells that underwent the MET phase indeed were the ones that were ultimately re-
programmed. However, based on documented evidence it is highly likely that the first 
transition in iPS induction in prostate primary fibroblast cells is the MET.   
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Figure 5.3. Increase in Oct4 levels in prostate primary fibroblasts at 7 days post transduction. 
 
 
Figure 5.4. Increase in SOX2 levels in prostate primary fibroblasts at 7 days post transduction 
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Figure 5.5. Increase in NANOG levels in prostate primary fibroblasts at 7 days post 
transduction 
 
 
Figure 5.6. MET changes in prostate primary stroma post transduction. Following 
transduction prostate stroma down-regulate SNAIL and SLUG levels and up-regulate levels 
of E-Cadherin. 
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5.3.2.2. EMT transcript changes in prostate primary epithelia  
Transduction of prostate epithelial cells proved to be challenging in that the cells did not 
survive the transduction process and owing to technical limitations analysis of these cells 
proved to be extremely difficult. The preliminary analysis demonstrated that there was an 
initial rise in the levels of E-Cadherin (after Day 7 post transduction)(Figure 5.7). However, 
unlike the case for prostate stroma, the mesenchymal transcripts, Slug and Snail were not 
down-regulated (Figure 5.8 and 5.9). This may potentially suggest a block in the MET 
process causing failure of iPS induction in these cells. A more detailed scrutiny of this 
phenomenon including analysis of an extended set of pluripotency mRNA transcripts and 
other EMT markers at different time points is needed, but this is beyond the scope of this 
study. 
 
 
 
Figure 5.7. E-Cadherin expression is up-regulated in prostate epithelial cells post transduction 
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Figure 5.8. Mesenchymal marker Slug is not down-regulated following transduction (Day 7) 
with OSKM factors. 
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Figure 5.9. Mesenchymal marker Snail fails to be down-regulated following transduction 
(Day 7) with OSKM factors. 
Given the transcript changes were not favourable, the prostate epithelia did not survive the 
transduction process and additionally there were associated technical limitations,  this may 
help to explain why the prostate epithelia were not transduced with the re-programming 
cocktail.; The characterisation was however continued using the prostate-derived fibroblast 
cells.  
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5.3.3. De-differentiation in prostate primary epithelia 
Prostate epithelia were exposed to a pluripotent stem cell niche with the intention of de-
differentiating them to a primitive phenotype. Prostate primary epithelia were cultured (as 
described in Chapter 3) and a MACS sort was conducted to enrich for CD324+ve (EpCAM 
positive) cells. These cells were directly seeded onto MEF feeder plates and were cultured in 
pluripotent stem cells media until small rounded colonies started to appear. These were 
cultured for 3-4 weeks and the colonies thereby formed were denoted, prostatic epithelial 
pluripotent-like stem cells (PEPSC). After 7 days of initial culture, these cells were stained 
with SSEA4, Tra-1-60 and Hoerscht (see chapter 4). A live cell imaging for the surface 
markers without fixing the cells allowed these colonies to be cultured following the staining 
process and to observe their progress over time. 7 days following culture the colonies did not 
show evidence of any SSEA4+ve or Tra-1-60 +ve staining. Hoercsht is a cytotoxic dye and is 
excluded from the cells by the transmembrane ABCG2 transporter protein. Stem cells have a 
higher ability to exclude this dye since they have higher levels of ABCG2 while non-stem 
cells fail to exclude this toxic dye and stain blue (Scharenberg, Harkey et al. 2002). It was 
noted that the pluripotency markers were positive at 2 weeks following culture in the 
pluripotent stem cell niche (Figure 5.10). In addition the PEPSC cells up-regulated stem-cell 
transcripts namely CD133, CD44, NANOG and Oct4 and down-regulated AR, PSA and 
Nkx3.1 (Figure 5.11). These colonies however failed to expand and were thus deemed as 
partially de-differentiated. 
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Figure 5.10. Prostate epithelial cells grown in specific culture conditions form hESC-like 
colonies (left panel). Staining patterns for hESC markers in negative and positive control 
alongside stroma-derived stem cell colonies 
 
 191 
 
 
 
Figure 5.11. A schematic heat-map representing prostate stem markers and androgen 
regulated genes in prostate epithelia and prostate epithelial pluripotent-like stem cells. 
CD133, CD44, CD117, NANOG and Oct4 are upregulated in the prostatatic epithelial 
pluripotent-like stem cells (PEPSC)  
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These colonies were fixed and stained for nuclear transcript, Oct4. However, it was noted that 
although Oct4 was expressed in these cells it was not localised to the nucleus, but instead was 
present in the cytoplasm (Figure 5.12). This expression pattern is consistent with a 
multipotent stem cells phenotype (Zuk 2009). 
 
 
 
 
Figure 5.12. PEPSC colonies stain for Oct4 but this marker is localised to the cytoplasm 
instead of the nucleus.  
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65.3.4. Partial Pro-iPS colonies 
Prostate stroma at week 3-4, following transduction with the OSKM/OSLN factors formed 
small irregular colonies that stained very brightly for SSEA4 and Tra-1-60 and were arguably 
Hoercsht positive (Figure 5.13) . However, these colonies failed to expand in size and did not 
show the characteristic morphology of human pluripotent stem cells and were thus regarded 
as partially re-programmed iPS colonies. 
 
 
 
 
 
 
 
 
 
 
Figure 5.13. Staining patterns in H9 hESC and in prostate-derived iPS-like colonies.  Primary 
stoma (negative control), hESC colony (positive control) (top left panel). Stroma-derived 
stem cell colony along with staining pattern (bottom left panel). Staining patterns for hESC 
markers in negative and positive controls alongside stroma-derived stem cell colonies. 
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35.4 Discussion and Conclusion 
In summary, this chapter provides an insight for some of the possible mechanisms that drive 
pluripotency and de-differentiation in the prostate cells (Figure 5.14). A mesenchymal to 
epithelial transition-like phase seems to drive pluripotency in primary prostate fibroblast cells 
while the prostate epithelia seemed resistant to this MET phase but on the other hand seemed 
to become more invasive. There seems to be an aberrant signalling pathway in prostate 
epithelia that acts to block the re-programming process . This mechanism needs a further 
scrutiny, of possible aberrant epigenetic mechanisms occurring in the re-programming 
process. Several signalling pathways regulate iPS re-programming and the Initiation stage in 
the re-programming is controlled by several factors (Figure 5.15).Cellular tracking and 
single-cell analysis of prostate stroma and epithelia during the re-programming will be 
essential in elucidating the possible road-blocks instrumental in pluripotency induction in the 
human prostate.  
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Figure 5.14. A schematic diagram representing the MET process during iPS induction in the 
prostate.  Transduced prostate stroma are observed to undergo a mesenchymal-epithelial 
transition at 7 days following transduction. After another 6-7 weeks, these cells form Pro-iPS 
colonies. In contrast, primary prostate epithelia do not form completely re-programmed iPS 
colonies (Zhao, Sun et al. 2013). We noted that these cells acquired higher levels of 
mesenchymal transcripts.  
 196 
 
 
 
 
 
 
Figure 5.15 Schematic diagram demonstrating the transcriptional regulatory network in 
embryonic stem cells. Synergism of BMP with the OSKM factors during the Intial MET 
phase may be potentially mediated through interactions of Smad1, Oct4 and SOX2 to 
regulate the iPS induction process 
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Chapter 6 
6. Phenotypic characterisation of Pro-iPS cells 
6. 1. Introduction 
This chapter will describe the phenotypic characterisation of Pro-iPS cells. The prostate-
derived pluripotent stem cell lines were characterised through expression marker analyses. 
Gene expression analysis was carried out for a panel of 6 embryonic transcripts. Exogene 
silencing was confirmed through real-time PCR using a primer sequence was specifically 
directed against the lentiviral backbone. iPS colonies express endogenous transcripts around 
Day13-14 post-transduction (Stadtfeld, Maherali et al. 2008). Endogenous pluripotent 
transcript expression was checked in the Pro-iPS lines by designing primers specifically 
coding the 3’ untranslated region of the gene. The panel of genes tested included Oct4, 
SOX2, NANOG, gdf3, Dnmt3b and Rex1. All of these genes were expressed at levels similar 
to and/or higher than the embryonic stem cell line H9 (Moad, Pal et al.). 
Immunofluorescence staining was performed using a panel of 5 different markers including, 
surface markers SSEA4, Tra-1-81 and Tra-1-60 and the nuclear markers NANOG and Oct4. 
Immunocytochemistry was also applied to detect levels of alkaline phosphatase because 
undifferentiated pluripotent stem cells are demonstrated to express high levels of alkaline 
phosphatase (Thomson, Itskovitz-Eldor et al. 1998, Takahashi, Tanabe et al. 2007, Yu, 
Vodyanik et al. 2007). Pro-iPS cells expressed all the pluripotent surface markers and 
demonstrated nuclear localisation for all the nuclear markers (Moad, Pal et al.) further 
corroborating their pluripotent status over simply multipotency (Zuk 2009). 
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6.2. Aims 
1. To characterise Pro-iPS cell lines for presence of pluripotent transcripts and to compare 
these transcripts expression against H9 human embryonic stem cells 
2. To confirm the expression of pluripotent markers in the Pro-iPS cells 
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6.3. Specific Methods and Results 
6.3.1. Transcript analyses 
Pro-iPS cells expressed endogenous transcripts SOX2 and Oct4 at levels that were similar to 
or higher than human H9 cells (Figure 6.1 and 6.2) (Moad, Pal et al.). Figures 6.1 and 6.2 
summarise SOX2 and Oct4 expression levels in prostate stroma, prostate stroma 6 days 
following transduction, H9 human embryonic stem cells, skin-iPS cells and 14 clones of Pro-
iPS cells. For both SOX2 and Oct4 transcripts the endogenous gene levels were measured 
using primers that specifically encoded detected the 3’ untranslated region of the gene. 
Parental prostate stroma showed negligible expression of endogenous Oct4 and SOX2 when 
compared against Pro-iPS clones. Prostate fibroblasts collected 7 days following transduction 
showed very high expression of the endogenous transcripts. This demonstrates that, in 
prostate cells the endogenous transcripts are switched on as early as Day 7 post transduction 
and the levels of these genes remain the same and/or increase following the complete re-
programming process.  
All 14 Pro-iPS clones expressed transgene-independent SOX2 (Figure 6.1). For clones 1 and 
4 the levels of these were very similar to levels in the H9 cells. However, SOX2 levels were 
on an average 5 folds higher in Pro-iPS clones 2,3,5,6,7,8,10,11,12,13 and 14. Clone 9 
expressed SOX2 at levels that were 9 fold higher than H9 cells. Non-transduced fibroblasts 
were used as negative control. Endogenous SOX2 levels were also measured in prostate 
stroma at an early post-transduction stage, around day 10. An increase in endogenous gene 
expression at this stage confirmed that the cells had not only been successfully transduced by 
the virus but also that the iPS-induction phase had already started at this time. Transcript 
levels were also measured in skin-iPS cells (kindly provided by Prof. L Lako, Newcastle 
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University) since conventionally iPS cells are derived from skin and therefore these cells 
were used for comparison against Pro-iPS to test the role of epigenetic imprinting towards 
lineage fidelity. 
A larger number of the Pro-iPS clones, namely clones 2, 3, 5, 6, 7, 9, 11, 12, 13 and 14 
expressed endogenous Oct4 that were very similar to levels seen in the H9 cells (Figure 6.2). 
However, Oct4 levels were very high in Pro-iPS clones 1, 4, 8 and 9. The endogenous 
expression for early transduced prostate stroma for Oct4 is very similar to H9 cells and this 
may be associated with a greater number of Pro-iPS clones acquiring an expression profile 
that was more consistent with the H9 cells than the scenario for SOX2. Since all the clones 
were derived from the same patient, it is possible that there is an association between prostate 
and Oct4 that causes the expression profile for this particular gene to be more embryonic 
stem cell-like than the expression profile for SOX2. 
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 Figure 6.1. Endogenous SOX2 levels in the 14 Pro-iPS clones, H9, stroma cells post transduction 
and parental stroma cells. Endogenous SOX2 expression was minimal in non-transduced prostate 
stroma. Within 7 days of transduction, levels of endogenous SOX2 were up-regulated. Both the 
skin-iPS and Pro-iPS cells expressed SOX2 that were at a similar level to or higher than SOX2 
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levels in the H9 cell line.                                                                                            
 
Figure 6.2. Endogenous Oct4 levels in the 14 Pro-iPS clones, H9, stroma cells post 
transduction and parental stroma cells. Endogenous Oct4 levels were upregulated by prostate 
stroma at 7 days following transduction and the expression levels remained elevated in the 
fully formed Pro-iPS cell lines. Furthermore, Oct-4 expression levels were variable amongst 
the different cell lines. This may be a consequence of multiple integrations of the transgene 
and/or due to a variation in the integration site. Both these events can have downstream 
implications and affect the genetic machinery of the transduced prostate cells. H9 cDNA was 
kindly provided by Prof. L Lako, Newcastle University. 
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High levels of endogene expression is a favourable characteristic of a pluripotent stem cell 
phenotype since this suggests that the cells have been successfully reprogrammed and that 
they do not need to rely on the transgene for pluripotency and survival (Stadtfeld, Maherali et 
al. 2008). However, one major concern with such high levels of expression is that it may 
potentially indicate viral genome integration as well as aberrant and incomplete transgene 
silencing. Hence, the next step was to check for the expression of the transgene in the Pro-iPS 
clones. 
6.3.2 Testing exogene expression in Pro-iPS cells 
 
Exogene levels were tested in all the 14 Pro-iPS cell lines (Figure 6.3). Expression of the 
endogene along with the absent exogene expression is consistent with the fully re-
programmed or Class II iPS cells (Hotta and Ellis 2008). There is evidence to suggest that in 
retroviral-transduction, the exogene becomes silenced once the iPS cells are independent of 
the transgene stimulation by virtue of their own endogenous pluripotent transcripts (Maherali, 
Sridharan et al. 2007, Okita, Ichisaka et al. 2007, Wernig, Meissner et al. 2007).  
In order to examine the persistence of the transgene, PCR was performed using a primer pair 
encoding sequences that specifically target the lentiviral backbone. H9 embryonic stem cells 
were used as the negative control while prostate fibroblast at Day10 post-transduction was 
used as the negative control. Clones 1, 2, 3, 9, 10 and 13 showed negligible transgene 
expression while Clones 4, 5, 6, 7, 8, 11, 12 and 14 showed almost absent transgene 
expression. These results appeared to suggest that re-programming in the Pro-iPS cells was 
potentially complete with possible silencing of the transgene. Confirmation of the transgene 
however can only be attained through analysis of the exogene-integration sites in the re-
programmed cells.  
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Figure 6.3. Exogene expression in Pro-iPS cell lines.  Transgene levels were measured by 
using a primer pair that specifically amplified a sequence in the lentiviral backbone of the 
exogene construct. H9 embryonic stem cells were used as a negative control since they dol not 
express any exogenous pluripotent transcripts. Stroma cells at 7 days post transduction 
expressed very high levels of the transgene and this was used as a positive control.  
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6.3.3. Expression of other pluripotent transcripts in Pro-iPS cells  
Levels of four other pluripotent transcripts, namely NANOG, dnmt3b, gdf3 and Zfp42 
were tested and compared with the H9 embryonic cells (Figure 6.4). For these 
experiments, Clone 4 was chosen as the representative clone for the Pro-iPS cells. Pro-
iPS cells expressed these transcripts at levels very similar to the H9 cells. Along with pro-
viral silencing, expression of dnmt3b and REX1 is associated with the fully re-
programmed state (Chan, Ratanasirintrawoot et al. 2009).  
 
 
 
Figure 6.4. Expression of pluripotent transcripts NANOG, gdf3, dnmt3b and Rex1 
(Zfp42) in Pro-iPS clone 4 and H9 cells. NANOG and dnmt3b levels were remarkably 
similar between Pro-iPS and H9 cells. Gene expression levels here refer to the total gene 
levels which represents the endogenous transcript levels. 
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46.3.4. Expression marker analysis in Pro-iPS cells 
The Pro-iPS cells stained positive for alkaline phosphatase (Figure 6.5), a surface marker 
that is expressed by pluripotent cells (International Stem Cell, Adewumi et al. 2007, 
O'Connor, Kardel et al. 2008, Ramirez, Gerbal-Chaloin et al. 2011) . Alkaline phosphates 
is a marker for pluripotency but is not associated with the fully re-programmed state and 
is insufficient on its own to denote complete re-programming (Chan, Ratanasirintrawoot 
et al. 2009).   
 
 
        
 
Figure 6.5. Pro-iPS cells express the pluripotent surface marker alkaline phosphatase  a. 
X10 magnification b. X20 magnification and c. X 40 magnification 
 
 
 
 
 
a. b
. 
c 
 207 
 
Pro-iPS cells also expressed surface markers SSEA4, Tra-1-81 and Tra-1-60 as well as 
the nuclear markers Oct4 and NANOG (Moad, Pal et al.). This has been demonstrated in 
figures 6.6 and 6.7. Figure 6.6 demonstrates the expression of SSEA4, TRA-1-81 and 
Oct4 in Pro-iPS cells. The Pro-iPS colonies express the surface markers SSEA4 and Tra-
1-81 in a honey-comb pattern. The staining also further corroborates the colony 
morphology to be tightly packed, without any evidence of central and/or peripheral 
differentiation which would be evident as areas of poor/absent staining. The colonies can 
be seen to be surrounded by MEF feeder cells that stain for nuclear marker DAPI but not, 
as expected for the pluripotency markers. Figure 6.7 depicts the pluripotent markers 
expression at a higher magnification. While the expression of SSEA4, Tra-1-81 and Tra-
1-60 is on the cell surface, Oct4 and NANOG expression localises to the nucleus. Nuclear 
expression of Oct4, NANOG and expression of Tra-1-60 is associated with the fully re-
programmed state (Chan, Ratanasirintrawoot et al. 2009). Together, these staining 
patterns validate the credibility of our thus formed Pro-iPS cells lines as being  fully re-
programmed to an embryonic stem cell level (Moad, Pal et al.). 
 
          
Figure 6.6. Expression of pluripotent markers in Pro-iPS colonies with absent staining in non-
pluripotent feeder MEF cells. MEF cells outside the colonies were used as negative control 
and these cells did not express any of the pluripotent markers. a. SSEA4. b. TRA-1-81 and c. 
Oct4. Colonies shown here are all at X10 magnification. 
a. b. c. 
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Figure 6.7. Pro-iPS colonies express a panel of 3 surface markers, SSEA4, TRA-1-81 and 
TRA-1-60 and a panel of 2 nuclear markers, NANOG and Oct4. All images in the left 
column are at X 20 magnification and in the right panel are at X40 magnification. In addition, 
the left panel depicts the antibody staining without DAPI while the right-hand panel depicts 
the respective antibody staining merged with DAPI.  
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6.4. Discussion and conclusion  
In this chapter the phenotypic characterisation of the Pro-iPS has been described. Transcript 
analyses confirmed that the gene expression profile of the Pro-iPS cells with respect to 
pluripotency was comparable to the H9 embryonic stem cell line. Transgene silencing, 
expression of Tra-1-60, Dnmt3b and Zfp42 are identified as markers of the fully re-
programmed state. In contrast, GDF3, SSEA4, NANOG as well as alkaline phosphatase 
expression are not sufficient ,arkers of the fullt re-programmed iPS state (Moad, Pal et al. , 
Chan, Ratanasirintrawoot et al. 2009). The Pro-iPS cell lines also expressed pluripotent 
markers in a an embryonic stem cell-specific manner, where core pluripotency molecules 
Oct4 and NANOG were localised to the nucleus alone (Moad, Pal et al.).  
After confirming the phenotypic characterisation of these cells, the next obvious step would 
be to test their functional properties in terms of their lineage plasticity and differentiation 
capacities. This is detailed in Chapter 7.  
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Chapter 7.  
Functional characterisation of Pro-iPS cells 
7.1. Introduction 
The functional characterisation of Pro-iPS cells was carried out with two major objectives: 
firstly to test whether the Pro-iPS cells would differentiate into all the three germ-layer 
derivatives namely ectoderm, mesoderm and endoderm. The most  irrevocable test of 
pluripotency of a cell is its germline competence, a feature that is demonstrated in murine 
pluripotent cells by means of chimera formation (Okita, Ichisaka et al. 2007). It is not 
possible to demonstrate chimeras in human iPS cells and therefore pluripotent functionality 
has been demonstrated in human iPS cells by means of in vivo teratoma formation 
(Takahashi, Tanabe et al. 2007, Yu, Vodyanik et al. 2007).  
The next objective is to test the core hypothesis of this thesis, that is, the lineage fidelity of 
the Pro-iPS cells in terms of their tendency to differentiate into prostate. The justification 
behind sourcing iPS cells from the prostate rather than the more accessible skin tissue was 
based on the speculation that the retained epigenetic memory in prostate derived iPS cells 
would make these cells more inclined towards a prostate-specific differentiation route.  
 
7.2. Aims 
1. To test whether Pro-iPS cells would differentiate into all the three germ layers – ectoderm, 
mesoderm and endoderm 
2. To compare lineage fidelity of Pro-iPS cells and skin-iPS cells towards prostatic 
phenotype. 
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7.3. Specific methods and results 
7.3.1. AR levels in Pro-iPS cells 
One of the characteristics of iPS cell induction is the fact that fully re-programmed skin-iPS 
cells fail to express fibroblast specific marker – CD90/Thy 1. In other words, the fully re-
programmed state is characterised by loss of expression of lineage or differentiation markers 
(Stadtfeld, Maherali et al. 2008). Hence, AR levels were checked during re-programming of 
prostate and it was observed that during the course of de-differentiation the prostate 
fibroblasts down-regulated AR expression (Figure 7.1). Since no PSA expression is apparent 
in prostate stroma it was decided not to evaluate the status of this gene. PSA is an androgen 
responsive gene and is secreted by following activation of functional AR by ligand. Hence, in 
the scenario of decreasing AR levels it is unlikely to correlate with an increase in PSA 
expression by the re-programming fibroblasts. AR expression was also noted in skin-iPS cells 
(Figure 7.1) and this can be accounted for by the fact that AR expression is previously 
demonstrated in skin cells (Keenan, Meyer Iii et al. 1975). Both prostate epithelia and 
prostate stroma were found to express similar levels of AR (Figure 7.1). AR levels were 
observed to reduce by approximately half their initial value during the first 6 days post 
transduction. This was followed by a further 5-fold reduction in AR in the Pro-iPS cells 
(Figure 7.1) .  
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Figure 7.1. Changes in AR expression levels in prostate cells following viral transduction. 
Relative AR levels in primary prostate stroma, epithelia, stroma cells at 6 days following 
transduction and prostate iPS cells were compared with each other and against skin iPS cells. 
AR expression was observed to be reduced in the prostate stroma during the course of iPS 
induction.  
 
 
7.3.2. In vitro differentiation – Embryoid body formation 
The Pro-iPS cells were examined to demonstrate their ability to differentiate into the three 
germ layers in vitro by means of embryoid body formation in human pluripotent stem cell 
media in the absence of bFGF (Figure 7.2). Pro-iPS cell clumps when cultured in the absence 
of b-FGF on low-adhesion plates for 7-10 days were noted to form three dimensional 
structures. It was also observed that these three-dimensional embryoid bodies contained areas 
that were apparently darker than adjacent areas (Figure 7.2). It is possible that these areas 
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represent foci of necrosis due to insufficient gas and nutrient transfer. It is also possible that 
these areas represented regions where the constituent embryoid body forming cells were 
undergoing various differentiation processes. These bodies were transferred onto 0.1% 
gelatin coated plates for another 7-10 days in order to facilitate adherence and to demonstrate 
differentiation into cells representing the ectoderm, mesoderm and endoderm (Moad, Pal et 
al.). The differentiation of Pro-iPS cell-derived embryoid bodies into the three embryonic 
lineages is demonstrated in Figure 7.3. Example of cells representing the ectoderm includes 
those of the peripheral nervous system, that is, neuronal like cells. Cells representing the 
mesoderm include mesenchyme myocyte-like cells while cells representing the endodermal 
lineage include the cobble-stoned epitheloid cells (Figure 7.3). The differentiated germ layers 
were further characterised for their respective markers (Figures 7.4- 7.9). 
 
 
      
 
Figure 7.2. Pro-iPS cells when cultured in the absence of b-FGF on low-adhesion plates form 
spherical structures that resemble embryoid bodies. a. X 10 magnification . b. X20 
magnification. C. X 40 magnification.  
 
a. b. c. 
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Figure 7.3. Pro-iPS derived embryoid bodies differentiate  into all three germ layers – the 
Ectoderm, Mesoderm and Endoderm. Examples of ectoderm-derived cells includes neurons 
and differentiation into this germ layer was depicted by the presence of neuronal-like 
offshoots arising from the Pro-iPS embryoid bodies.   
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The next step was to analyse the Pro-iPS differentiated cells in order to confirm their lineage 
and to this end 1-2 transcript specific for each of the three lineages were employed, namely 
PAX6 (Figure 7.4) and β-III tubulin (Figure 7.9) for ectoderm, αSMA (Figure 7.5) and CD 
31 (Figure 7.9) for mesoderm and α-feto protein for endoderm (Figure 7.6 and Figure 7.9). 
As expected, Pro-iPS embryoid body-differentiated cells expressed their specific lineage 
transcripts (Moad, Pal et al.). It would be expected that during the course of differentiation 
into the three germ layer derivatives that the  embryoid-body derived cells should down-
regulate pluripotent transcripts. Failure to do so may potentially indicate the persistence and 
possible integration of the provirus (Stadtfeld, Maherali et al. 2008). Pro-iPS embryoid 
bodies were found to down-regulate pluripotent transcripts Oct4 and SOX2 during 
differentiation (Figure 7.7 and 7.8), further corroborating the RT-PCR results in Chapter 6 
that suggested the potential silencing of the provirus (Moad, Pal et al.).  
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Figure 7.4. Pro-iPS derived embryoid bodies differentiate into cells of ectodermal lineage. 
PAX6 expression (ectoderm-specific marker) is up-regulated by Pro-iPS cells during 
differentiation of embryoid bodies. 
 
 
 
 
Figure 7.5.  Pro-iPS derived embryoid bodies differentiate into cells of mesodermal lineage. 
αSMA expression (mesoderm-specific marker) is up-regulated by Pro-iPS cells during 
differentiation of embryoid bodies. 
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Figure 7.6. Pro-iPS derived embryoid bodies differentiate into cells of endodermal lineage. 
AFP expression (endoderm-specific marker) is up-regulated by Pro-iPS cells during 
differentiation of embryoid bodies. 
 
 
 
 
Figure 7.7. Following differentiation of Pro-iPS to embryoid bodies, these differentiated cells 
down-regulate the core pluripotency factor Oct-4. This further corroborates data from 
Chapter 6 suggesting silencing of the exogenous transcript (Figure 6.3) 
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Figure 7.8. Following differentiation of Pro-iPS to embryoid bodies, these differentiated cells 
down-regulate the core pluripotency factor SOX2.  This experiment further validates 
silencing of the exogenous transcripts that was discussed in Chapter 6 (Figure 6.3) 
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Figure 7.9. Characterisation of Pro-iPS embryoid body differentiation through 
immunofluorescence staining. Following differentiation, Pro-iPS-derived embryoid bodies 
express βIII-tubulin (marker for ectoderm), CD 31 (marker for mesoderm) and AFP (α-feto 
protein marker for endoderm). The panels on the left show the individual antibody staining 
merged with DAPI (for localisation of the nucleus) while the panels on the right shows the 
individual antibody staining without DAPI. All the three markers shown demonstrate a 
cytosolic expression pattern that is consistent with the literature  
AFP - endoderm 
CD 31 - mesoderm 
βIII tubulin - ectoderm 
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7.3.3. In vivo differentiation – teratoma formation 
The ability of Pro-iPS cells to differentiate into the three germ layers in vivo was depicted by 
the formation of teratomas at 3 weeks after s/c injection into NOD/SCID Ƴ mice (Figure 7.10 
and Figure 7.11). Pro-iPS cells formed small solid tumours at the site of injection and these 
demonstrated rapid growth over the next week. The mice were euthanised as per the relevant 
license and tumours were dissected out, weighed, measured and processed either for 
immunohistochemistry (fixed in 4% PFA) or  for trichrome stains (fixed in Buoin’s fluid). A 
total of 9 mice were injected, 7 of them showed formation of solid tumours as shown in 
Figure 7.10 below. The dimensions of the tumours  were plotted alongside the body weight of 
each  mice against time following injection. Generally, it was noted that over the course of 
the experiments, the weight of the mice showed a tendency to remain constant while there 
was in most cases a rapid growth in tumour size. Formation of solid tumours that grow 
rapidly over time at the site of injection suggest that these would be more likely to be 
consistent with a teratoma on the grounds of histopathology (Gertow, Przyborski et al. 2007).  
For the above detailed experiments, three Pro-iPS clones were tested (clones-1, -3 and -4 
based on their gene expression profile) and each clone was injected into three mice (Figure 
7.10). All three mice injected with Pro-iPS clones-1 and -3  formed tumours, while only one 
mouse injected with Pro-iPS clone-4 exhibited tumour formation. One of the three mice 
injected with Pro-iPS clone-3, grew an intra-abdominal tumour – the tumour could not be 
seen externally. The mouse was euthanised as it was doing very poorly and became inactive. 
On dissection an intra-abdominal tumour was noted that measured 2.4 cm3 in volume. The 
tumour had an osseous/cartilagenous feel to it and was fixed in 4% PFA/Bouins fluid. 
Teratoma formation by these Pro-iPS cells has also been described by Dr Simon Hayward’s 
group at Vanderbilt University Medical Centre, TN, USA (Figure 7.11) (Moad, Pal et al.). 
Figure 7.11 in addition shows teratoma formation by UT-iPS cells, whereby all the three 
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germ layers have been depicted. The possibility of carcinomatous change in urological-iPS-
dervied teratomas has been appropriately critiqued as a limitation of the iPS technology 
(Wezel and Southgate 2013). Our research group acknowledge this as a valid risk and 
recognise future emphasis should be on improving methods of re-programming such as 
transgene-free re-programming approaches as well as xeno-free culture methods (Pal, Moad 
et al. 2013).  
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Figure 7.10. Formation of teratomas  in Pro-iPS cells. Pro-iPS clone 3 when injected s/c into 
NOD/SCID Ƴ mice formed detectable tumours at week 7, week 5 and week 8 for mouse 1, 2 
and 3, respectively. Once externally visible they grew rapidly over the next week. Mouse  3 
formed an intra-abdominal tumour possibly as a result of the injection going beyond the 
subcutaneous region to the abdomen. Pro-iPS clone 1 when injected s/c into NOD/SCID Ƴ 
mice formed tumours at week 5, week 6 and week 5 for mouse 4, mouse 5 and mouse 6, 
respectively. Once externally visible they grew rapidly over the next week. Pro-iPS clone 4 
formed only one tumour from one of the three mice at around week 5 and was harvested at 
week 7. 
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Figure 7.11. Histology from a teratoma formed by Pro-iPS cells. The histopathological 
analyses was kindly performed by Prof. Simon Hayward, Vanderbilt University, USA.  Pro-
iPS derived teratoma demonstrated neuronal epithelial differentiation, UT-iPS (Urinary 
Tract-iPS) demonstrate ddifferentiation into all the three germ layers (Moad, Pal et al.). 
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7.3.4. Lineage-specific differentiation of Pro-iPS and skin-iPS towards a prostate-specific 
route 
It is well established that the prostate mesenchyme regulates prostate epithelial differentiation 
and function and this concept was utilised to analyse prostatic differentiation through stroma-
conditioned media (Moad, Pal et al. , Lawrence, Taylor et al. 2013, Pal, Moad et al. 2013). 
Skin-iPS cells were used as control. The aim here was to evaluate whether prostate-derived 
iPS cells would show greater lineage fidelity by virtue of their primary epigenetic memory 
and whether this would make them more inclined towards prostatic differentiation. The first 
step was to establish culture conditions that would promote a prostatic differentiation. To this 
end, prostate stroma-conditioned media was generated by feeding prostate stroma cells with 
RPMI-1640 medium supplemented with 10% FCS and 10nM dihydrotestosterone. 
Dihydrotestosterone was used to stimulate the prostate stroma cells with the expectation that 
this would facilitate the differentiation process. The prostate primary fibroblast cells were fed 
with the stroma-conditioned media every 48 hours. Conditioned media was filtered through a 
0.2 micron filter and further supplemented with 10nM dihydrotestosterone prior to use. 
Pro-iPS cell clumps were suspended in the prostate stroma-conditioned media and grown on 
low adhesion dishes for 7-10 days. This resulted in the formation of 3-D structures that were 
likened to potential prostatospheres. Some of these structures were fixed in formalin and 
paraffin embedded and stained with H&E in order to determine the presence of any possible 
luminal architecture. Some other structures were transferred onto 0.1% gelatin coated plates 
and maintained in the stroma-conditioned medium as described above. On Day 21 the cells 
started to emerge from the spheroids. There were mesenchymal and epitheloid cell types 
noticed. In particular, clusters of epitheloid cells surrounded by mesenchymal cells were 
noted (Figure 7.12). Clusters of epitheloid differentiation was observed as 60-70% 
differentiation in Pro-iPS cells. Cells treated with RPMI-1640 media were used as a control 
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arm and no epitheloid structures were noted in the absence of conditioned media. 
Subsequently, the cells were trypsinised and were put through a CD324 (HEA/EpCaM) sort 
and the positive cells were cultured for another 5 days to enable them to seed out on the 
plates. The cells were then characterised for the epithelial marker CD 24 (Figure 7.13) and 
prostate markers (AR and PSA) (7.14-7.16). The same protocol was duplicated for skin-iPS 
cells. It was observed that when skin-iPS clumps were cultured in prostate stroma 
conditioned media, they did not possess the same predilection towards prostatic 
differentiation as was observed for the Pro-iPS cells. After treating skin-iPS and Pro-iPS with 
stroma-conditioned media, a 2-fold increase was noted in AR transcripts.I In contrast, the 
Pro-iPS cells demonstrated a 270 fold increase in AR levels following treatment with stroma-
conditioned media (Figure 7.14) (Moad, Pal et al.). In addition, PSA expression was only 
induced in the Pro-iPS cells following treatment with stroma-conditioned media (Figure 7.15) 
(Moad, Pal et al.). Immunofluorescence staining of the Pro-iPS-derived cells further 
confirmed localisation of AR in the nucleus supporting its functional status, while PSA being 
a secretory protein was localised to the cytoplasm (Figure 7.16) (Moad, Pal et al.). 
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Figure 7.12.Effect of prostate-stroma conditioned media on Pro-iPS-derived spheroids. Pro-
iPS cell clumps formed spheroids when cultured in stroma-conditioned media. These 
spheroids, when seeded onto gelatin coated flasks differentiated to form clusters of epitheloid 
cells surrounded by mesenchymal cells. a. Pro-iPS in stroma conditioned media after 3 weeks 
in culture X10. b. Pro-iPS differentiated epitheloid cells at week 3 of culture X20 
magnification. c. Prostate epithelia primary culture X10. d. Prostate epithelia primary culture 
X20.  
 
 
a. b. 
c. d. 
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Figure 7.13. Expression of CD 24 epithelial marker in prostate cells. Prostate stroma was 
used as negative control. CD 24 expression was noted in Pro-iPS cells. This is not unexpected 
since iPS cells are epitheloid and are known to express epithelial markers (Li, Liang et al. 
2010, Samavarchi-Tehrani, Golipour et al. 2010). Prostate epithelial cells were used as 
positive control. Pro-iPS-derived cells up-regulated CD 24 expression as compared to Pro-
iPS suggesting that they were possibly epitheloid. 
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Figure 7.14. AR induction in Pro-iPS and skin-iPS following treatment with prostate-stroma 
conditioned media. AR induction was elevated around 270 fold in prostate while it is only 
elevated 2-fold in skin iPS cells. 
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Figure 7.15. Pro-iPS epithelioid cells express PSA. Prostate stroma was used as negative 
control. Pro-iPS cells did not express any PSA denoting that the AR in Pro-iPS cells is 
functionally inactive. Post differentiation PSA levels in Pro-iPS-derived cells and prostate 
epithelia were comparable.  
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Figure 7.16. Immunofluorescent staning of Pro-iPS-derived epitheloid cultures demonstrate 
expression of AR and PSA. PSA being a secreted protein was evident in the cytoplasm of the 
differentiated cells. Nuclear localisation of AR in these cells further endorsed the AR protein was 
functionally active. Panels on left show DAPI staining merged with AR/PSA. Right hand panel are 
stained for either PSA or AR alone.  
 
 
 
 
AR staining in pros-iPSC following 
differentiation 
PSA staining in pros-iPSC following 
differentiation 
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The author was keen to evaluate 3-dimensional differentiation in the putative prostatic spheroids was 
next examined. To this end, Pro-iPS clumps were cultured in prostate stroma-conditioned media for 
10 days and the resulting spheroids were paraffin embedded, sectioned and stained with 
Haematoxylin and Eosin. Results demonstrated possible luminal architecture (Figure 7.17). 
However, the possibility of necrotic pockets forming within the spheroids due to inefficient and 
uneven mass transfer cannot be ruled out as accounting for the apparent lumen. Staining the 
spheroids for AR and PSA should be conducted to validate the 3-dimensional differentiation in these 
spheroids. Alternatively, 3-dimensional differentiation may be achieved by culturing Pro-iPS cells in 
3-dimensional synthetic scaffolds. The architecture of these scaffolds is such that the 200 micron 
thickness (example: Alvetex, Reinnervate) simulates an in vivo environment and allows for uniform 
gas and nutrient amongst individual cells. The scaffolds can then be paraffin embedded, sectioned 
and evaluated for architecture as well as expression of prostate-specific markers. It is well 
established that 3-dimensional cell culture improves cell function and demonstrates differentiation in 
a more efficient manner (Maltman and Przyborski 2010, Xia, Nivet et al. 2013).  
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Figure 7.17. Analysis of Pro-iPS-spheroids following exposure to stroma-conditioned media. 
Pro-iPS-derived spheroids show possible luminal-type architecture on H&E. However, the 
methodology behind the spheroid culture did not take into account use of matrix or scaffold 
and therefore it is possible that the conjectured ‘luminal’ areas are in fact necrotic pockets.  
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5.4 Discussion and Conclusion 
In this chapter, the functional properties of Pro-iPS with respect to pluripotency has been 
described through in vitro formation of embryoid bodies and in vivo formation of teratomas 
(Moad, Pal et al.). The Pro-iPS cells differentiated into cells representing all the three germ 
layers, namely ectoderm, mesoderm and endoderm. It has also been shown that Pro-iPS cells 
retained lineage fidelity with respect to prostate-specific differentiation (Moad, Pal et al.). 
This further substantiates the concept of retained epigenetic memory during stem-cell re-
programming (Kim, Doi et al. 2010, Polo, Liu et al. 2010, Bar-Nur, Russ et al. 2011). 
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Chapter 8 
Discussion and Conclusion 
The Pro-iPS cell model provides a pertinent model to decipher some of the canonical 
signalling pathways in prostate lineage plasticity that may regulate prostate development and 
differentiation. It also provides a new vehicle to test epigenetic signatures in the androgen-
receptor signalling during the process of prostatic differentiation. A major critique of the Pro-
iPS and UT-iPS cell model (Moad, Pal et al.) is that it has been assumed that imprinted gene 
signature of the tissue of origin infers incompletely reprogramming of cells (Wezel and 
Southgate). It is well characterised that de facto completely reprogrammed germ-line-
competent murine iPS cells and pluripotent human iPS cells retain epigenetic memory during 
somatic cell reprogramming (Aasen, Raya et al. 2008, Aoi, Yae et al. 2008, Miura, Okada et 
al. 2009, Kim, Doi et al. 2010, Polo, Liu et al. 2010, Bar-Nur, Russ et al. 2011, Lister, 
Pelizzola et al. 2011, Lee, Seo et al. 2012). However, this epigenetic memory is transient and 
gets erased with increased passage number (Polo, Liu et al. 2010). UT-iPS and Pro-iPS cells 
were used at passage numbers below 50 and it is therefore justifiable that the origin-tissue 
specific epigenetic memory will be retained in these cells at this stage of early passage (Kim, 
Doi et al. 2010). Whether this tissue-specific imprinting would get erased at higher passages 
remains unknown and needs further investigation. This further calls for scrutiny of epigenetic 
signatures in the iPS cells and underscores the need for individual cellular tracking at the 
molecular level. It will be interesting to track epigenetic signatures at single cell levels 
through the process of de-differentiation and differentiation of these urological cells – this 
would further clarify currently unanswered questions on the epigenetic status of somatic cell 
re-programming and their consequent differentiation into target lineages. 
The most definitive test for pluripotency is formation of chimeras that prove the generated 
iPS cells to be germ-line competent (Okita, Ichisaka et al. 2007). However, this test is not 
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feasible in humans and therefore the gold-standard for demonstrating that a cell has been 
fully re-programmed in human-iPS cell lines is by means of teratoma formation (Takahashi, 
Tanabe et al. 2007, Yu, Vodyanik et al. 2007). The teratomas shown (Figure 8.1) reflect 
uncoordinated differentiation but the main objective here is to show pluripotency, which is 
what the terotomas demonstrated. In vivo engraftments with either bladder or urogenital sinus 
mesenchyme were undertaken but these experiments were not optimised to investigate 
directed differentiation, and the mesenchyme served to enhance engraftment rates and growth 
(Kanai, Ishii et al. 2008, Lawrence, Taylor et al. 2013). Although the directed differentiation 
to generate prostate and bladder-like structures in vivo would further support our finding, we 
do demonstrate the ability for terminal epithelial differentiation with induced expression of 
AR and PSA in the prostate derived iPS cells and induction of uroplakins and claudins in the 
urinary tract derived iPS cells. The use of conditioned medium to induce differentiation was 
criticised (Wezel and Southgate) but these are established and well characterised techniques 
(Baskin, Hayward et al. 1996, Bayne, Ross et al. 1998, Hashiba, Noguchi et al. 2000, Tian, 
Bharadwaj et al. 2010, Taylor, Toivanen et al. 2012, Lawrence, Taylor et al. 2013). The need 
to assess the effect of conditioned media from various sources on the UT-iPS and Pro-iPS 
cells would further clarify their inherent in vitro differentiation abilities as well as lineage 
commitments. Although this is beyond the scope of the study herein, the study of the iPS cell 
lines generated by us pave a foundation for such assessments. Our group with other 
colleagues have recently noted that UT-iPS and Pro-iPS cells when differentiated in vivo with 
bladder or prostate instructive mesenchyme differentiate into urological lineage.  These 
studies confirm that in the absence of any tissue-specific-instructions, the UT-iPS and Pro-
iPS cells differentiate to represent all the three germ layers whereas they retain an inherent 
ability towards urological differentiation when subjected to lineage-specific differentiation 
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strategies. This suggests an inherent fidelity of these cells towards tissue-specific 
differentiation that may be directed by an epigenetic status – this needs further investigation.  
 
 
 
Figure 8.1. Teratoma formation in Pro-iPS cells. Pro-iPS cells were injected in NOD/SCID 
mice. Cells were injected subcutaneously and the mice were closely observed for the 
formation of any tumours. Tumours were measured and harvested when they were of desired 
Tooth-like structure Bone-like structure 
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size (Chapter 2). On examining the gross morphology, some tumours depicted tooth-like 
structures and cartilage/bone-like structures within them. 
Media conditioned by the respective organ-specific stroma directed a lineage specific 
differentiation only in the respective organ-specific iPS cells; the same conditioned media 
failed to induce the same extent of lineage-specific differentiation in skin-iPS cells (Moad, 
Pal et al.). Our data emphasise the potential importance of the source from which iPS cells 
are generated as a consideration for organ-specific development studies. The role of 
urological mesenchyme in maintaining the respective tissue homeostasis has been well 
documented (Taylor and Risbridger 2008) . Although histologically, all mesenchyme are 
highly similar to each other it has been reported that the genetic make-up of each type of 
mesenchyme is distinct with the net result that both bladder and prostate mesenchyme have 
their own characteristic gene expression profile and are phenotypically distinct (Goo, 
Goodlett et al. 2005).  This corroborates the role of mesenchyme in regulating lineage fidelity 
and this principle was used by us in the in vitro differentiation of UT-iPS and Pro-iPS cells 
(Moad, Pal et al.). It was our observation that media conditioned by the respective organ-
specific stroma directed a lineage specific differentiation only in the respective organ-specific 
iPS cells (Figure 8.2); the same conditioned media failed to induce the same extent of 
lineage-specific differentiation in skin-iPS cells (Moad, Pal et al.). A detailed analysis of 
tissue-specific mesenchyme conditioned media is warranted although this is at present 
beyond the scope of our study. The need to assess the effect of conditioned media from 
various sources on the UT-iPS and Pro-iPS cells will further clarify their inherent in vitro 
differentiation abilities as well as lineage commitments. Although this is beyond the scope of 
our study the iPS cell lines generated by us pave a foundation for such assessments. Analysis 
of in vitro UT-iPS and Pro-iPS differentiation models will also facilitate the scrutiny of 
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various canonical pathways as well as epigenetic mechanisms that potentially regulate 
prostate development and carcinogenesis.  
 
 
 
Figure 8.2. Differentiation of Pro-iPS in the presence and absence instructive mesenchyme-
derived factors. Differentiation of Pro-iPS cells into teratomas in the absence of instructive 
mesenchyme; however when exposed to prostate mesenchyme conditioned media these 
differentiate into prostatic lineage 
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The fact that UT-iPS and Pro-iPS cells are able to differentiate into epithelial cells further 
corroborates their extent of pluripotency since it demonstrates that cells derived from an 
ectodermal lineage are able to give rise to endodermal cells. The fully re-programmed iPS 
cell state is marked by a phenotype that silences the parental fibroblast gene expression 
profile (Maherali, Sridharan et al. 2007, Maherali, Ahfeldt et al. 2008). The Pro-iPS cells 
demonstrated silencing of the parental tissue genes thereby suggesting that these cells were 
indeed devoid of the respective parental phenotype and instead had acquired an embryonic 
identity distinct from their initial cell type of origin. The fact that they nevertheless retain a 
parental epigenetic imprint may be explained by the fact that during the process of 
transcription factor-mediated re-programming the cells have been pushed against a 
differentiation gradient to an embryonic pluripotent state and thereby have the natural 
predilection to roll down the differentiation gradient unless restricted to the state of 
pluripotency by an epigenetic road-block (Hochedlinger and Plath 2009). Many concepts here 
as yet remain ambiguous and must be scrutinised in a step-wise fashion through single-cell 
tracking during the process of differentiation. Also as suggested, these cells should be 
subjected to different unrelated tissue-specific conditioned media to confirm their lineage 
commitments. A step-wise cellular-level analysis of molecular and epigenetic events will 
help to clarify and elaborate the precise mechanisms of de-differentiation and consequent re-
differentiation in these cells. 
It will be important to induce iPS cell generation in prostate and urinary tract epithelia and to 
track the molecular mechanisms behind somatic cell reprogramming in these cells (Wezel 
and Southgate). Epithelial cells are technically challenging cell cultures and often have 
limited life span in vitro. Poor cell quality and limited life span means that these cells may 
not be amenable to re-programming even when enriched for stem cell populations through 
surface markers (Richardson, Robson et al. 2004) which as yet are not necessarily 
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deterministic in purifying stem cell populations (Collins and Maitland 2009). For this purpose 
our iPS cell models are in place to serve as a starting population of pluripotent cells that can 
be made to differentiate to a multipotent adult stem cell state. This will unarguably need a lot 
more urological stem cell phenotypic characterisation. One strategy will be to use Pro-iPS 
and UT-iPS derived epithelial cell types as the starting population for iPS induction since it is 
well documented that these cells would be more susceptible to iPS cell induction due to 
favourable integration sites (Hochedlinger and Plath 2009, Robinton and Daley 2012). 
However, it has also been documented that there is no integration site dependent clonal 
selection during lentiviral re-programming and somatic cell re-programming by mean of 
lentiviral transduction is not dependant on insertional activation or deletion of genes or gene 
clusters (Winkler, Cantilena et al. 2010). 
The methodology of iPS re-programming has evolved over the years. The early attempts at 
re-programming involved of self-silencing Moloney-based retroviral vectors (Maherali and 
Hochedlinger 2008). This method is associated with several limitations such as the viral 
transduction infectivity is restrained to dividing cells thereby resulting in lower transduction  
efficiency (Miller, Adam et al. 1990). The re-programming efficiency is further limited by the 
fact that the transgene gets gradually silenced during the iPS-induction process itself 
(Stadtfeld, Maherali et al. 2008). Finally retrovirus transduction protocols are associated with 
transgene integration and this maintenance of the viral-gene expression further limits the 
utility the derived iPS cell lines (Dimos, Rodolfa et al. 2008, Park, Zhao et al. 2008). 
Lentiviral transduction protocols are more favourable than retroviral methods in that 
lentiviruses can infect non-dividing cell types (Naldini, Blömer et al. 1996). However 
lentiviral transduction are also associated with poor transgene silencing (Lois, Hong et al. 
2002) which limits the use of derived cell lines most specifically in terms of their clinical 
application. Drug-inducible lentiviral transduction protocols provide temporal control over 
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transcript factor expression and are therefore useful to analyse mechanism of iPS-re-
programming (Brambrink, Foreman et al. 2008, Stadtfeld, Maherali et al. 2008).  More recent 
advances in iPS re-programming include the use of non-integrating viral vectors such as the 
adenovirus (Stadtfeld, Nagaya et al. 2008), virus-free iPS generation through expression 
plasmids containing complementary DNA strands (Okita, Nakagawa et al. 2008), iPS 
generation facilitated by the use of small molecules such as Valproic acid (Huangfu, Maehr et 
al. 2008) and by direct delivery of transcription factors through protein transduction (Gump 
and Dowdy 2007, Bosnali and Edenhofer 2008).  
The generation of Pro-iPS cell lines was a tedious and challenging technique. Prostate cancer 
is a hetrogenous tumour and clinical variation between patient samples meant that the course 
of iPS-reprogramming in the prostate was not consistent. Improved technologies in iPS-
reprogramming are called for so that several lines of Pro-iPS can be established from 
different patient samples. Several road-blocks have been identified that slow-down the iPS 
re-programming process. It is well documented that inhibiting the tgf-β signalling pathway 
improves the efficiency of iPS-reprogramming, in particular it facilitates the initiation phase 
of iPS induction which is characterised by the messsenchymal to epithelial transition phase 
(Chapter 5) (Ichida, Blanchard et al. 2009, Maherali and Hochedlinger 2009, Massague 2012) 
. Hence it will be interesting to evaluate whether blocking the tgf-β signalling in human 
prostate epithelial and stroma re-programming would facilitate the initiation phase.  In 
addition, it has also been documented that iPS-induction is also facilitated by the transcription 
factor Glis1(Glis family Zinc Finger 1) which positively influences multiple re-programming 
networks involving c-Myc, Lin 28, NANOG, Wnt, ESrrb and the messencymal to epithelial 
transition phase (Maekawa, Yamaguchi et al. 2011). Furthermore, it has been recently 
revealed that Mbd3/NuRD (nucleosome re-modelling and deacetylation) repressor complex 
acts as a brier in iPS re-programming (Rais, Zviran et al. 2013). The levels of Mbd3 
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roadblock expression is significantly higher in skin than prostate (Rais, Zviran et al. 2013) 
and thus depleting MbD3 may improve iPS-generation efficiency in the  human prostate. It 
has been demonstrated that depleting Mbd3 along with the OSKM transduction protocol 
result in near 100% efficiency within seven days from human and mouse cells (Rais, Zviran 
et al. 2013). Given, the iPS-induction in human prostate was between 4-6 weeks long, it will 
be useful to explore these developments to generate Pro-iPS cell lines.  
Another strategic approach and development in iPS technology is the advent of in vivo re-
programming. It has been demonstrated that iPS re-programming can be attained in vivo 
through the OSKM factors  whereby the in vivo iPS cells are extremely similar to in vivo ES 
cells but distinct from in vitro iPS cells (Abad, Mosteiro et al. 2013). It will be interesting to 
assess in vivo cellular plasticity of the human prostate as that may reveal important 
information regarding prostate development as well as the role of epigenetic alterations 
during prostatic development and differentiation. In vivo generated iPS cells are more 
primitive and plastic and possess the differentiation status comparable to a totipotent stem 
cells in that they can be differentiated into embryonic as well as extraembryonic tissue 
derivatives (Abad, Mosteiro et al. 2013).  
An important step forwards from this work would be to assess the behaviour of the iPS cells 
from skin and prostate when co-cultured with instructive mesenchyme in vivo (Figure 8.3).  
This could reveal how the iPS cells would behave in a three-dimensional context and results 
will potentially provide information on the potential of these cells with respect to clinical use 
as well as in the context of other bio-clinical applications such as disease modelling, drug 
modelling as well as biomarker screening (Wezel and Southgate). It will also be important to 
establish a mean of tracking prostate stem cell differentiation in vitro. This can be achieved 
by lentiviral tagging of the Pro-iPS cells using a fluorescent protein. The differentiation of the 
Pro-iPS can then be examined uder different condition or in the presence of different 
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environments. Clonal evolution of prostate cancer can be further scrutinised through ectopic 
xenograft models using genetically barcoded Pro-iPS cells. The purpose of our model was to 
establish a means to facilitate the study of development of urological tissues and to capture an 
urologically-derived cell in a transient embryonic state such that it can be manoeuvred to re-
differentiate into its original tissue-specific lineage. This in turn has created a urological 
model albeit at its very incipient stage for further scrutiny of human growth and tissue-
specific development. 
 
 
 
Figure 8.3. Skin-iPS and Pro-iPS cells co-cultured with rat urogenital mesenchyme (prostate-
instructive mesenchyme) in vivo. Courtesy Prof. Simon Hayward and Dr. Omar Franco. 
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Abstract 
Background: Primary culture, animal and cell-line models of prostate and bladder 
development have limitations in describing human biology and novel strategies that describe 
the full spectrum of differentiation from foetal through to ageing tissue are required. Recent 
advances in biology demonstrate that direct reprogramming of somatic cells into pluripotent 
embryonic stem cell (ESC)-like cells is possible. These cells, termed induced pluripotent 
stem cells (iPSCs), could theoretically generate adult prostate and bladder, providing an 
alternative strategy to study differentiation. 
Objective: To generate human iPSCs derived from normal ageing human prostates (Pro-
iPSCs) and urinary tract (UT-iPSCs) and to assess their capacity for lineage directed 
differentiation.  
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Design, setting, and participants: Prostate and urinary tract stroma were transduced with 
OCT4, SOX2, KLF4 and cMYC genes to generate iPSCs.  
Outcome Measurements and Statistical Analysis: The potential for differentiation into 
prostate and bladder lineages was compared with classical skin-derived iPSCs. Student’s t 
test was used. 
Results and limitations: Successful reprogramming of prostate into Pro-iPSCs and bladder 
and ureter into UT-iPSCs was demonstrated by characteristic ESC morphology, marker 
expression and functional pluripotency in generating all three germ layer lineages. In contrast 
to conventional skin-derived iPSCs, Pro-iPSCs showed a vastly increased ability to generate 
prostate epithelial-specific differentiation as characterised by androgen receptor and PSA 
induction. Similarly, UT-iPSCs were shown to be more efficient than skin-derived iPSCs in 
undergoing bladder differentiation as demonstrated by expression of urothelial-specific 
markers, uroplakins, claudins and cytokeratin; and stromal smooth muscle markers α-SMA, 
calponin, and desmin. These disparities are likely to represent epigenetic differences between 
individual iPSC lines and highlight the importance of organ-specific iPSCs for tissue-specific 
studies.  
Conclusions: iPSCs provide an exciting new model to characterise mechanisms regulating 
prostate and bladder differentiation and to develop novel approaches to disease modelling. 
Regeneration of bladder cells also provides an exceptional opportunity for translational tissue 
engineering. 
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prostate and bladder cells into induced pluripotent stem cells. European Urology 
2013. In Press. Article selected as Platinum Priority, accompanied and 
highlighted by a Platinum Priority editorial article. Impact factor = 10.5 
2. Pal D, Moad M, Hepburn AC, Williamson SC, Robson CN, Heer R. Reply from 
Authors re: "Reprogramming Stromal Cell from the Urinary Tract and Prostate: A 
Trip to Pluripotency and Back?". European Urology 2013. In Press. Impact 
factor = 10.5 
3. Townes.C.L., Ali.A., Gross.N. , Pal.D., Williamson.S.C., Heer.R., Robson.C.N., 
Pickard.R., Hall.J. PSA enhances antimicrobial response of prostate epithelium 
against E.coli’. The Prostate, 2013. In Press. Impact factor = 3.8 
4. Singhapol.C, Pal.D., Porika.M., Nelson.G. , Saretzki.S.C. Mitochondrial 
telomerase protects cancer cells from nuclear DNA damage. PLOS One 2012. In 
press. Impact factor = 3.7 
5. Williamson.S.C., Hepburn.A.C., Coffey.K., Wilson.L, Pal.D., Leung.H.Y, 
Robson.C.N., Heer.R. Human α2β1HI CD133+VE epithelial prostate stem cells 
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express low levels of active androgen receptor. PLOS One, 2012. Impact factor 
= 3.7 
6.  Heer R, Glendinning RJ, Nesbitt CN, Pal D, Rix D, Menezes P, Johnson MI. 
Secondary haemorrhage following transurethral resection of bladder tumour — is 
it always related to infection?. British Journal of Medical and Surgical Urology 
2011 
7. Carr-Wilkinson.J., Prathalingam.N., Pal.D., Moad.M., Lee.N., Sundaresh.A., 
Lako.M., Murdoch.A. 
P., Herbert. H and Tweddle.D.A. Differentiation of human embryonic stem cells 
to sympathetic neurons: A model for understanding neuroblastoma pathogenesis. 
2013. Submitted for Publication in Stem Cells Translational Medicine, sister 
journal of Stem Cells which has an impact factor of 7.7. 
 
Conferences attended and level of participation: 
1. 8th NCRI Cancer Conference, Liverpool, November, 2012: 
a. Invited speaker in proffered paper session The Cancer cells and Model Systems II: 
Induced pluripotent stem cell (iPSC) reprogramming of the elderly human prostate into a 
primitive embryonic stem cell state - a model for prostatic development and 
carcinogenesis 
b. Poster presentation: A mesenchymal-epithelial transition in the prostate stroma marks 
the initiation of prostatic reprogramming to an embryonic-stem-cell state 
2. 20th Meeting of the EAU Section of Urological Research, 25-27 October 2012, 
Strasbourg: One of the 4 Marie Curie fellows (out of total 20) selected to give a talk at 
the PRO-NEST symposium of this conference:  Induced pluripotent stem cell 
reprogramming of the elderly human prostate. 
3. Annual Meeting of the Society of Academic and Research Surgery. 2012, Nottingham, 
UK:  
a. Oral presentation: The role of EMT in iPSC induction of prostate 
b. Oral presentation: iPSC re-programming in the Human prostate 
4. NEUS (North-East association of Urological Surgeons). 2012. Newcastle, UK  
 Oral presentation: Can’t find prostate stem cells? – Let’s make one!.  
5. North-East Post graduate conference. 2012. Newcastle, UK 
 Oral presentation: Induced pluripotent stem-cell reprogramming in the human 
prostate.  
6. 9th World Congress on Urological Research, Innsbruck, Austria, 2011 
 Poster presentation: The role of EMT in iPS induction of human prostate 
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7. Annual Meeting of the Society of Academic and Research Surgery. 2011, Dublin, 
Ireland  
a. Oral presentation: Characterising potential for pluripotency induction in human 
prostate tissue.   
b. Oral presentation: Stem-cell regulatory protein Piwil2 enriches for known stem-cell 
and cancer stem-cell        markers in prostate cancer cells.  
8. 8th NCRI Cancer Conference, Liverpool, November, 2010 
a. Poster presentation: Piwil2 expression selects for known stem-cell and cancer stem-
cell markers in LNCaP prostate cancer cell line 
b. Poster presentation: A study of pluripotency potential within the human prostate 
tissue and establishment of a model to understand prostate growth, development and 
carcinogenesis 
 
Leadership, Management and Communication skills: 
1. NICR Teaching and Training Committee Postgraduate representative, Newcastle 
University: 2010 – 2012. Key responsibilities: Represent all students at the institute, 
student welfare, first point of communication between students and faculty 
2. Graduate School Committee Representative, Medical School, Newcastle University: 
2011. Key responsibilities: Represent students across all institutes at faculty level, 
participate in academic board meetings so as to plan, review and enforce 
administrative policies for student welfare and training. 
3. Clinical and research demonstrator: demonstrating clinical skill to junior medical 
students and laboratory skills to BSc and PhD students.  
 
Research Skills; 
•Establishing primary culture of patient-derived cells – epithelia, stroma.  Subculturing 
primary cells over time 
•Characterisation and genetic manipulation of human primary cells – normal and 
tumorigenic 
•3D models and analysis, developing prostatospheres 
•Karyotyping and karyotypic analysis using relevant software 
•Lentiviral transduction of patient –derived primary cell types eg: stroma, epithelia and 
foreskin fibroblast cells  
•Human Pluripotent stem cell culture (hES and iPS culture and propagation) 
•Immunofluorescence and immunocytochemistry – confocal and live cell imaging 
•Molecular biology techniques: handling RNA, mRNA synthesis, RT-PCR, qPCR  
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•FACS 
•Animal studies – teratoma assays (witnessed and assisted in procedures involving 
injection of genetically manipulated primary cells, daily observation of tumour growth, 
harvesting and dissecting tumours under ethical guidelines and animal-welfare regulations, 
orthotopic xenograft assays). Awareness of animal welfare regulations whilst 
experimentation. 
•DNA fingerprinting 
 
1. Research assistant/associate in the Leukemic Stem Cell Group under the direct 
supervision of Prof. Josef Vormoor and Prof. Olaf Heidenreich, Newcastle 
University: 2013 –2014. 
Research Skills: 
1. Project : Self-renewal genes and pathways in Lymphoid malignancies 
 Culture of Leukaemic cells lines , suspension cultures 
 Transduction of Leukaemic cell lines 
 Culture of murine stromal cell lines – for co-culture purposes 
 FACS 
 Basic molecular biology technique: DNA extraction and handling, PCR 
amplification, cloning, validation, Analytical Gel analysis 
 Awareness in basic bioinformatics analyses: GSEA, pathway mapping 
2. Project (Pilot): Ex vivo culture models to grow patient-derived B-ALL cells 
 Culture of patient-derived primary messenchymal stem cells (hMSC) 
 Osteoblastic andEndothelial differentiation of hMSC 
 Culture and differentiation of hMSC in 3D scaffolds 
 Co-culture of Leukaemic cell lines with hMSC/hMSC-derived cells in 3D 
scaffolds 
 PFA fixation, paraffin embedding and sectioning of 3D scaffolds for the 
purposes of immunostaining 
 
